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ABSTRACT 
Nonsegmented negative-sense RNA viruses (nsNSVs) include the human pathogens 
respiratory syncytial virus (RSV) and Ebola virus (EBOV). The genomes of these viruses 
are replicated and transcribed by a virus-encoded RNA dependent RNA polymerase 
(RdRp). The RdRps of nsNSVs initiate RNA synthesis in a primer-independent (de novo) 
manner. RSV RdRp initiates replication opposite the uridine at template position 1 (T1U) 
and transcription opposite the cytidine at template position 3 (T3C). The EBOV RdRp 
initiation site(s) was not known. We sought to better understand nsNSV RNA synthesis 
initiation by investigating the factors affecting initiation including promoter sequence, 
initiating NTPs, and RdRp structural determinants.  
We investigated the importance of promoter sequence for ebolavirus RNA synthesis 
initiation. Most nsNSVs have complementary genomic ends, however published 
ebolavirus sequences lack complementarity. We sequenced ebolavirus genomic termini 
and discovered the 3′ end has sequence variability and an overhang compared to the 5′ end 
of the replication product. Characterization of promoter sequence requirements for 
  x 
initiation revealed ebolavirus RdRp initiates internally (T2C) in contrast to most nsNSV 
RdRps, including RSV RdRp which initiates replication from T1U .  
We investigated the role of promoter sequence along with initiating NTPs for RSV 
RNA synthesis initiation. We showed that initiation by the RSV RdRp at T1U and T3C 
occurred independently of each other with the same RdRp selecting the two sites. Site 
selection could be modulated by the relative concentrations of ATP versus GTP. RSV 
template mutation analysis indicated the RdRp could bind ATP and CTP, or GTP, 
independently of template nucleotides. The data suggest a model in which the RdRps innate 
affinity for particular NTPs, coupled with a repeating sequence element within the 
promoter, allows precise initiation of replication at T1U or transcription at T3C.  
Other RNA virus polymerases utilize a priming residue to form base stacking 
interactions with the initiating NTP and stabilize the initiation complex. The RSV RdRp 
priming residue has not been described. Our data suggest RSV RdRp large subunit L 
proline 1261 is involved in initiation from T1U and T3C, but not RNA elongation. Alanine 
substitution analysis revealed the initiation defect at T3C, but not T1U, was partially 
rescued by increasing initiating NTP levels. These data suggest proline 1261 is the RSV 
priming residue and is more strictly required for terminal initiation (T1U) than internal 
initiation (T3C).  
The nsNSV have divergent initiation mechanisms and better understanding will aid in 
rational antiviral and vaccine design. 
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CHAPTER ONE: INTRODUCTION 
The nonsegmented negative-sense RNA viruses 
The nonsegmented negative-sense RNA viruses (nsNSVs) of the order Mononegavirales 
include the human pathogens: respiratory syncytial virus (RSV), Ebola virus (EBOV), 
Marburg virus (MARV), human parainfluenza virus 3 (HPIV3), Nipah virus (NiV), 
measles virus (MeV), and mumps virus (MuV). The order is organized into eleven families, 
though this is updated frequently as new viruses are sequenced and classified. Four of the 
most studied families include: Pneumoviridae, Filoviridae, Paramyxoviridae, and 
Rhabdoviridae. These viruses all utilize similar overall replication strategies, while also 
having developed distinct mechanistic details for viral replication. The work in this 
dissertation largely focuses on the RNA synthesis initiation mechanisms of the 
pneumovirus RSV, formally named Human orthopneumovirus, and the filovirus EBOV, 
Zaire ebolavirus. How these viruses relate to and illuminate the diversity of the nsNSVs 
will be discussed. 
Disease and intervention strategies 
Clinical significance and disease burden 
There are several human pathogens in the Mononegavirales order that have a significant 
impact on public health. RSV is the leading cause of lower respiratory tract infection in 
young children, infecting approximately 33 million children and resulting in approximately 
3.2 million hospitalizations globally each year (140). The majority of children are infected 
with RSV by the age of 2 (129). RSV also has a significant health impact on elderly 
populations (17). Ebola virus and Marburg virus, both filoviruses, have been shown to 
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cause disease in humans with case fatality rates of up to 90%. Before 2014, there were only 
about 2,000 total reported cases of Ebola virus disease (13). However, two more recent 
major outbreaks have occurred, one in West Africa from 2014-2016 resulting in 28,600 
cases and 11,325 deaths, and the second major outbreak currently ongoing in the 
Democratic Republic of the Congo, which began in 2018. 
Therapeutics 
As these viruses impact public health, work has been done to develop treatment and 
prevention therapies against infection. The humanized, monoclonal antibody Palivizumab, 
targets an epitope in the antigenic site of RSV fusion (F) protein, which is responsible for 
attachment and fusion (37). Palivizumab is the only licensed intervention for the prevention 
of severe respiratory disease caused by RSV for high-risk infants, including pre-term 
infants and those with bronchopulmonary dysplasia, chronic lung disease, and congenital 
heart disease (21, 92). Palivizumab prophylaxis does not prevent RSV infection, but 
diminishes the severity of the disease and results in fewer hospitalizations (28, 92, 142). 
However, Palivizumab is costly and access is limited in certain areas, making the 
development of other therapies necessary (127). Ribavirin has previously been indicated 
for treatment of severe cases of RSV infection. Ribavirin has been shown to have antiviral 
activity in tissue culture and in a cotton rat model (64, 65). However, there is limited 
evidence of benefit in patients and it is not generally recommended for treatment (35, 54, 
141). Several other therapies are currently being tested and developed for RSV infection. 
Many small molecule inhibitors are being developed including those targeting F protein 
fusion and entry, glycoprotein (G), nucleoprotein (N), and of particular interest the RSV 
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polymerase complex (5, 51). Several therapies for EBOV disease have also been under 
development, with a greater focus on antibody treatments. ZMapp is a cocktail of three 
mouse-human chimeric antibodies found to have some efficacy in clinical trials at the end 
of the West Africa EBOV disease outbreak (28). In addition, remdesivir or GS-5734, a 
nucleotide analogue, was in development and shown to be a chain terminator for EBOV 
polymerase as well as RSV polymerase (71, 89, 159). A clinical trial of new therapies 
performed in the 2018 Democratic Republic of the Congo outbreak indicated two 
monoclonal antibodies-based treatments, mAb114 and REGN-EB3, were more effective 
than the previously available treatments and are in use (46, 144). However, there is still a 
need for the development of additional treatment options and a better understanding of 
potential drug targets.  
 
The virus-encoded RNA dependent RNA polymerase (RdRp) performs all viral RNA 
synthesis activities including genome replication and viral mRNA transcription. This 
polymerase is unique in comparison to cellular proteins and is thus an excellent target for 
therapeutics. Gaining a better understanding of the mechanistic details of nsNSV 
polymerase activities aids in rational drug design and development of polymerase 
inhibitors. 
Vaccines 
Vaccine development for RSV has been delayed after a formalin inactivated RSV vaccine 
developed and tested in the 1960s, was found to result in enhanced disease in those who 
subsequently became infected with RSV (72, 76). This was due in part to formalin-
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mediated destruction of neutralizing epitopes (106). The vaccine induced antibodies with 
low avidity and low affinity and had poor affinity maturation and toll-like receptor (TLR) 
activation of B cells, leading to pathogenesis (30). The vaccine led to high levels of binding 
antibodies and complement fixation titers and resulted in immune complex deposition in 
small airways (4). In addition, a Th2-biased CD4+ T cell response was observed causing 
an infiltration of eosinophils into the peribronchial spaces (79). Further development of 
RSV vaccines has proceeded with caution, with a focus on live, attenuated vaccine 
candidates and maternal immunization. A live, attenuated RSV vaccine candidate is under 
development which is sufficiently attenuated in infants (74). This candidate has been 
shown to be immunogenic against RSV and does not cause enhanced respiratory disease 
as was previously seen in recipients of a formalin inactivated RSV vaccine (167). In 
addition, subunit vaccines of F and G proteins are being evaluated (143).  
 
Towards the end of the West Africa EBOV disease outbreak, a vaccination was tested in a 
ring vaccination strategy and shown to be an effective containment measure and has been 
authorized for marketing by the European Commission (58). The vaccine is based on a 
recombinant vesicular stomatitis virus (VSV) expressing EBOV glycoprotein (GP). This 
vaccine has been used in two following outbreaks, including the 2018 outbreak in the 
Democratic Republic of the Congo (166). In addition, a vaccine developed by Johnson & 
Johnson has been approved by the World Health Organization and the European 
Commission for use in the Democratic Republic of the Congo outbreak. 
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Overview of the virus replication cycle 
Virion structure 
The virus particles of nsNSVs vary greatly in morphology, from the predominantly 
spherical particles of Sendai virus (SeV), a paramyxovirus, to the filamentous particles of 
RSV and the filoviruses. There is a large range in particle size as well from approximately 
50 to 540 nm in diameter and exceeding 500 nm in length for the filamentous particles; 
with EBOV virions being an average of 982 nm in length (6, 87, 88, 90). The virus 
glycoproteins are embedded in the cell-derived lipid envelope. The number of 
glycoproteins vary among the different families. RSV contains G, F, and the small 
hydrophobic protein (SH) whereas EBOV contains a single type of glyclprotein, GP. The 
matrix protein (RSV M, EBOV VP40) forms a layer lining the inside of the virion envelope 
(57, 67, 139). It is thought the matrix proteins mediate assembly and budding of the virion 
at the cell membranes by associating with the viral nucleoprotein (RSV N, EBOV 
nucleoprotein NP) and inducing curvature of the membrane (34, 57, 67). The single-
stranded viral genomic RNA is encapsidated in nucleoprotein and packaged into the virion 
as a nucleocapsid. This is typically a single copy for the nsNSVs but there is evidence some 
virions package numerous nucleocapsids (7). The polymerase components, the large 
catalytic subunit L, polymerase co-factor phosphoprotein (P, RSV) or VP35 (EBOV), and 
the transcription processivity factor M2-1 (RSV) or transcription factor VP30 (EBOV) are 
associated with the nucleocapsid in the virion along with EBOV VP24 (34, 81, 139). 
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Cellular entry 
The nsNSVs enter cells by attachment to cellular receptors, fusion of the viral envelope 
with the cell membrane or with endosomal membranes following receptor-mediated 
endocytosis, and release of the nucleocapsid into the cytoplasm. Cellular entry can be 
broken down into two major processes: attachment which is mediated by binding between 
viral glycoproteins and cellular receptors, and fusion of the viral membrane with the 
cellular membrane mediated by the fusion protein. Viruses from different families, and 
even between genera of the nsNSVs have been shown to utilize different cellular receptors 
for attachment and have different mechanisms of entry. Despite efforts, receptors for many 
of these viruses have not been conclusively identified, likely complicated by the diversity 
of glycoproteins and cellular tropism by these viruses (23, 59, 68, 100). The nsNSVs have 
evolved divergent mechanisms of entry after attachment. For instance, the pneumovirus F 
protein alone is sufficient for attachment and fusion at the cell membrane (73), whereas the 
paramyxoviruses require both the glycoprotein and the fusion protein (132). The filoviruses 
enter the cell by macropinocytosis. Following endosomal trafficking in the cell, GP binds 
to the intracellular receptor Niemann-Pick C1 (NPC1) prior to fusion in the endosome (27). 
Regardless of the details of cellular entry, following release of the viral nucleocapsid into 
the cytoplasm viral transcription and genome replication can occur (Figure 1). 
RNA production and protein expression 
In the cytoplasm, inclusion bodies form and are thought to be sites of viral replication and 
transcription (19, 61, 134). Transcription is carried out by the virus-encoded RdRp to 
produce subgenomic capped and polyadenylated (polyA) mRNAs (164). The viral mRNAs 
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are translated by cellular machinery to produce the viral proteins. Genome replication, 
referred to hereafter as replication, is also performed by the RdRp to produce encapsidated 
negative-sense genomic RNA and the replication product, positive-sense antigenomic 
RNA (Figure 1).  
Assembly and release 
Assembly of viral particles occurs at the plasma membrane and is thought to be mediated 
by the matrix protein associating with lipid rafts at the plasma membrane, inducing 
curvature of the membrane, and association with the nucleocapsid (19, 34, 57, 67, 81, 139). 
Virions bud from the plasma membrane and the infected cell ultimately undergoes cell 
death. The nsNSV replication cycle is depicted in Figure 1 using RSV as an example 
(Figure 1). 
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Figure 1. Overview of the RSV replication cycle.(1) Attachment: RSV attaches to cell 
surface receptors using the F and G glycoproteins. (2) Entry: RSV enters the cell via fusion 
at the cell membrane, releasing nucleocapsids into the cytoplasm. (3) Transcription: the 
RSV polymerase transcribes the capped and polyadenylated viral mRNAs. (4) Protein 
synthesis: viral mRNAs are translated by cellular machinery to synthesize viral proteins. 
(5) Genome replication: the RSV polymerase uses the genome as a template to synthesize 
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the complementary antigenome replication intermediate, which is used as a template to 
synthesize additional copies of genomic RNA. Genome and antigenome are encapsidated 
by NP and form helical nucleocapsids. (6) Assembly and release: viral proteins traffic to 
the plasma membrane. Nucleocapsids and viral proteins are assembled at the cell surface, 
with glycoproteins inserted into the plasma membrane. Progeny virions bud from the 
plasma membrane. Not to scale. Glycoproteins SH, F, and G depicted in dark blue. M 
protein is shown in tan coating the virion envelope in black. NP encapsidating genome and 
antigenome shown in purple. Polymerase complex: L shown in light blue, P shown in red, 
M2-1 shown in green. Viral mRNA cap shown in yellow. A(n) represents polyA tail.  
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RNA synthesis 
Genome structure and organization 
The viruses of the order Mononegavirales have nonsegmented negative-sense RNA 
genomes and share common genome organization. The genomes of the different families 
of the order vary in length with RSV at ~15 kilobases (kb) and EBOV at ~19 kb. The 
genome is a template for both replication and transcription. The genomes contain several 
genes flanked by gene start (GS) and gene end (GE) sequences and separated by intergenic 
regions of varying lengths (8, 9, 84) . Some GE sequences overlap with the GS sequence 
of the next gene (3′ to 5′) and do not contain an intergenic region. The number of genes 
vary among the order’s families with 10 for RSV and 7 for EBOV (Figure 2). The genomes 
have two non-coding extragenic regions: the leader region (Le) at the 3′ end, and the trailer 
region (Tr) at the 5′ end, which contain cis-acting sequences involved in replication and 
transcription (41, 103, 113). 
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Figure 2. Schematics of RSV and EBOV genomes. The negative-sense genomes of RSV 
and EBOV are shown. The genomes are flanked by Le regions at the 3′ ends and Tr regions 
at the 5′ ends. GS and GE signals are shown as black and white bars, respectively. Genes 
are shown as blue boxes. RSV gene order: NS1, NS2, N, P, M, SH, G, F, M2, L. EBOV 
gene order: NP, VP35, VP40, GP, VP30, VP24, L. Non-coding regions including the Le, 
Tr, and intergenic regions are shown as a black horizontal line. L genes comprise ~40% of 
the total genome length and are thus interrupted by vertical black lines and not shown to 
scale. Le, Tr, GS, GE, and intergenic regions also not to scale.  
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Polymerase components 
The RdRp of the nsNSVs consist of a complex of two viral proteins, the well conserved 
~250 kDa large polymerase subunit (L) and a co-factor protein, which diverges in size and 
sequence between families (164). The pneumovirus co-factor is P while VP35 is the co-
factor for the filoviruses. L contains all the enzymatic domains required for genome 
replication and transcription and P/VP35 is an essential co-factor which assists L 
expression and association with the nucleocapsid (111). L and P/VP35 are the only two 
proteins essential for RNA synthesis, although some pneumoviruses and filoviruses require 
another viral protein as a transcription factor. This is the M2-1 transcription factor for RSV 
and VP30 for the filoviruses (20). VP30 is required for ebolavirus transcription and 
enhances but is not required for marburgvirus transcription (104, 105). 
Transcription 
Instead of accessing the genes internally, the nsNSV RdRps start transcription from a 
promoter near 3′ end of the genome and move along the genome transcribing each gene to 
synthesize subgenomic capped and polyadenylated mRNAs (113, 164). The polymerase 
re-initiates RNA synthesis at each gene junction by responding to a GS signal at the 3′ end 
of the viral genes, it then transcribes the gene, capping, methylating, and polyadenylating 
the mRNAs (10, 113, 153). Polyadenylation and release is signaled by the GE signal at the 
5′ end of the viral gene with the RdRp stuttering on the uridine (U) tract to generate the 
polyA tail (164). The polymerase scans to the GS signal of the next viral gene and 
synthesizes each of the subgenomic capped and polyadenylated mRNAs in this fashion 
(Figure 3) (33, 84). At each gene junction the polymerase may dissociate from the template 
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and as transcription relies on a single promoter at the 3′ end of the genome this results in a 
transcription gradient where the genes located at the 3′ end are transcribed more frequently 
than the genes located towards the 5′ end of the genome (1, 66, 164). It has been shown the 
RSV RdRp is recruited to and initiates transcription and replication from the same promoter 
within the Le region (22, 39, 99) but at two distinct sites (111, 113, 115). The RSV RdRp 
initiates transcription opposite template position 3 (T3) of the Le, synthesizes an ~25 nt Le 
transcript, releases the nascent RNA and scans to the first GS signal where it re-initiates 
RNA synthesis to transcribe the first viral mRNA (10, 113, 153). Conversely, evidence 
suggests the rhabdovirus VSV RdRp initiates transcription directly at the first GS signal 
and only initiates replication from the Le region (165). As yet, the mechanism of 
transcription initiation in the filoviruses is not known. 
Genome replication 
Genome replication is also carried about by the viral RdRp and utilizes a promoter at the 
3′ end of the Le. The RSV and VSV polymerases initiate replication at the 3′ end of the 
genome opposite template position 1 (T1), ignores the GS and GE signals, and synthesizes 
a full-length complementary RNA known as the antigenome or replication product (Figure 
3). The RdRp then uses the promoter at the 3′ end of the Trailer complement (TrC) on the 
antigenome to synthesize additional copies of the genome. The promoters within the Le 
and TrC are highly similar to each other. The pneumo- and rhabdoviruses contain a single 
promoter element (PE) within the Le and TrC regions of the genome (41, 161–163). 
However, the filo- and paramyxoviruses contain a bipartite promoter consisting of two PEs 
(62, 80, 148, 160). The first PE lies at the 3′ end of the Le region similar to pneumoviruses, 
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but the second PE is located within the 3′ untranslated region (UTR, negative-sense) of the 
first viral gene, downstream of the GS signal. This second PE is necessary for efficient 
replication in the filoviruses, but the effect on transcription is not well understood (160). 
The genomic and antigenomic RNA is concurrently encapsidated by N or NP protein 
during synthesis. N/NP monomers assemble end-to-end with adjacent N/NP monomers 
bound to the RNA to form the helical nucleocapsid. P/VP35 has been shown to interact 
with N/NP as well as L and is thought to bridge the interaction of the polymerase with the 
encapsidated RNA. The polymerase needs to displace the N/NP protein from the RNA to 
allow the RNA to enter the polymerase template channel and for RNA synthesis to occur. 
The template is presumably re-encapsidated following exit from the polymerase. A 5′ AC 
sequence has been shown to be important for the encapsidation of nascent RSV RNA 
products (112). Encapsidation is thought to protect the genomic and antigenomic RNA 
from cellular nucleases and prevent detection by cellular sensors.  
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Figure 3. Schematic of RSV genome replication and transcription.  The negative-sense 
genome is shown in the middle. The viral mRNAs are shown at the bottom with the cap 
represented by mG and the polyA tail represented by A(n). The positive-sense antigenome 
replication product is shown at the top. The TrC contains the promoter for replication from 
the antigenome (green arrow). The Le contains the promoter for replication from the 
genome (green arrow). 
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Scientific proposal 
As described in the introduction, the viral RdRp of the nsNSVs performs genome 
replication and transcription of the viral mRNAs during infection. The mechanisms of how 
the RdRps initiate RNA synthesis, and the differences in these mechanisms across the 
Mononegavirales order, is not well understood. The goal of the following studies was to 
gain a better understanding of the RNA synthesis initiation mechanisms of different 
nsNSVs. Work focused on the RdRps of RSV and EBOV, but how these results illuminate 
the molecular biology of the Mononegavirales order is discussed. Gaining a better 
understanding of these processes critical to viral replication is important to aid in rational 
drug design and vaccine development against these pathogens. In this dissertation, we 
specifically investigate the mechanism of RNA synthesis initiation and the factors involved 
for RSV in Chapters Three and Four, and the mechanism of initiation for EBOV in Chapter 
Five. In Chapter Three, we investigate the factors involved in directing the RSV 
polymerase to initiate genome replication and transcription at two distinct sites within the 
same promoter. In Chapter Four, we investigate the structural determinants of the RSV 
RdRp involved in stabilizing the formation of the initiation complex. In Chapter Five we 
determine the sequences of the ebolavirus genome ends, identify the replication initiation 
sites on the ebolavirus genomes, and analyze the sequence requirements for initiation of 
RNA synthesis.  
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Part one: Mechanism for de novo initiation at two sites in the respiratory syncytial virus 
promoter (Chapter Three) 
The nsNSV polymerases initiate RNA synthesis in a primer-independent (de novo) manner. 
RSV RdRp has previously been shown to initiate opposite the uridine at template position 
1 (T1U) as with most other nsNSVs for genome replication, however it also initiates 
internally opposite the cytidine at template position 3 (T3C) for transcription, in contrast 
to other nsNSVs. We investigated the factors affecting RSV genome replication and 
transcription initiation site selection and how a single promoter could direct the RSV RdRp 
to initiate RNA synthesis at two distinct sites. Specifically, we investigated the effect of 
modulating initiating nucleoside triphosphate (NTP) concentrations on initiation from both 
sites and whether the RdRp could bind initiating NTPs independently of template 
nucleotides as suggested previously (109, 112). 
Part two: The putative priming loop of the RSV polymerase is involved in coordinating 
the RNA synthesis initiation complex (Chapter Four) 
Work with other RNA virus polymerases has shown they utilize a priming residue to 
perform de novo initiation of RNA synthesis at position +1 of the promoters. In these cases, 
an aromatic or ring-based (proline/histidine) residue that extends into the central catalytic 
cavity of the RdRp is involved in the coordination of the initiation complex for RNA 
synthesis initiation, by forming base stacking interactions with the initiating NTP. We 
hypothesized the RSV RdRp has a ring-based residue that extends into the central catalytic 
cavity that is important for stabilizing the RNA synthesis initiation complex. We analyzed 
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potential priming residues in the RSV RdRp and investigated the requirements of the 
priming residue for initiation of replication and transcription. 
Part three: Ebolavirus polymerase uses an unconventional genome replication 
mechanism (Chapter Five) 
Most nsNSVs have complementary and nearly identical genomic ends. However, 
published ebolavirus genome sequences indicated a lack of complementarity. It is generally 
thought the nsNSV RdRps initiate replication from position +1 of the promoters. To better 
understand to details of ebolavirus RNA synthesis initiation, an accurate knowledge of 
genome terminal sequences was required. We sequenced ebolavirus genomic and 
antigenomic ends, determined the site(s) of ebolavirus RNA synthesis initiation, and 
examined the promoter sequence requirements for initiation. 
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CHAPTER TWO: MATERIALS & METHODS 
Gel recipes 
6% acrylamide 7M urea 1X TBE: Prepared by dissolving 42 g urea (Sigma Aldrich) in 15 
mL 40% AccuGel (19:1 acryl:bis-acryl) acrylamide (National Diagnostics), 10 mL 10X 
Tris(hydroxymethyl)aminomethane (Tris)/Borate/ethylenediaminetetraacetic acid 
(EDTA) (TBE) buffer (AmericaBio), and filled to 100 mL in MilliQ H2O. Filter-sterilized 
using a 0.2 μm pore size surfactant-free cellulose acetate (SFCA) membrane (Nalgene or 
Corning).  
 
8% acrylamide 7M urea 1X TBE: Prepared by dissolving 42 g urea in 20mL 40% AccuGel 
(19:1 acryl:bis-acryl) acrylamide, 10 mL 10X TBE, and filled to 100 mL in MilliQ H2O. 
Filter-sterilized using a 0.2 μm pore size SFCA membrane (Nalgene or Corning). 
 
20% acrylamide 7M urea 1X TBE: Prepared by dissolving 96.6 g urea in 105 mL 40% 
AccuGel (19:1 acryl:bis-acryl) acrylamide, 21 mL 10X TBE, and 16.8 mL MilliQ H2O. 
Filter-sterilized. Filter-sterilized using a 0.2 μm pore size SFCA membrane (Nalgene or 
Corning). 
 
25% acrylamide 7M urea 1X TTE: Prepared by dissolving 21.6 g urea in 37.5 mL 40% 
AccuGel (19:1 acryl:bis-acryl), 3 mL 20X Tris/Taurine/EDTA (TTE), and 3 mL MilliQ 
H2O. Filter-sterilized using a 0.45 μm pore size SFCA membrane (Nalgene or Corning). 
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Gel polymerization for 0.8 mm thickness gels: For every 55 mL of gel mix, 550 μL of 10% 
ammonium persulfate (APS) (Sigma-Aldrich), and 55 μL 1,2-Bis(dimethylamino)ethane; 
N,N,N’,N’-Tetramethyl-1,2-diaminoethane (TEMED) (Sigma-Aldrich) was added and 
gently swirled. Gels were cast and allowed to polymerize 1-2 hours at room temperature 
or overnight.  
 
Gel polymerization for 0.4 mm thickness gels: For every 30 mL of gel mix, 300 μL of 10% 
APS, and 6 μL TEMED was added and gently swirled. Gels were cast and allowed to 
polymerize 1-2 hours at room temperature or overnight. After running, gels were dried 
down at 80°C for 4 hours under vacuum seal.  
 
1.5% Agarose-formaldehyde gels (Northern blot analysis): Gels were prepared by 
dissolving 1.5 g agarose (Sigma-Aldrich) in 86.4 mL MilliQ H2O, then adding 10 mL 10X 
3-(N-morpholino)propanesulfonic acid (MOPS) buffer (American Bioanalytical) and 3.6 
mL 36.7% formaldehyde (Sigma-Aldrich).  
 
10% acrylamide gels with 4% stack: 10% gel mix was prepared by mixing 1.375 mL dH2O, 
1.875 mL 1M Tris pH 8.8 (Sigma-Aldrich), 25 μL 20% sodium dodecyl sulfate (SDS) 
(AmericanBio), 1.67 mL 30% Protogel (37.5:1 acryl:bis-acryl) (National Diagnostic), 30 
μL 10% APS, 6 μL TEMED and pour into plates until ~3/4 of the plate height. Add a layer 
of 100% isopropanol (AmericanBio) to even out gel mix and allow to polymerize for 30 
minutes. Remove isopropanol and rinse with MilliQ H2O. 4% gel mix was prepared by 
  
21 
mixing 3.66 mL MilliQ H2O, 0.625 mL 1M Tris pH 6.8, 25 μL 20% SDS , 0.66 mL 30% 
Protogel (37.5:1 acryl:bis-acryl) (National Diagnostic), 30 μL 10% APS, and 6 μL TEMED 
and added to the top of the 10% SDS acrylamide gel. Allowed to polymerize for 30 minutes 
before use. 
Cell culture 
BSRT7/5 cells (11) were cultured in Glasgow Minimal Essential Medium (GMEM) 
(Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Gibco), 1% GlutaMAX 
Supplement (Invitrogen), and 2% Minimal Essential Medium (MEM)-Amino Acids 
Solution (Gibco) under 1 mg/mL Geneticin (Gibco) selection on alternating passages. 
HEp-2 cells (ATCC CCL-23) were cultured in Opti-MEM Reduced Serum Medium 
(Gibco) supplemented with 2% FBS and 1% GlutaMAX Supplement. African green 
monkey kidney cells (Vero: ATCC-CRL 1586), human hepatocellular carcinoma cells 
(Huh7) (J. Alonso, Texas Biomedical Research Institute, San Antonio, TX), Egyptian fruit 
bat (Rousettus aegyptiacus) cells (R05T) (70), and human embryo kidney cells (HEK 
293T: ATCC-CRL-3216) were cultured in Dulbecco’s modified eagle medium (DMEM) 
(Invitrogen) supplemented with10% FBS (Gibco), 50 units/mL penicillin, and 50 mg/mL 
streptomycin. Sf21 cells (Gibco) were cultured in Sf-900 II serum-free medium (Gibco). 
BSRT7/5, HEp-2, Vero, Huh7, R05T, and HEK 293T cells were incubated at 37°C 5% 
CO2. For passaging, cells were washed in 1X phosphate buffered saline (PBS) (Sigma-
Aldrich) and disrupted with 0.25% Trypsin-EDTA (Gibco) and split twice per week. Sf21 
cells were grown in monolayer, suspension as shaker cultures at 125 rotations per minutes 
(rpm), or suspension as spinner flasks at 75 rpm and incubated at 26°C.  
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Virus infections 
Ebolavirus infections: EBOV human isolates Kikwit (GenBank: KR867676) and Mayinga 
(GenBank: AF086833), Reston virus (RESTV) macaque isolate Pennsylvania (GenBank: 
AY769362) and porcine isolate Philippines 2008 (GenBank: FJ621583), and Sudan virus 
(SUDV) human isolate Boniface (GenBank: FJ968794) stocks were grown in Vero cells. 
Virus titers were determined in VeroE6 cells by 50% tissue culture infectious dose 
(TCID50) assay for EBOV and SUDV, and focus-forming assay for RESTV. Cells seeded 
at 50–70% confluency in T75 or T150 flasks were infected with EBOV, RESTV, or SUDV 
at a multiplicity of infection (MOI) of 0.01 for EBOV and 0.001 for RESTV and SUDV, 
or mock infected. When the infected cells showed a significant cytopathic effect or 15 d 
post infection, supernatants containing viral particles were clarified by low-speed 
centrifugation (5,000 x g) before polyethylene glycol (PEG) precipitation of the viral 
particles (23). All work with infectious EBOV, RESTV, and SUDV was performed by Dr. 
Laure Deflubé-Owen in the biosafety level 4 (BSL-4) facility of the Integrated Research 
Facility, Rocky Mountain Laboratories, Division of Intramural Research, NIAID, NIH, 
Hamilton, MT following standard operating procedures approved by the Institutional 
Biosafety Committee (IBC). 
 
RSV infections: HEp-2 cells were infected with RSV A2 at an MOI of 3 or mock infected 
and incubated at 37°C for 0, 4, 8, 12, or16 hours. Total cellular RNA was isolated and 
purified as described below using TRIzol. 
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Plasmids 
Plasmids expressing RSV minigenomes used were previously described (109, 153). Non-
replicating minigenomes used were Le46G (wild-type (wt) Le promoter) and DM124 (TrC 
promoter) (41, 109). Plasmids required for RNA synthesis were pTM1 vectors containing 
open reading frames (ORFs) of the N (HG53), P (HG60), M2-1 (C32.2), and wt L (pBP31) 
RSV proteins expressed under the control of a T7 promoter (generously provided by Peter 
Collins, NIH and described previously (52)). The C75Δ plasmid was used to synthesize a 
negative-sense chloramphenicol acetyltransferase (CAT) riboprobe (124). The DM28 
plasmid was used to synthesis a positive-sense CAT riboprobe (99). pTM1-L plasmids 
containing mutations in the RSV L ORF were generated as described below. Plasmids 
expressing EBOV minigenomes p2,0 3E5E firefly luciferase (Fluc) and p2,0 3E5E 
enhanced green fluorescent protein (eGFP) were used as described previously (105, 136, 
154). Non-replicating EBOV minigenomes with mutations in the Le region were 
constructed as described below (29). Plasmids required for RNA synthesis were pTM1 
vectors containing ORFs of the NP, VP35, VP30, L, and L subunit catalytic mutant (Lsynth-
) EBOV proteins and were used as described previously (105, 107). RSV L (wt and D811A) 
and P ORFs in a pFastBacDual vector were used as described previously to generate 
recombinant baculoviruses for RSV polymerase expression (111). RSV mutant L ORFs 
were generated in the pFastBacDual plasmids as described below for expression in 
baculovirus systems. HPIV3 and MARV wt and mutant L ORFs were generated in the 
pFastBacDual plasmids as described below for expression in baculovirus systems. 
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Table 1. Plasmids. 
Name Use Source 
Le46G RSV non-replicating 
minigenome 
Fearns lab 
DM124 RSV non-replicating 
minigenome 
Fearns lab 
MP28 RSV CAT minigenome Fearns lab 
pTM1-L RSV (pBP31) RSV minigenome assays Peter Collins, NIH 
pTM1-L RSV FLAG RSV minigenome assays Generated by T.N.Cressey 
pTM1-N RSV (HG53) RSV minigenome assays Peter Collins, NIH 
pTM1-P RSV (HG60) RSV minigenome assays Peter Collins, NIH 
pTM1-M2-1 RSV (C32.2) RSV minigenome assays Peter Collins, NIH 
C75Δ Negative-sense CAT 
riboprobe synthesis 
Fearns lab 
DM28 Positive-sense riboprobe 
CAT synthesis 
Fearns lab 
pTM1-L EBOV EBOV minigenome assays Mühlberger lab 
pTM1-Lsynth- EBOV EBOV minigenome assays Mühlberger lab 
pTM1-L EBOV AUG EBOV minigenome assays Generated by T.N.Cressey 
pTM1-NP EBOV EBOV minigenome assays Mühlberger lab 
pTM1-VP35 EBOV EBOV minigenome assays Mühlberger lab 
pTM1-VP30 EBOV EBOV minigenome assays Mühlberger lab 
p2.0 3E5E firefly luciferase EBOV replicating 
minigenome 
Mühlberger lab 
p2.0 3E5E eGFP EBOV replicating 
minigenome 
Mühlberger lab 
3E’5E’ ΔCAT ΔTrΔGS 1G EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
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3E’5E’ firefly luciferase 
ΔTrΔGS 1G 
EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ ΔCAT ΔTr 1G EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ firefly luciferase 
ΔTr 1G 
EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ ΔCAT 1G EBOV replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ firefly luciferase 1G EBOV replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ ΔCAT ΔTrΔGS 1A EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ firefly luciferase 
ΔTrΔGS 1A 
EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ ΔCAT ΔTrΔGS 1C EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ firefly luciferase 
ΔTrΔGS 1C 
EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ ΔCAT ΔTrΔGS 1U EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ firefly luciferase 
ΔTrΔGS 1U 
EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ ΔCAT ΔTrΔGS 1Δ EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ firefly luciferase 
ΔTrΔGS 1Δ 
EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ ΔCAT ΔTrΔGS 
+GCCG 
EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ firefly luciferase 
ΔTrΔGS +GCCG 
EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
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3E’5E’ ΔCAT ΔTrΔGS 
+CCG 
EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ firefly luciferase 
ΔTrΔGS +CCG 
EBOV non-replicating 
minigenome 
Generated by T.N.Cressey 
3E’5E’ ΔCAT ΔTrΔGS 
1Δ2Δ 
EBOV non-replicating 
minigenome 
Mühlberger lab 
3E’5E’ ΔCAT ΔTrΔGS 
1Δ2U 
EBOV non-replicating 
minigenome 
Mühlberger lab 
3E’5E’ ΔCAT ΔTrΔGS 
1G2U 
EBOV non-replicating 
minigenome 
Mühlberger lab 
3E5E ΔCAT 1Δ2U firefly 
luciferase 
EBOV replicating 
minigenome 
Mühlberger lab 
3E5E ΔCAT 1G2U firefly 
luciferase 
EBOV replicating 
minigenome 
Mühlberger lab 
pBP24-L RSV RSV L fragment shuttle 
vector (KasI to SacII) 
Fearns lab 
pBP25-L RSV RSV L fragment shuttle 
vector (SacII to FseI) 
Fearns lab 
pBP24-L RSV F629A RSV L ORF shuttle vector Generated by T.N.Cressey 
pTM1-L RSV F629A RSV minigenome assays Generated by T.N.Cressey 
pBP24-L RSV F704A RSV L ORF shuttle vector Generated by T.N.Cressey 
pTM1-L RSV F704A RSV minigenome assays Generated by T.N.Cressey 
pBP24-L RSV W785A RSV L ORF shuttle vector Generated by T.N.Cressey 
pTM1-L RSV W785A RSV minigenome assays Generated by T.N.Cressey 
pBP25-L RSV P1261A RSV L ORF shuttle vector Generated by T.N.Cressey 
pTM1-L RSV P1261A RSV minigenome assays Generated by T.N.Cressey 
pTM1-L RSV FLAG 
P1261A 
RSV minigenome assays Generated by T.N.Cressey 
pFastBacDual-L-P RSV 
P1261A 
RSV L-P expression in 
baculovirus system 
Generated by T.N.Cressey 
pBP25-L RSV W1262A RSV L ORF shuttle vector Fearns lab (Sarah Noton) 
pTM1-L RSV W1262A RSV minigenome assays Fearns lab (Sarah Noton) 
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pTM1-L RSV FLAG 
W1262A 
RSV minigenome assays Generated by T.N.Cressey 
pFastBacDual-L-P RSV 
W1262A 
RSV L-P expression in 
baculovirus system 
Fearns lab (Sarah Noton) 
pBP25-L RSV W1262Y RSV L ORF shuttle vector Fearns lab (Sarah Noton) 
pTM1-L RSV W1262Y RSV minigenome assays Fearns lab (Sarah Noton) 
pFastBacDual-L-P RSV 
W1262Y  
RSV L-P expression in 
baculovirus system 
Fearns lab (Sarah Noton) 
pBP25-L RSV P1274A RSV L ORF shuttle vector Generated by T.N.Cressey 
pTM1-L RSV P1274A RSV minigenome assays Generated by T.N.Cressey 
pTM1-L RSV FLAG 
P1274A 
RSV minigenome assays Generated by T.N.Cressey 
pFastBacDual-L-P RSV 
P1274A 
RSV L-P expression in 
baculovirus system 
Generated by T.N.Cressey 
pBP25-L RSV Y1276A RSV L ORF shuttle vector Generated by T.N.Cressey 
pTM1-L RSV Y1276A RSV minigenome assays Generated by T.N.Cressey 
pTM1-L RSV FLAG 
Y1276A 
RSV minigenome assays Generated by T.N.Cressey 
pFastBacDual-L-P RSV 
Y1276A 
RSV L-P expression in 
baculovirus system 
Generated by T.N.Cressey 
pFastBacDual-L-P RSV wt RSV L-P expression in 
baculovirus system 
Fearns lab 
pFastBacDual-L-P RSV 
D811A 
RSV L-P expression in 
baculovirus system 
Fearns lab 
pFastBacDual-L-P HPIV3 
wt  
HPIV3 L-P expression in 
baculovirus system 
Fearns lab (Afzaal Shareef) 
pFastBacDual-L-P HPIV3 
D773A 
HPIV3 L-P expression in 
baculovirus system 
Fearns lab (Afzaal Shareef) 
pFastBacDual-L-P HPIV3 
P1213A 
HPIV3 L-P expression in 
baculovirus system 
Generated by T.N.Cressey 
pFastBacDual-L-P HPIV3 
Y1214A 
HPIV3 L-P expression in 
baculovirus system 
Generated by T.N.Cressey 
pFastBacDual-L-P HPIV3 
F1215A 
HPIV3 L-P expression in 
baculovirus system 
Generated by T.N.Cressey 
pFastBacDual-L-P MARV 
wt  
MARV L-P expression in 
baculovirus system 
Fearns lab (Afzaal Shareef) 
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pFastBacDual-L-P MARV 
D744A 
MARV L-P expression in 
baculovirus system 
Fearns lab (Afzaal Shareef) 
pFastBacDual-L-P MARV 
P1217A 
MARV L-P expression in 
baculovirus system 
Generated by T.N.Cressey 
pFastBacDual-L-P MARV 
Y1218A 
MARV L-P expression in 
baculovirus system 
Generated by T.N.Cressey 
pGEM T easy pTC1 Empty vector with KasI 
added 
Generated by T.N.Cressey 
pTC2 HPIV3 L shuttle HPIV3 L ORF shuttle 
vector (KasI to NsiI) 
Generated by T.N.Cressey 
pTC3 MARV L shuttle MARV L ORF shuttle 
vector in pGEM T easy 
(KasI to NheI) 
Generated by T.N.Cressey 
pCDNA3.0 3E5E firefly 
luciferase 
EBOV polII minigenome Mühlberger lab 
pCDNA3.0 3E5E +NheI 
firefly luciferase 
EBOV polII minigenome Generated by T.N.Cressey 
pCAGGS 3E5E firefly 
luciferase 
EBOV polII minigenome Generated by T.N.Cressey 
pCDNA3.0 3E5E eGFP EBOV polII minigenome Mühlberger lab 
pCDNA3.0 3E5E +NheI 
eGFP 
EBOV polII minigenome Generated by T.N.Cressey 
pCAGGS 3E5E eGFP EBOV polII minigenome Generated by T.N.Cressey 
 
Cloning 
Ligations: DNA fragments were ligated as described following, unless otherwise noted. 
Fragments were ligated using T4 DNA ligase (New England Biolabs), according to the 
manufacturer’s instructions. Ligation control reactions included separate ligations 
reactions without the ligase, without the vector fragment, or without the insert fragment. 
 
Transformations: Transformations were performed as described following, unless 
otherwise noted. NEBuilder Assembly reactions or 2 μL ligation reactions were 
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transformed into 50 μL DH10β E. coli (New England Biolabs) chemically competent cells 
by heat shock at 42°C for 30 seconds, chilled on ice for 5 minutes, and recovered after 
addition of 450 μL Super Optimal Broth with Catabolite repression (SOC) media incubated 
at 37°C for 1 hour shaking at 225 rpm. Transformants were selected using Lennox Luria 
Broth (LB) agar (Sigma Aldrich) plates containing 100 mg/mL carbenicillin (Fisher 
Scientific). Colonies were used to inoculate cultures in Terrific Broth (Fisher Scientific). 
Plasmids were purified using the QIAprep Spin Miniprep Kit (Qiagen), according to the 
manufacturer’s instructions.  
 
Plasmid clone screening: Restriction digests and sequencing (GENEWIZ) were done to 
confirm insert. Glycerol stocks were made (15% glycerol) and plasmids purified for 
transfections using the QIAGEN Hi-Speed Plasmid Midi Kit (Qiagen), according to the 
manufacturer’s instructions. 
 
Cloning of RSV mutant L genes for polymerase expression: pFastBacDual (Invitrogen) 
vectors containing wt or D811A L ORF and wt P ORF tagged with hexahistidine separated 
from the ORF by a Tobacco Etch Virus (TEV) protease cleavage site were generated as 
described previously (111). Dr. Sarah Noton generated pFastBacDual plasmids with wt 
RSV P and mutant RSV L genes coding for W1262A and W1262Y variant proteins. Other 
mutations were first generated in a shuttle vector (pBP24 or pBP25) fragment of the L gene 
in pGEM T easy shuttle vectors using site-directed mutagenesis and Q5 High-Fidelity 
DNA Polymerase (New England Biolabs) according to the manufacturer’s instructions. 
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These substitution mutations causing F629A, F704A, and W785A in pBP24 or P1261A, 
P1274A, and Y1276A in pBP25 substitutions in the L ORF were made in shuttle vectors 
using the primers described in Table 2. L gene fragments were assembled using NEBuilder 
HiFi DNA Assembly Cloning kit (New England Biolabs) according to the manufacturer’s 
instructions to insert the mutations into the full length L ORF in pFastBacDual. Following 
transformation, isolation, and clone screening, these plasmids were used to generate 
bacmids as described below. 
 
Cloning of RSV mutant L genes for use in minigenome assay: Mutant RSV L fragments in 
pGEM T easy shuttle vectors made as described above (insert), and pTM1-L wt (vector) 
were digested with SacII and FseI (New England Biolabs) at 37°C according to the 
manufacturer’s instructions. pTM1-L wt was also incubated with calf intestinal 
phosphatase (CIP) according to the manufacturer’s instructions. Fragments were gel 
extracted using the QIAquick gel extraction kit according to the manufacturer’s 
instructions.  
Table 2. Primers used in cloning. 
Name Sequence (5′ to 3′) Purpose 
TNC 1 CATGCCCGTCgccAACAGGCAG RSV L 
Y1276A Q5 
mutagenesis 
FWD 
TNC 2 GTCTTTTTTTCCTGGGTG RSV L 
Y1276A Q5 
mutagenesis 
REV 
TNC 7 CCAGGAAAAAAAGACCATGgccGTCTACAACAGG RSV L 
P1274A Q5 
mutagenesis 
FWD 
  
31 
TNC 8 GTGGAGGAGCCGACCCAGGGCTTAGTAGG RSV L 
P1274A Q5 
mutagenesis 
REV 
TNC 5 ACCTACTAAGgccTGGGTCGG RSV L 
P1261A Q5 
mutagenesis 
FWD 
TNC 6 CCCCTCTCGCCCCTGGTC RSV L 
P1261A Q5 
mutagenesis 
REV 
TNC 9 GGGCCGCATGgcCGCCATGCAG RSV L 
F629A Q5 
mutagenesis 
FWD 
TNC 
10 
ACGGACAGCTCGCGTTCC RSV L 
F629A Q5 
mutagenesis 
REV 
TNC 
11 
CCTGTCTAAGgcCAACCAGGCC RSV L 
F704A Q5 
mutagenesis 
FWD 
TNC 
12 
TCGGTGATGATGGAGCAC RSV L 
F704A Q5 
mutagenesis 
REV 
TNC 
13 
CCAGAAGCTGgcGACTATCGAGGCTATCAGC RSV L 
W785A Q5 
mutagenesis 
FWD 
TNC 
14 
CACCAGCCCTCGATGCCG RSV L 
W785A Q5 
mutagenesis 
REV 
KasI 
FWD 
CTGTCCATGCTGAGGGGCGCCTTCATCTACAG  pFastBacDua
l RSV L 
NEBuilder 
assembly 
pBP24 
SacII 
REV 
GCAGAGACTCGCCGCGGTATTCCAGTTCC  pFastBacDua
l RSV L 
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NEBuilder 
assembly 
pBP24 
SacII 
FWD 
GGAACTGGAATACCGCGGCGAGTCTCTGC  pFastBacDua
l RSV L 
NEBuilder 
assembly 
pBP25 
FseI 
REV 
CAGAATCCAGTGGCCGGCCAGGTTGGTA  pFastBacDua
l RSV L 
NEBuilder 
assembly 
pBP25 
TNC 
30  
ggcgccTGCATAGCTTGAGTATTCTATAGTG pGEM T 
easy KasI site 
insertion 
FWD 
TNC 
31 
GGATCCCACATGGGTGCA pGEM T 
easy KasI site 
insertion 
REV 
TNC 
32 
CCTGCGCGTGgCTTACTTTGG HPIV3 L 
P1213A Q5 
mutagenesis 
FWD 
TNC 
33 
CTGCTGACACCTGTCTCTG HPIV3 L 
P1213 Q5 
mutagenesis 
REV 
TNC 
34 
GCGCGTGCCTgcCTTTGGTTCAG HPIV3 L 
Y1214A Q5 
mutagenesis 
FWD 
TNC 
35 
AGGCTGCTGACACCTGTC HPIV3 L 
Y1214A Q5 
mutagenesis 
REV 
TNC 
36 
CGTGCCTTACgcTGGTTCAGTCACCGATGAG HPIV3 L 
F1215A Q5 
mutagenesis 
FWD 
TNC 
37 
CGCAGGCTGCTGACACCT HPIV3 L 
F1215A Q5 
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mutagenesis 
REV 
TNC 
38 
AAATAGAGCGgCATACATCGG MARV L 
P1217A 
FWD 
TNC 
39 
CCAATGGTCCATGCAAGTC MARV L 
P1217A 
REV 
TNC 
40 
TAGAGCGCCAgcCATCGGTTCAC MARV L 
Y1218A 
FWD 
TNC 
41 
TTTCCAATGGTCCATGCAAG MARV L 
Y1218A 
REV 
TNC 
43 
GATCCATGGGTACAGATTACAAGGATGACGACGATA
AGAGTACAGATTACAAGGATGACGACGATAAGAGT
ACCATG 
RSV L 
FLAG(2) 
insert  
TNC 
44 
GATCCATGGTACTCTTATCGTCGTCATCCTTGTAATC
TGTACTCTTATCGTCGTCATCCTTGTAATCTGTACCC
ATG 
RSV L 
FLAG(2) 
insert 
3057 CAGCGGGTTTAAACGGGCCCGCTAGCGAGTTCCGAT
CTAGGGAGCTC 
pCDNA3.0 
3E5E NheI 
insert 
3058 GAGCTCCCTAGATCGGAACTCGCTAGCGGGCCCGTT
TAAACCCGCTG 
pCDNA3.0 
3E5E NheI 
insert 
3059 CAGGTCGGACCGCGAGGAGG 3E’5E’ 
shortened Le 
amplification 
FWD 
3060 GCGCATATGTGATTACAGTAACAATTTCAATTTAAA
TTCCG 
3E’5E’ 
shortened Le 
amplification 
REV 
3061 GGCGGCCGCAGACTAGATAATAATCTTCG 3E’5E’ 
shortened Tr 
amplification 
FWD 
3062 GCGCATCGATCGAAATTAATACGACTCAC 3E’5E’ 
shortened Tr 
amplification 
REV 
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3078 CATATGAAGATCTCATGGGCAAATATTATACGCAAG
GCGACAAGG 
ΔCAT 
reporter gene 
FWD 
3079 GCGGCCGCCCATGGGCAGTTACGCCCCGCCCT ΔCAT 
reporter gene 
REV 
 
Cloning of HPIV3 mutant L genes for polymerase expression: Afzaal Shareef generated 
pFastBacDual (Invitrogen) vectors containing wt or D773A HPIV3 (accession number 
NC_001796.2) L ORF tagged with FLAG on the N-terminus and wt P ORF tagged with 
hexahistidine separated from the ORF by a TEV protease cleavage site on the C terminus. 
pGEM T easy plasmid was modified to introduce a KasI restriction site into the multiple 
cloning site. This was generated using Q5 site-directed mutagenesis according to the 
manufacturer’s instructions. pGEM T easy modified and pFastBacDual HPIV3 wt was 
digested with KasI and NsiI (New England Biolabs) and Cutsmart Buffer (New England 
Biolabs) for ~3 hours at 37°C. Fragments were purified using QIAquick Gel Extraction Kit 
(Qiagen) according to the manufacturer’s instructions. Fragments were ligated, 
transformed, isolated, and screened as described above. The shuttle vector containing the 
L fragment was used as a template to generate mutations in L for P1213A, Y1214A, and 
F1215A substitutions in the L ORF using Q5 site-directed mutagenesis according to the 
manufacturer’s instructions. To generate pFastBacDual plasmids containing the above 
mutations: P1213A, Y1214A, and F1215A shuttle vectors and pFastBacDual wt were 
digested with KasI and NsiI and Cutsmart Buffer (New England Biolabs) for ~3 hours at 
37°C. Digested pFastBacDual wt was incubated CIP (New England Biolabs) for 1 hour at 
37°C. Fragments were purified using QIAquick Gel Extraction Kit (Qiagen) according to 
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the manufacturer’s instructions. Fragments were ligated, transformed, isolated, and 
screened as described above. 
 
Cloning of MARV mutant L genes for polymerase expression: Afzaal Shareef generated 
pFastBacDual (Invitrogen) vectors containing wt or D744A MARV (accession number 
NC_001608) L ORF tagged with HA separated from the ORF by a TEV protease cleave 
site at the N-terminus and wt P ORF tagged with hexahistidine separated from the ORF by 
a TEV protease cleavage site at the C-terminus. pGEM T easy modified and pFastBacDual 
MARV wt was digested with KasI and NheI (New England Biolabs) and Cutsmart Buffer 
(New England Biolabs) for ~3 hours at 37°C. Fragments were purified using QIAquick 
Gel Extraction Kit (Qiagen) according to the manufacturer’s instructions. Fragments were 
ligated using T4 DNA ligase (New England Biolabs), according to the manufacturer’s 
instructions to insert L fragment from KasI to NheI sites into pGEM T easy to generate a 
shuttle vector. Ligation reactions were transformed, isolated, and screened as described 
above. The shuttle vector containing the L fragment was used as a template to generate 
mutations in L for P1217A and Y1218A substitutions in the L ORF using Q5 site-directed 
mutagenesis according to the manufacturer’s instructions. To generate pFastBacDual 
plasmids containing the above mutations: P1217A and Y1218A shuttle vectors and 
pFastBacDual wt were digested with KasI and NsiI and Cutsmart Buffer (New England 
Biolabs) for ~3 hours at 37°C. Digested pFastBacDual wt was incubated with CIP (New 
England Biolabs) for 1 hour at 37°C. Fragments were purified using QIAquick Gel 
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Extraction Kit (Qiagen) according to the manufacturer’s instructions. Fragments were 
ligated, transformed, isolated, and screened as described above. 
 
Cloning of mutant Le EBOV minigenomes: Minigenome mutants were generated based on 
the negative-sense EBOV minigenome 3E5E (105) as described previously (29). To 
optimize antiminigenome detection in the Northern blot analysis, the minigenome was 
shortened from its original length of 1879 nt to 505 nt. In the shortened minigenome, the 
trailer region contains the 129 terminal nucleotides of the EBOV Mayinga genome 
sequence and is flanked by a hammerhead ribozyme (HH) (107). The Le region is identical 
to minigenome 3E5E and is fused to a truncated version of the CAT reporter gene (ΔCAT, 
the CAT2 fragment from (41)). Precise 3′ ends are generated by hepatitis delta virus 
ribozyme (HdV) activity (105). To construct single-cycle replication minigenomes, the 
terminal 25 nucleotides of the Tr were removed (120). This had two effects, first it deleted 
the promoter at the 3′ end of the antigenome, preventing production of newly synthesized 
genome RNA; it also inactivated a hammerhead ribozyme positioned between the Tr and 
the T7 promoter, so that the minigenome contained an irrelevant 5′ addition that did not 
resemble the EBOV promoter. To destroy the EBOV-specific GS signal required to initiate 
transcription (103), uridine residues 57, 60, and 61, which are located within the conserved 
GS signal, were substituted with adenosine (ΔGS) (numbers refer to EBOV Mayinga 
sequence, GenBank AF086833). 
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Cloning of EBOV minigenomes (shortened Le): The terminal 128 nucleotides of the Le 
sequence was amplified from pCDNA3.0 3E5E eGFP and pCDNA3.0 3E5E eGFP ΔGS 
from the RsrII site within the HdV ribozyme to the 128th nucleotide of the leader using 
primers 3059 and 3060 and Pfu HotStart polymerase (Agilent). Primer 3060 introduced an 
NdeI site at the end of the leader sequence. Polymerase chain reaction (PCR) products were 
purified using QIAquick PCR purification kit, digested with RsrII and NdeI, and gel 
extracted using QIAquick gel extraction kit according to the manufacturer’s instructions. 
p2,0 3E5E Fluc was digested with RsrII and NdeI to remove the full-length Le sequence 
and incubated with CIP and gel extracted using QIAquick gel extraction kit according to 
the manufacturer’s instructions. Digested PCR products were ligated with digested vector 
using T4 DNA ligase (New England Biolabs), according to the manufacturer’s instructions 
to generate p2,0 3E’5E Fluc and p2,0 3E’5E ΔGS Fluc. Ligation reactions were 
transformed into New England Biolabs Turbo Competent E. coli (New England Biolabs. 
Plasmids were isolated, and screened as described above. Glycerol stocks were made and 
plasmids purified for transfections using the QIAGEN Plasmid Maxi Kit (Qiagen), 
according to the manufacturer’s instructions. 
 
Cloning of EBOV minigenomes (shortened Tr): The terminal 129 nucleotides of the Tr 
sequences was amplified from pCDNA3.0 3E5E eGFP and pCDNA3.0 3E5E eGFP ΔTr 
from the 129th nucleotide from the terminus (numbering according to wt, not truncated 
sequence) to the ClaI site outside the T7 promoter using primers 3061 and 3062. Primer 
3061 introduces a NotI site upstream of the 129th nucleotide. PCR products were purified 
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using QIAquick PCR purification kit, digested with NotI and ClaI, and gel extracted using 
QIAquick gel extraction kit according to the manufacturer’s instructions. p2,0 3E’5E Fluc 
and p2,0 3E’5E Fluc ΔGS with NotI and ClaI and incubated with CIP according to the 
manufacturer’s instructions. Vector fragment was gel extracted using the QIAquick gel 
extraction kit to remove the full-length Tr region. Digested PCR fragments and vector were 
ligated using T4 DNA ligase (New England Biolabs), according to the manufacturer’s 
instructions to generate p2,0 3E’5E’ Fluc 1G, p2,0 3E’5E’ Fluc ΔTr 1G, and p2,0 3E’5E’ 
Fluc ΔTrΔGS 1G.  
 
Cloning of mutant Le EBOV firefly luciferases minigenomes with shortened leader and 
trailer: PCR fragments containing mutations corresponding to the 3′ terminus of the Le 
were generated by PCR amplification using primers 3059 and 3060 Pfu HotStart 
polymerase (Agilent) as described above and pCDNA3.0 3E5E eGFP ΔTrΔGS 1A Δ1, 1C, 
+GCCG, and +CCG as templates. PCR products were purified using QIAquick PCR 
purification kit, digested with RsrII and NdeI, and gel extracted using QIAquick gel 
extraction kit according to the manufacturer’s instructions. p2,0 3E’5E Fluc ΔTrΔGS 1G 
was digested with RsrII and NdeI, incubated with CIP, and gel extracted according to the 
manufacturer’s instructions. Digested PCR products were ligated with digested vector 
using T4 DNA ligase (New England Biolabs), according to the manufacturer’s instructions 
to generate p2,0 3E’5E’ Fluc ΔTrΔGS 1A Δ1, 1C, +GCCG, and +CCG. Ligation reactions 
were transformed into New England Biolabs Turbo Competent E. coli (New England 
Biolabs). Plasmids were isolated, and screened as described above. Glycerol stocks were 
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made and plasmids purified for transfections using the QIAGEN Plasmid Maxi Kit 
(Qiagen), according to the manufacturer’s instructions. 
 
Cloning of mutant Le EBOV minigenomes with ΔCAT reporter gene: To replace the Fluc 
reporter gene from p2,0 3E’5E’ Fluc minigenomes with ΔCAT, minigenome plasmids 
were digested with NdeI and NotI, incubated with CIP, and gel extracted according to the 
manufacturer’s instructions. ΔCAT was amplified from MP28 (124) using primers 3078 
and 3079 Pfu HotStart polymerase (Agilent). Primer 3078 introduces and NdeI site. Primer 
3079 introduces NcoI and NotI sites. PCR product was purified using QIAquick PCR 
purification kit, digested with NdeI and NotI, and gel extracted using QIAquick gel 
extraction kit according to the manufacturer’s instructions. Digested PCR products were 
ligated, transformed, isolated, and screened as described above to generate p2,0 3E’5E’ 
ΔCAT 1G, p2,0 3E’5E’ ΔCAT ΔTr 1G, and p2,0 3E’5E’ ΔCAT ΔTrΔGS 1G, 1A Δ1, 1C, 
+GCCG, and +CCG. Glycerol stocks were made and plasmids purified for transfections 
using the QIAGEN Plasmid Maxi Kit (Qiagen), according to the manufacturer’s 
instructions. 1Δ2Δ, 1G2U, 1Δ2U EBOV minigenomes (Figure 45) were generated by Dr. 
Adam Hume. 
 
Cloning of RNA polymerase II (polII) EBOV minigenome: The sequence of the 3E5E 
minigenome (105) was previously inserted into vector pcDNA3 under the control of the 
CMV promoter (107). An NheI restriction site was inserted in the pcDNA3-based 
minigenomes upstream of the HDV ribozyme sequence using Gibson Assembly (New 
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England Biolabs) and annealed oligos as described below. Oligos were designed to create 
an insert to introduce an NheI site between the ApaI and EcoRI sites in pCDNA3 3E5E 
using complementary sequences and Gibson Assembly (New England Biolabs). 10 μM 
oligo 3057 and 10 μM oligo 3058 were annealed in 1X T4 DNA ligase buffer (New 
England Biolabs) at 95°C for 5 minutes and temperature was decreased at a rate of 
5°C/minute until it reached 25°C. pCDNA3 3E5E polII was digested with ApaI in 1X 
Cutsmart Buffer (New England Biolabs) at 25°C for 1 hour. pCDNA 3E5E polII was 
further digested with EcoRI at 37°C for 1 hour and purified using QIAquick PCR 
Purification Kit (Qiagen). Digested vector and annealed oligos were incubated in 1X 
Gibson Assembly Master Mix (New England Biolabs) according to the manufacturer’s 
instructions. Assembly reactions were ligated, transformed in New England Biolabs Turbo 
E. coli competent cells, isolated, and screened as described above. To create a pCAGGS 
version of the polII minigenome, both the pCDNA 3E5E eGFP and firefly luciferase 
minigenome plasmids with added NheI site (generated as described above) and pCAGGS 
empty vector were digested with NheI (New England Biolabs) in 1X Cutsmart Buffer (New 
England Biolabs) at 37°C for 3 hours. Digested fragments were purified by gel extraction 
using the QIAquick gel extraction kit (Qiagen) according to the manufacturer’s 
instructions. Digested insert containing the minigenome and pCAGGS empty vector were 
ligated using T4 DNA ligase (New England Biolabs), according to the manufacturer’s 
instructions. Ligations were transformed in New England Biolabs Turbo competent E. coli 
cells, isolated, and screened as described above. Glycerol stocks were made and plasmids 
purified for transfections using the QIAGEN Plasmid Maxi Kit (Qiagen), according to the 
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manufacturer’s instructions. This generated the RNA polymerase II 3E5E eGFP and firefly 
luciferase minigenomes in the pCAGGS plasmid backbone under control of the CAG 
promoter, which was used in (107). 
 
Cloning of FLAG(2) tagged L genes: A FLAG(2) tag 
(GTDYKDDDDKSTDYKDDDDKST) was added to the N terminus of the L ORF in 
pTM1-L RSV to confirm expression of wt and variant L proteins in BSRT7/5 in 
minigenome assays. RSV pTM1-L wt was digested with BamHI-HF (New England 
Biolabs) in 1X Cutsmart buffer and incubated at 37°C for 3 hours. RSV pTM1-L wt was 
further incubated with CIP (New England Biolabs) for 1 hour at 37°C. Digested RSV 
pTM1-L wt was gel extracted using QIAEX II Gel Extraction Kit (Qiagen) according to 
the manufacturer’s instructions. The FLAG(2) insert with BamHI compatible ends was 
made by annealing 10 μM each oligo TNC 43 and TNC 44 in annealing buffer at 95°C for 
5 minutes and temperature was decreased at a rate of 5°C/minute until it reached 25°C. The 
annealed oligos were ligated with digested RSV pTM1-L wt using T4 DNA Ligase (New 
England Biolabs) according to the manufacturer’s instructions. pTM1-L wt FLAG(2) was 
purified using the QIAprep Spin Miniprep Kit (Qiagen), according to the manufacturer’s 
instructions. Restriction digests and sequencing were done to confirm insert. To insert the 
FLAG(2) tag into RSV pTM1-L mutant plasmids (P1261A, W1262A, P1274A, Y1276A), 
all plasmids were digested with XhoI and SacII (New England Biolabs) in 1X Cutsmart 
buffer at 37°C for 1 hour. RSV pTM1-L wt FLAG(2) was further incubated with CIP for 
1 hour at 37°C. The 8.1 kb band from digested RSV pTM1-L wt FLAG(2) and 3.7 kb from 
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RSV pTM1-L P1261A, W1262A, P1274A, Y1276A were gel extracted using the 
QIAquick gel extraction kit (QIAGEN) according to the manufacturer’s instructions. 
Fragments were ligated, transformed, isolated, and screened as described above. 
Making Chemically Competent cells 
A 200 mL bacto tryptone broth (combine 5 g yeast extract, 20 g tryptone, 5 g magnesium 
sulfate in 1000 mL pH 7.6). DH10β E. coli culture was started from a 2 mL starter culture 
and incubated at 37°C shaking at 225 rpm. Culture growth was stopped when the 
Absorbance at 600 nm reached 0.600. Cells were chilled for approximately 15 minutes on 
ice then harvested by centrifugation at 3724 x g for 5 minutes at 4°C. Media was discarded 
and cells were resuspended in 10 mL TFB I (30 mM potassium acetate, 100 mM rubidium 
chloride, 10 mM calcium chloride, 50 mM manganese chloride, 15% glycerol (v/v), pH 
5.8) and diluted to 80 mL with sterile MilliQ H2O. After incubation on ice for 5 minutes, 
cells were centrifuged at 3724 x g for 5 minutes at 4°C. Buffer was discarded and cells 
were resuspended in 8 mL TFB II (10 mM MOPS, 75 mM calcium chloride, 10 mM 
rubidium chloride, 15% glycerol (v/v), pH 6.5). After incubation on ice for 15 minutes cells 
were aliquoted and flash frozen using a dry ice ethanol bath and stored at -80°C.  
PAGE purification and deprotection of RNA oligonucleotides 
Gel preparation: 20% acrylamide 7M urea 1X TBE gels with 0.75 mm spacers were made. 
22 mL of appropriate gel mix was polymerized with 220 μL 10% APS and 6 μL TEMED. 
Gels were allowed to polymerize for at least one hour. Gels were pre-run for 30 minutes at 
10W in 1X TBE running buffer. 
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RNA preparation: RNA was diluted to 3 μg/μl and mixed 1:1 with 2X STOP buffer (1.2 
mL 95% deionized formamide (AmericanBio), 20 mM UltraPureTM EDTA (Invitrogen), 
0.1% w/v bromophenol blue (BPB) (Sigma Aldrich), 0.1% w/v xylene cyanol (XC) (Sigma 
Aldrich) and incubated at 95°C for 5 minutes. 30-45 μg RNA was loaded per well (~20-30 
μL) and the gel was run at 10W until bromophenol blue is approximately ¾ of the gel 
height from the top. Gel was placed on plastic wrap on a thin-layer chromatography (TLC) 
PEI cellulose F coated sheet (Fischer Scientific). RNA bands were located by ultraviolet 
(UV) shadowing in a dark area, portions of gel containing RNA were cut out using a razor 
blade and transferred to 1.5 mL microcentrifuge tubes. 
  
Solubilize the gel fragments: The gel fragments were crushed thoroughly with a 1 mL filter-
tip into a fine white powder. 900 μL 0.3M sodium-acetate, pH 5.2 (Thermo Fischer 
Scientific) was added to the crushed acrylamide and samples were rocked overnight at 4°C. 
   
Purify RNA: Samples were centrifuged at 16,100 x g for 10 minutes at 4°C. Two tubes 
were prepared for each sample with 8 μL glycogen (5 mg/mL) (Invitrogen) and 10 μL 4M 
sodium chloride (NaCl) (Sigma Aldrich). Samples were split into two 400 μL fractions and 
added to the prepared tubes containing glycogen and NaCl, avoiding pipetting the 
acrylamide. 1 mL of 100% ethanol was added to the samples. Samples were vortexed for 
30 seconds and then stored at -20°C overnight. For maximum recovery, an additional 900 
μL of 0.3M sodium-acetate, pH 5.2 was added to the acrylamide to perform a second 
elution. The second elution samples were rocked for several hours at 4°C. Centrifugation 
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and precipitation of RNA was repeated as described above for the second elution. Samples 
were centrifuged at 16,100 x g or 30 minutes at 4.0°C. Supernatant as discarded and pellets 
were washed three times in 1 mL 70% ethanol, combining two pellets at each wash. 
Samples were centrifuged at 16,100 x g for 5 minutes at 4°C for each wash. The final RNA 
pellet was air-dried for 10-15 minutes. 
  
Deprotection of 2′ ACE protected RNA: 400 μl of 2′ deprotection buffer (Dharmacon) was 
added to each tube of RNA and pellets were resuspended. Samples were incubated at 60°C 
for 20 minutes. Samples were lyophilize using a SpeedVac system (Savant, AES1010) to 
dryness. Pellets were resuspended in 50 μL RNase-free dH2O. Final samples were 
centrifuged at max speed for 5 minutes at 4°C and transferred to a fresh tube to remove any 
residual acrylamide. RNA concentrations were determined using a NanoDrop 2000 UV-
Vis spectrophotometer (Thermo Fisher Scientific). If RNA samples were ordered high 
performance liquid chromatography (HPLC) or polyacrylamide gel electrophoresis 
(PAGE) purified, RNA was only deprotected. 
Radiolabeling of oligonucleotides 
5′-end labelling of RNA or DNA oligos with 32P: 2 μL 10 μM (2 μM) RNA or DNA oligo 
was mixed with 1 μL 10X polynucleotide kinase (PNK) buffer (New England Biolabs), 3 
μL RNase-free dH2O, 3 μL [γ-32P]-ATP or [γ-32P]-GTP (3000 Ci/mmol or 6000 Ci/mmol) 
(Perkin Elmer), and 1 μL T4 PNK (New England Biolabs) in a total volume of 10 μL. 
Reactions were incubated at 37°C for 20-30 minutes. 90 μL RNase-free H2O was added to 
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reactions to be used in primer extension analysis. Labelled oligonucleotides were stored at 
-20°C. 
 
Labelling and alkaline hydrolysis of RNA oligonucleotides to make RNA ladders for in 
vitro RNA synthesis assays: 5 μL 100 μM (2 μM) RNA oligo corresponding to Tr 1-25, Tr 
3-25, Le complement (LeC) 1-14, or LeC 1-14 was mixed with 1 μL 10X PNK buffer (New 
England Biolabs), 3 μL [γ-32P] ATP or 3 μL [γ-32P] GTP (3000 curies (Ci)/mmol or 6000 
Ci/mmol) (Perkin Elmer), and 1 μL T4 PNK (New England Biolabs) in a total volume of 
10 μL. Reactions were incubated at 37°C for 30 minutes. 0.6 μL yeast transfer ribonucleic 
acid (tRNA) (9.4 mg/mL) (Sigma Aldrich) and 20 μL alkaline hydrolysis buffer (50 mM 
sodium carbonate pH 9.2, 1 mM EDTA) were added to the 10 μL labelling reaction on ice 
and mixed. 6 μL of the RNA buffer mixture was added to each of 5 tubes. The tubes were 
incubated at 95°C. One tube each was transferred to ice after a total of 2, 3, 4, 5, and 6 
minutes incubation and 6 μL 2X STOP buffer was added. Ladders were heated to 95°C for 
5 minutes and 0.5 μL each sample was run on a 20% acrylamide 7M urea 1X TBE gel. Gel 
was exposed for 15-45 minutes to film at room temperature. The ladder fractions which 
combined would yield an approximately even distribution of all RNA bands were 
combined and used as markers in the in vitro RNA synthesis assays. 
 
Northern riboprobe synthesis: Plasmid DM28 was used to synthesize riboprobe to detect 
negative-sense CAT minigenomes. DM28 was digested with PstI (New England Biolabs) 
and purified with the Qiagen gel extraction kit. Plasmid C75Δ was used to synthesize 
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riboprobe to detect positive-sense CAT mRNA and anti-minigenome. C75Δ was digested 
with XbaI (New England Biolabs) and purified with the Qiagen gel extraction kit. 
Riboprobes were synthesized by mixing 2.5 μL 10X RNA pol buffer (New England 
Biolabs), 2.5 μL 100 mM dithiothreitol (DTT), 1 μL murine RNase inhibitor (New England 
Biolabs), 2.5 μL ribonucleoside triphosphate (rNTP) mix (0.5 mM rNTP used as the radio-
label, 2.5 mM all other rNTPs), 10 μL [α-32P]  rNTP (3000 Ci/mmol) (Perkin Elmer), 500 
digested gel extracted plasmid, 2 μL T7 RNA polymerase (New England Biolabs), RNase-
free H2O to a total volume of 25 μL. Reactions were incubated at 37°C for 1 hour. 2 μL 
deoxyribonuclease (DNase) I (New England Biolabs) was added and incubated at 37°C for 
10 minutes. 1 μL 0.5 M EDTA and 25 μL ribonuclease (RNase) -free H2O was added. 54 
μL acid phenol:chloroform (5:1) (Invitrogen) was added, mixed by vortexing, and briefly 
centrifuged to separate the upper aqueous phase containing riboprobe. Columns were 
prepared in 1 mm syringes plugged with glass wool (Acros Organic, Fischer Scientific) 
and filled to 1 mL with G-50 Sephadex beads (Fischer Scientific) in Tris-EDTA (TE) 
buffer. Columns were washed twice with TE. Upper aqueous phase was added to the 
column and fraction collected. 100 μL TE was added for an additional seven fraction 
collections. Fractions 5-8 typically contained the labelled probe, confirmed using a Geiger-
Mueller counter, and were pooled and stored at -20°C.  
Transfections 
RSV pTM1-based minigenome in BSRT7/5 cells: BSRT7/5 cells were seeded at 4 x 105 
cells/well in a 6 well plate. The next day when cells were ~70% confluent, the cells were 
transfected using Lipofectamine 2000 (Thermo Fisher Scientific). Each well was 
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transfected with 100 ng pTM1-L , 400 ng pTM1-N, 500 ng pTM1-P, 100 ng pTM1-M2-1, 
and 200 ng minigenome plasmid unless otherwise indicated. 150 μL OptiMEM and DNA 
were added to polystyrene tubes, vortexed 3 times briefly, and incubated at room 
temperature for 5 minutes. 8 μL Lipofectamine 2000 was combined with 100 μL OptiMEM 
for each well, vortexed 3 times briefly, and incubated at room temperature for 5 minutes. 
108 μL of Lipofectamine 2000/OptiMEM mix was added to DNA/OptiMEM, vortexed 3 
times briefly, and incubated at room temperature for 20 minutes. BSRT7/5 cells were 
washed with OptiMEM and 0.75 mL OptiMEM was added. Transfection mix was added 
to BSRT7/5 cells and incubated for 6 hours or overnight at 37°C, 5% CO2. 0.5 mL 
OptiMEM containing 6% FBS was added for a final FBS 2% concentration and cells were 
incubated at 37°C, 5% CO2. 2 days after transfection, cells were harvested as described 
below. 
 
Transfections to confirm variant RSV L expression using FLAG(2) tagged L variants: A 
FLAG(2) tag was added to the N-terminus of the P1261A, W1262A, P1274A, and Y1276A 
L variants in the T7 expression vector as described above. BSRT7/5 cells were seeded at 4 
x 105 cells/well in a 6 well plate. The next day when cells were ~70% confluent, the cells 
were transfected using Lipofectamine 2000 (Thermo Fisher Scientific). Each well was 
transfected with 1 μg pTM1-L FLAG(2) (wt, P1261A, W1262A, P1274A, Y1276A or no 
L plasmid) and 2 μg pTM1-P. 150 μL OptiMEM and DNA were added to polystyrene 
tubes, vortexed 3 times briefly, and incubated at room temperature for 5 minutes. 8 μL 
Lipofectamine 2000 was combined with 100 μL OptiMEM for each well, vortexed 3 times 
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briefly, and incubated at room temperature for 5 minutes. 108 μL of Lipofectamine 
2000/OptiMEM mix was added to DNA/OptiMEM, vortexed 3 times briefly, and 
incubated at room temperature for 20 minutes. BSRT7/5 cells were washed with OptiMEM 
and 0.75 mL OptiMEM was added. Transfection mix was added to BSRT7/5 cells and 
incubated for 6 hours at 37°C, 5% CO2. 0.5 mL OptiMEM containing 6% FBS was added 
for a final FBS 2% concentration and cells were incubated at 37°C, 5% CO2. 2 days after 
transfection, cells were harvested as described below. 
 
EBOV pTM1-based single-round replicating, non-transcribing minigenome assay: 
BSRT7/5 cells were seeded at 4 x 105 cells/well in a 6 well plate. The next day when cells 
were ~70% confluent, the cells were transfected using Lipofectamine LTX with PLUS 
Reagent (Thermo Fisher Scientific). Each well was transfected with 100 ng pTM1-L or 
pTM1-Lsynth-, 500 ng pTM1-NP, 500 ng pTM1-VP35, 100 ng pTM1-VP30, and 1.5 μg 
minigenome plasmid unless otherwise indicated. Transfection control wells were 
transfected with equal amounts of DNA (2.2 μg pCAGGS empty and 500 ng pCAGGS 
mCherry). 500 μL OptiMEM, DNA, and 2.5 μL PLUS reagent were added to polystyrene 
tubes, vortexed 3 times briefly, and incubated at room temperature for 5 minutes. 6.25 μL 
Lipofectamine LTX was added to transfection mix, vortexed 3 times briefly, and incubated 
at room temperature for 30 minutes. BSRT7/5 cells were washed with PBS and 1 mL 
OptiMEM was added. Transfection mix was added to BSRT7/5 cells and incubated for 5 
hours at 37°C, 5% CO2. 0.5 mL OptiMEM containing 3% FBS was added and cells were 
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incubated at 37°C, 5% CO2. Next day, 1.5 mL media was replaced BSRT7/5 culture media. 
2 days after transfection, cells were harvested as described below. 
 
EBOV replication and transcription competent minigenome assays: HEK 293T cells were 
seeded at 2 x 105 cells/well in a 12 well plate. The next day when cells were ~70% 
confluent, the cells were transfected using TransIT-LT1 Transfection Reagent (Mirus Bio 
LLC) according to the manufacturer’s instructions. Each well was transfected with 500 ng 
pCAGGS-L or pCAGGS-Lsynth-, 250 ng pCAGGS-NP, 250 ng pCAGGS-VP35, 50 ng 
pCAGGS-VP30, 1 μg pCAGGS-T7, 50 ng pTM1-β-galactosidase, and 1 μg of the 
indicated firefly luciferase minigenome plasmid. Transfection control wells were 
transfected with equal amounts of DNA (2.2 μg pCAGGS empty and 500 ng pCAGGS 
mCherry). 2 days after transfection, cells were harvested as described below. 
Luciferase and β-galactosidase assays 
Following transfection as described above, cells were harvested using 1X reporter lysis 
buffer (RLB) (Promega). Prior to lysis, media was discarded and cells were washed with 
1X PBS. For lysis of a 6 well plate, 600 μL 1X RLB was added and incubated for 20 
minutes with gentle shaking at room temperature. For lysis of a 12 well plate, 300 μL 1X 
RLB was added. After lysis, samples were transferred to 1.5 mL microcentrifuge tubes, 
vortexed, and centrifuged 3000 x g for 5 minutes at room temperature. Supernatants were 
transferred to new 1.5 mL microcentrifuge tubes and used immediately for firefly luciferase 
activity or stored at -20ºC. The luciferase assay was performed in 96-well format with a 
LUMIstar Omega luminometer (BMG Labtech) using 50 μL of lysate, or appropriate 
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dilution in 50 μL, and 50 μL of the luciferase assay reagent (Promega). To account for 
potential differences in transfection efficiency, luciferase values were normalized to β-
galactosidase values. Undiluted cell lysates (50 μL) were mixed with 50 μL of 2X Assay 
Buffer (Promega) and incubated for 30 min at 37 °C. Reaction was terminated by adding 
150 μL of 1 M sodium carbonate (Promega). β-galactosidase values were measured on a 
Tecan Spark microplate reader at 420 nm and normalized to a standard curve generated 
with the β-galactosidase provided by Promega. 
RNA isolation 
Ebolavirus infected cells RNA isolation: Pelleted viral particles, cell pellets, and 
monolayers of infected cells were lysed using TRIzol reagent (Invitrogen). To concentrate 
virions, supernatants from infected cells were harvested and pre-cleared from cell debris 
by centrifuging at 1500 rpm for 10 minutes at 4°C. Virus particles were concentrated by 
PEG precipitation. 175 mL pre-cleared supernatant was mixed with 12.25 g PEG 8000 and 
4.02 g NaCl and stirred overnight at 4°C. Samples were centrifuged at 6,000 rpm for 45-
60 minutes at 4°C. The pellet was dissolved in 1.5 TriFast reagent (Peqlab) (55). RNA was 
purified as described below. This work was performed by Dr. Laure Deflubé-Owen 
following the BSL-4 standard operating procedures for RNA purification approved by the 
IBC of the NIAID Rocky Mountain Laboratories.  
 
TRIzol extraction with additional phenol-chloroform purification step: Cells and media 
were harvested by scraping cells (Biologix Research) and transferring to 1.5 mL 
microcentrifuge tube by pipetting. Samples were centrifuged at 2,000 x g, 4°C for 5 
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minutes. Supernatant was aspirated and pellets were briefly vortexed. 1 mL TRIzol 
(Invitrogen) was added to each sample and vortexed to resuspend pellet. Samples were 
incubated for 5 minutes at room temperature and either stored at -80°C or immediately 
processed. 0.2 mL chloroform:isoamyl alcohol 24:1 (Sigma Aldrich) was added to each 
sample, shaken for 15 seconds by hand, and incubated at room temperature for 3 minutes. 
Samples were centrifuged at 12,000 x g, 4°C for 15 minutes. Following centrifugation, 
~570 μL of the upper aqueous phase was transferred, avoiding the interphase, to new 
microcentrifuge tubes containing 0.5 mL isopropanol (American Bioanalytical). Samples 
were mixed by vortexing and incubated at room temperature for 10 minutes. Samples were 
centrifuged at 12,000 x g, 4°C for 10 minutes. Supernatant was removed and pellet dried 
briefly. Pellet was resuspended in 300 μL RNase-free H2O. 33 μL 2M NTE (2M NaCl, 40 
mM Tris pH 7.4, 1 mM EDTA) buffer was added and samples were vortexed. 330 μL acid 
phenol:chloroform (5:1) (Invitrogen) was added to each sample and shaken for 15 second 
by hand. Samples were centrifuged at 7,000 x g, 4°C for 3 minutes. ~300 μL of the upper 
aqueous phase was transferred to new microcentrifuge tubes containing 330 μL 
chloroform:isoamyl alcohol 24:1 and shaken for 15 seconds by hand. Samples were 
centrifuged at 7,000 x g, 4°C for 3 minutes. ~270 μL of the upper aqueous phase was 
transferred to new microcentrifuge tubes containing 700 μL 100% ethanol and mixed by 
inverting. Samples were stored at -80°C for on ice for 5 minutes to precipitate RNA before 
continuing. Samples were centrifuged at 20,000 x g (or full-speed), 4°C for 20 minutes. 
Supernatant was removed by pipetting and pellets were washed in 1 mL 70% ethanol. 
Samples were centrifuged at 20,000 x g (or full-speed), 4°C for 20 minutes. Supernatant 
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was removed by pipetting and pellets were dried briefly. Pellets were resuspended in 50 
μL RNase-free H2O and frozen on dry ice before storage at -80°C.  
Primer extension analysis 
Primer extension reactions: Primers for reverse transcription were end-labelled as 
described above (see Table 3). 2 μL 5′-end phosphorylated primers (0.2 μM) was mixed 
with 2 μL 10X buffer reverse transcriptase (Qiagen), 1 μL 10 mM deoxyribonucleoside 
triphosphate (dNTP) mix, 9 μL RNase-free H2O, 5 μL RNA sample (minigenome) or 2 μg 
RNA sample (virus infection). Samples were heated to 80°C for 3 minutes then placed on 
ice for 1 minute. 1 μL Sensiscript (Qiagen) was added to each sample and samples were 
incubated at 37°C for 90 minutes. Reactions were inactivated at 70°C for 15 minutes. 20 
μL 2X STOP buffer was added to each and heated to 95°C for 5 minutes before storage at 
-20°C or loaded on a 6 or 8% acrylamide 7M urea 1X TBE gel. 
Table 3. DNA oligos used in ebolavirus primer extension assays. 
Experiment Primer purpose Sequence (5′ - 3′) Primer # 
EBOV 
genome 
primer 
extension 
RT primer –  
TrC 17-41  
AATTTAAAAATAAATCTATTTCTTC 2739 
TrC 1-41 +1 
marker 
AATTTAAAAATAAATCTATTTCTTCTTTTTTGT
GTGTCCAA 
2741 
TrC 2-41 +2 
marker 
AATTTAAAAATAAATCTATTTCTTCTTTTTTGT
GTGTCCG 
2852 
EBOV 
antigenome 
and anti-
minigenome 
primer 
extension 
RT primer –  
Le 14-35 n  
GATCCTAAAAATTCTTCTTTCT 2735 
Le 1-35 +1 
marker 
GATCCTAAAAATTCTTCTTTCTTTTTGTGTGTC
CG 
2737 
Le 2-35 +2 
marker 
GATCCTAAAAATTCTTCTTTCTTTTTGTGTGTC
C 
2851 
SUDV 
genome 
primer 
extension 
RT primer –  
TrC 16-36  
TTAAAAAATCTGTATTTTCTC 2963 
TrC 1-36 +1 
marker 
TTAAAAAATCTGTATTTTCTCTTTTTTGTGTGT
CCG 
2964 
TrC 2-36 +2 
marker 
TTAAAAAATCTGTATTTTCTCTTTTTTGTGTGT
CC 
3015 
RT primer –  AATCTTAAAAACTTTTCTTTCT 2961 
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SUDV 
antigenome 
primer 
extension 
Le 14-35  
Le 1-35 +1 
marker 
AATCTTAAAAACTTTTCTTTCTTTTTGTGTGTC
CG 
2962 
Le 2-35 +2 
marker 
AATCTTAAAAACTTTTCTTTCTTTTTGTGTGTC
C 
3014 
RESTV 
genome 
primer 
extension 
RT primer –  
TrC 20-42  
AAAACATTATAAAAAACCAATTT 2766 
TrC 1-42 +1 
marker 
CACAAAAAGTCTTAAAAAACCTTTTTTCTTTTT
GTGTGTCCG 
2765 
TrC 2-42 +2 
marker 
AAAACATTATAAAAAACCAATTTTTTCCTTTTT
GTGTGTCC 
2854 
RESTV 
antigenome 
primer 
extension 
RT primer –  
Le 14-35  
AGTCTTAAAAAACCTTTTTTCT  2959 
Le 1-35 +1 
marker 
AGTCTTAAAAAACCTTTTTTCTTTTTGTGTGTC
CG 
2960 
Le 2-35 +2 
marker 
AGTCTTAAAAAACCTTTTTTCTTTTTGTGTGTC
C 
3013 
RSV genome 
primer 
extension 
RT primer TrC 
13-35 
TACGAGATATTAGTTTTTGAGAC 
 
 
TrC 1-35 +1 
marker 
TACGAGATATTAGTTTTTGAGACTTTTTTTCTC
GT 
 
TrC 3-35 +3 
primer 
TACGAGATATTAGTTTTTGAGACTTTTTTTCTC  
RSV 
antigenome 
primer 
extension 
RT primer – Le 
15-39 
TTTGGTTTATGCAAGTTTGTTGTAC  
Le 1-39 +1 
marker 
TTTGGTTTATGCAAGTTTGTTGTACGCATTTTT
TCCCGT 
 
Le 3-39 +3 
marker 
TTTGGTTTATGCAAGTTTGTTGTACGCATTTTT
TCCC 
 
 
Marker preparation: Primers to be used as markers were end-labelled as described above. 
Marker dilutions were prepared in reverse transcription reaction buffer (1X buffer RT, 0.2 
mM dNTPs) and an equal volume of 2X STOP buffer was added. Markers were heated to 
95°C for 5 minutes before loading on a 6 or 8% acrylamide 7M urea 1X TBE gel. Markers 
were typically diluted 1/4000 x.  
 
Gel electrophoresis: 6 or 8% acrylamide 7M urea 1X TBE gels were prepared as described 
above. Gels were pre-run at 35 mA (for 1 gel) or 70 mA (for 2 gels on the same power 
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pack) in 1X TBE buffer. Wells were cleaned using a metal spatula and rinsed using a 
syringe and 1X TBE buffer prior to sample loading. 20 μL samples were loaded on gel and 
gels were run at 35 mA (for 1 gel) or 70 mA (for 2 gels on the same power pack). When 
the BPB has run out of the bottom of the gel, 3MM Chr chromatography paper (Whatman) 
was applied to the gel and used to peel the gel off the glass plate. The gel was covered in 
saran wrap or in cellophane pre-soaked in water and vacuum dried at 80°C for 2 or more 
hours. Gels were exposed to film (GE Healthcare Amersham Hyperfilm MP) for 
autoradiography or to phosphor screens to be imaged by a Molecular Dynamics 
phosphorimager. 
Rapid Amplification of cDNA ends (RACE) and sequencing 
RACE of ebolavirus RNAs: For 3′ RACE, 2 μg of total intracellular RNA (viral genome 
and antigenome) or 500 ng of virion RNA was tailed with ATP or CTP using Escherichia 
coli poly(A) polymerase (New England Biolabs), followed by heat inactivation of the 
enzyme according to the manufacturer’s instructions. First-strand cDNA synthesis was 
performed using primers that annealed to the poly(A) or poly (C) tail, and Sensiscript 
(Qiagen) reverse transcriptase was used to reverse transcribe the tailed RNA according to 
the manufacturer’s instructions. The resulting cDNA was amplified by PCR using a 
sequence-specific primer and a primer that annealed to the poly(A) or poly(C) tail (Table 
4). For 5′ RACE, 2 μg of total intracellular RNA (viral genome and antigenome) or 500 ng 
viral RNA (genome) was annealed to a virus-specific primer and reverse transcribed using 
Sensiscript reverse transcriptase, according to the manufacturer’s instructions. Following 
purification, the cDNA was tailed with dCTP or dATP using terminal transferase (New 
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England Biolabs). The tailed cDNA was PCR amplified using a nested virus-specific 
primer and a primer that annealed specifically with the dATP or the dCTP tail. All PCRs 
were performed using Platinum Taq PCR (Invitrogen).  
 
Sequencing of RACE: RACE PCR products were gel purified (Qiagen) and either 
sequenced directly or cloned into the pCR2.1 vector (TA TOPO cloning kit; Life 
Technologies) for sequencing of individual cDNA clones. All sequencing traces were 
analyzed using the SeqMan, DNASTAR Lasergene software. Segments of the sequencing 
traces were copied from SeqMan and inserted in the Figures in Chapter Five. 
Table 4. DNA oligos used in RACE. 
Experiment Primer purpose Sequence (5′ - 3′) Primer # 
3′ RACE 
genome 
RT primer – 
adaptor + tail 
GAGGACTCGAGCTCAAGCATGCA
TTTTTTTTTTTTTTT or 
GAGGACTCGAGCTCAAGCATGCA
TGGGGGGGGGGGGGGG 
2720 
Or 
2721 
PCR primer 1 – 
tail adaptor 
GAGGACTCGAGCTCAAGC 2722 
 
PCR primer 2 – 
EBOV specific 
GCTTGTTTGACTGTGAACTAATGC
TG 
2742 
PCR primer 2 – 
SUDV specific 
CACTTATCAAGAAGGTTAGAATT
G 
2847 
PCR primer 2 – 
RESTV specific 
GAACTTCTCGCGAAATGGATTC 2768 
5′ RACE 
genome 
RT primer – 
EBOV specific 
GATAAAATTAAAAGAAAAGGCAG
GAC 
2745 
RT primer – 
SUDV specific 
ACAGCCAAAATATTTCCTAGGGC
CG 
2850 
RT primer – 
RESTV specific 
TTAAATGATAATGATCTTGGGAAC
TCG 
2771 
PCR primer 1 - 
tail 
GAGGACTCGAGCTCAAGCATGCA
TTTTTTTTTTTTTTT or 
GAGGACTCGAGCTCAAGCATGCA
TGGGGGGGGGGGGGGG 
2720 
Or 
2721 
PCR primer 2 – 
EBOV specific 
GATAAAATTAAAAGAAAAGGCAG
GAC 
2745 
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PCR primer 2 – 
SUDV specific 
ACAGCCAAAATATTTCCTAGGGC
CG 
2850 
PCR primer 2 – 
RESTV specific 
TTAAATGATAATGATCTTGGGAAC
TCG 
2771 
3′ RACE 
antigenome 
RT primer – 
adaptor + tail 
GAGGACTCGAGCTCAAGCATGCA
TTTTTTTTTTTTTTT or 
GAGGACTCGAGCTCAAGCATGCA
TGGGGGGGGGGGGGGG 
2720 
Or 
2721 
PCR primer 1: 
tail adaptor 
GAGGACTCGAGCTCAAGC 2722 
PCR primer 2 – 
EBOV specific 
AATGGTAATAGCCTTAATCTTTGT
GTA 
2744 
PCR primer 2 – 
SUDV specific 
TTACATAAGTATTAAGAAAAAAT
TAC 
2849 
PCR primer 2 – 
RESTV specific 
GTCGCATTTAAACATGCTATCTTC
AG 
2770 
5′ RACE 
antigenome 
RT primer – 
EBOV Le NP-
VP35 IGR 
GGTTTTAATCTTCATCATTAG 
 
2881 
RT primer – 
SUDV Le NP-
VP35 IGR 
ATGAAGGTTTTAATCTTCATCATG
GA 
 
2885 
RT primer – 
RESTV Le NP-
VP35 IGR 
ATGAAGGTTTTAATCTTCATCAAA
TG 
 
2883 
PCR primer 1 - 
tail 
GAGGACTCGAGCTCAAGCATGCA
TTTTTTTTTTTTTTT or 
GAGGACTCGAGCTCAAGCATGCA
TGGGGGGGGGGGGGGG 
2720 
Or 
2721 
PCR primer 2 – 
EBOV specific 
nested 
GTCTGAGGTGGGACTTGTGATG 2743 
PCR primer 2 – 
SUDV specific 
nested 
GTGGACTAAAGGGATACCTCGGG 2848 
PCR primer 2 – 
RESTV specific 
nested 
GAAGAGTCCCAAGATCACTAGAC
ATACC 
 
2769 
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Northern blot analysis 
Pre-stain marker preparation: 6 μL DynaMarker Pre-stain marker for RNA High 
(BioDynamics Laboratory) was mixed with 5 μL RNase-free H2O, 2 μL 10X MOPS 
(American Bioanalytical), 7 μL 36.5 – 38% formaldehyde (Sigma Aldrich), 20 μL 95% 
deionized formamide (AmericanBio), and 6.6 μL 6X gel loading dye (ThermoFisher 
Scientific). The ladder sample was heated to 65°C for 10 minutes and transferred to ice 
before loading on gel. 
 
RNA sample preparation: Total RNA amounts in ng were normalized to be equal and were 
diluted in RNase-free H2O to a total volume of 11 μL and mixed with 2 μL 10X MOPS 
(American Bioanalytical), 7 μL 36.5 – 38% formaldehyde (Sigma Aldrich), 20 μL 95% 
deionized formamide (AmericanBio), and 6.6 μL 6X gel loading dye (ThermoFisher 
Scientific). The samples were heated to 65°C for 10 minutes and transferred to ice before 
loading on gel.  
 
Gel electrophoresis: A 1.5% Agarose-formaldehyde gels was prepared as described above 
and samples were loaded. Gels were run in 1X MOPS (American Bioanalytical) buffer at 
90V for 3-4 hours until BPB dye was approximately 4/5th of the gel length from the wells. 
 
Transfer: RNA was transferred from agarose gels to 0.45 μm pore size Nytran nylon 
membrane (GE Healthcare, Whatman) using TurboBlotter Downward Capillary System 
(GE Healthcare). Nitrocellulose membrane and paper was cut to size of gel (11 x 14 cm). 
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3M NaCl 8 mM NaOH alkaline transfer buffer was prepared by mixing 175.32 g NaCl and 
8 mL 1M NaOH to 1 L in MilliQ H2O. Pre-soak membrane in transfer buffer for 30 
minutes. Turboblotter transfer stack was assembled according to manufacturer’s 
instructions and transferred for at least 4 hours. Stacks contained 3MM chromatography 
paper (Whatman, Fischer) and gel blotting grade GB003 paper (Whatman, GE Healthcare) 
After transfer, blots were neutralized by shaking in 6X saline sodium citrate (SSC) 
(AmericanBio) buffer for 15 minutes, air-dried, and UV-crosslinked at 1200 Joules in a CL 
1000 Ultra Violet Crosslinker before storage at room temperature or immediate 
hybridization. 
 
Hybridization: Blots were pre-hybridized for 1 hour at 65°C for 20 mL of 6X SSC, 2X 
Denhardt’s solution (Sigma Aldrich), 0.1% SDS (American Bioanalytics), 0.1 mg/mL 
sheared salmon sperm (Invitrogen) DNA hybridization buffer. Sheared salmon sperm 
DNA was heated to 95°C before addition to the hybridization buffer. 20-30 μL riboprobe 
was added and blots were hybridized overnight. Wash blots twice for 1 hour with 2X SSC, 
0.1% SDS wash buffer followed by a 15 minute wash with 0.1X SSC, 0.1% SDS wash 
buffer. Blots were air-dried and wrapped in saran wrap before exposure to film (GE 
Healthcare Amersham Hyperfilm MP) for autoradiography or to phosphor screens to be 
imaged by a Molecular Dynamics phosphorimager. 
Generating the recombinant bacmid 
To generate the recombinant bacmid, MAX Efficiency DH10Bac competent cells (Thermo 
Fisher) were transformed with pFastBacDual plasmids containing RSV L and P, HPIV3 L 
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and P, and MARV L and VP35 ORFs. Competent cells were thawed on ice. For each 
transformation, 100 μL of competent cells were transferred to pre-chilled 14 mL round-
bound polypropylene tubes. 1 ng of pFastBacDual was added to each transformation. Cells 
were incubated on ice for 30 minutes then heat shocked at 42ºC for 45 seconds. Cells were 
chilled on ice for 2 minutes. 900 μL SOC medium was added to each transformation. Cells 
were incubated for 4 hours at 37ºC shaking at 225 rpm. Prepare 10 fold serial dilutions (10-
1, 10-2) with SOC medium following incubation. 100 μL of each dilution and undiluted 
cells were spread on LB agar plates containing 50 μg/mL kanamycin sulfate (Sigma), 7 
μg/mL gentamicin (Sigma), 10 μg/mL tetracycline hydrochloride (Sigma), 100 μg/mL 
bluo-gal (Sigma), 40 μg/mL isopropyl-β-D-thiogalactoside (IPTG) (Sigma), and 5 g/mL 
NaCl (Sigma). Plates were incubated for 48 hours at 37ºC. White colonies were picked and 
streaked on new plates containing 50 μg/mL kanamycin sulfate (Sigma), 7 μg/mL 
gentamicin (Sigma), 10 μg/mL tetracycline hydrochloride (Sigma), 100 μg/mL bluo-gal 
(Sigma), 40 μg/mL IPTG (Sigma), and 5 g/mL NaCl (Sigma).  
Bacmid culturing and purification 
White colonies were picked from second LB agar plates and used to inoculate LB cultures 
containing either 50 μg/mL kanamycin, 7 μg/mL gentamicin, and 10 μg/mL tetracycline, 
or 50 μg/mL kanamycin and 7 μg/mL gentamicin. Cultures were grown for 24 hours at 
30ºC shaking at 225 rpm. Cultures were used to make glycerol stocks and for purification 
of bacmid DNA. Bacmid DNA was purified using PureLink HiPure Plasmid DNA 
purification kit (Invitrogen) or as described below: 
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1.5 mL of bacterial culture was transferred to a 1.5 mL microcentrifuge tube and 
centrifuged at 14,000 x g for 1 minute at room temperature. Supernatant was removed by 
aspiration and cells were resuspended in 0.3 mL solution 1 (15 mM Tris-HCl pH 8.0, 10 
mM EDTA, 100 μg/mL RNase A) by pipetting. 0.3 mL solution 2 (0.2 M NaOH, 1% SDS) 
was added and mixed by inverting gently. Samples were incubated for 5 minutes at room 
temperature. 0.3 mL 3M potassium acetate, pH 5.5 was added slowly and mixed during 
addition. Samples were places on ice for 5-10 minutes. Samples were centrifuged at 14,000 
x g for 10 minutes at 4ºC. 0.7 mL of supernatant was transferred to new 1.5 mL 
microcentrifuge tubes containing 0.8 mL 100% isopropanol and inverted to mix. Samples 
were stored at -20ºC overnight or chilled at -20ºC for 30 minutes before continuing 
processing. Samples were centrifuged for 15 minutes at 14,000 x g at 4ºC. Supernatant was 
removed and pellets were washed with 0.5 mL 70% ethanol. Samples were centrifuged for 
5 minutes at 14,000 x g at 4ºC and supernatant was removed. After air drying briefly, 
pellets were resuspended in 40 μL Tris-EDTA (TE) buffer pH 8.0. 
Bacmid verification 
PCR verification of insert: A PCR was done to confirm insert is present in the recombinant 
bacmid. 50 ng bacmid DNA was mixed with 5 μL 5X LongAmp buffer (New England 
Biolabs), 1.5 μL 5 mM dNTPs (Promega), 1 μL 10 μM M13F primer, 10 μM M13R primer, 
1 μL LongAmp Taq polymerase (New England Biolabs), and H2O to a total volume of 25 
μL. A no DNA sample was used as a control. Amplification was performed over 15 cycles 
with the following cycler conditions: initialization for 5 minutes at 94ºC, denaturation for 
30 seconds at 94ºC, annealing for 45 seconds at 55ºC, elongation for 8 minutes at 65ºC, 
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and a final elongation step for 10 minutes at 65ºC. PCR products were visualized by 0.7% 
agarose (Sigma) gel and post-stained in 1X Gel Red (Phenix research). The expected size 
of PCR product if insert was successful was 9365 bp.  
 
Checked full-length bacmid DNA quality: 300 ng bacmid DNA in 2X DNA loading dye 
BPB/XC  (Thermo Fisher) was visualized by 0.5% agarose gel run for approximately 16 
hours at 23V at 4ºC. Gels were post-stained in 1X ethidium bromide (Sigma) for 1 hour 
and destained in 1X Tris/Acetate/EDTA (TAE) (American Bioanalytical) for 20 minutes 
before visualization. 
Producing recombinant baculovirus 
Recombinant baculovirus was generated by transfected Sf21 cells as follows. For a 1 well 
transfection in a 6 well plate: 1 μg bacmid DNA was added to 100 μL Grace’s Insect 
Medium, unsupplemented (Invitrogen). Cellfectin mix was prepared by combining 8 μL 
Cellfectin II Reagent (Invitrogen) with 100 μL Grace’s Insect Medium. 108 μL cellfectin 
mix was added to DNA mixture, vortexed briefly and gently, and incubated at room 
temperature for 15 minutes. Following incubation, DNA/cellfectin mixture was added 
dropwise to cells and incubated at 27ºC. 1 x 106 cells were seeded in 2 mL Grace’s Insect 
Medium from suspension cultures in log phase growth 1 hour prior to transfection. Media 
was replaced with 2 mL SF900 II serum free medium 5 hours or overnight after 
transfection. Unless otherwise noted, recombinant baculovirus was harvested 6 days after 
transfection by transferring the supernatant to conical tubes and centrifuging at 500 x g for 
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5 minutes at 4ºC. Supernatant (recombinant baculovirus) was transferred to fresh tubes 
avoiding cellular debris and stored at 4ºC. 
Recombinant baculovirus test expression 
To confirm expression of L and P from recombinant baculoviruses, test expressions were 
done. 1 x 106 Sf21 cells were seeded into 6 well plates in 2 mL Sf900 II medium and 
allowed to attach for at least 1 hour. Varying amounts of recombinant baculovirus was 
added to cells, typically 40 μL, or mock infected. Cells were incubated at 27ºC for 3 days. 
Cells were harvested by scraping into media and transferring to microcentrifuge tubes. 
Samples were centrifuged at 1200 x g for 15 minutes at 4ºC. Supernatant was removed and 
cell pellets were washed in 1X PBS. Samples were centrifuged again at 1200 x g for 15 
minutes at 4ºC. Supernatant was removed and cell pellets were resuspended in 500 μL lysis 
buffer (50 mM NaH2PO4 (Sigma), 150 mM NaCl (Sigma), 20 mM imidazole (Sigma), 
0.5% NP40 (IGEPAL CA-630, Sigma), pH 8.0). Samples were centrifuged at 20,000 x g 
(max speed) for 15 minutes at 4ºC. The soluble cell lysate supernatant was transferred to 
new microcentrifuge tubes. Soluble cell lysates were analyzed in SDS-PAGE gels. For 
RSV preps, expression was confirmed by Western blot for His-P. For MARV, expression 
was confirmed by Western blot for HA-L. For HPIV3, expression was confirmed by 
Western blot for FLAG-L.  
Polymerase expression and purification 
RSV polymerase: Sf21 suspension cell cultures in log phase at approximately 1 x 106 
cells/mL were infected with recombinant baculovirus encoding RSV L and His-P proteins. 
72-84 hours after infection, cells were harvested by centrifugation at 1200 x g for 15 
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minutes at 4°C. Supernatant was removed and cells were washed in 10 mL cold sterile PBS 
for a 50 mL culture. Cell pellet was centrifuged again at 1200 x g for 15 minutes at 4°C 
and supernatant was removed. For a 50 mL culture, pellet was resuspended in 4 mL lysis 
buffer (50 mM NaH2PO4 (Sigma), 150 mM NaCl (Sigma), 20 mM imidazole (Sigma), 
0.5% NP40 (IGEPAL CA-630, Sigma), pH 8.0) with cOmplete Mini EDTA-free Protease 
Inhibitor Cocktail (1 tablet per 10 mL lysis buffer) (Roche). Cell lysate was incubated on 
ice for 15 minutes. 400 μL nickel-nitrilotriacetic acid (Ni-NTA) agarose resin 50% slurry 
(Thermo Fisher Scientific) was washed twice with sterile H2O and once with lysis buffer, 
centrifuging after each wash at 700 x g for 2 minutes at 4°C and removing supernatant. 
Total cell lysate was centrifuged at 22,000 x g for 15 minutes at 4°C. The soluble cell lysate 
(supernatant) was added to resin and binding was allowed to occur for 2 hours at 4°C 
rocking. At end of binding, sample was centrifuged at 700 x g for 2 minutes at 4°C and the 
flow through supernatant was discarded. The resin was washed three times with 4 mL 60 
mM imidazole wash buffer (50 mM NaH2PO4, 150 mM NaCl, 60 mM imidazole, 0.5% 
NP40, pH 8.0) and twice with 100 mM imidazole wash buffer (50 mM NaH2PO4, 150 mM 
NaCl, 100 mM imidazole, 0.5% NP40, pH 8.0). After addition of each wash buffer, the 
resin was resuspended by inverting, incubated on ice for 2 minutes, centrifuged at 700 x g 
for 2 minutes at 4°C, and wash buffer supernatant was discarded. Protein was eluted in 1.5 
mL 250 mM imidazole elution buffer (50 mM NaH2PO4, 150 mM NaCl, 250 mM 
imidazole, 0.5% NP40, pH 8.0) by inverting, incubating on ice for 5 minutes, and 
centrifuging at 700 x g for 2 minutes at 4°C. Eluted protein supernatant was dialyzed 
overnight in Slide-A-Lyzer 10 kDa molecular weight cut off dialysis cassettes (Thermo 
  
64 
Fisher) and dialysis buffer (150 mM NaCl, 20 mM pH 7.4, 10% glycerol). Eluted protein 
was further dialyzed for 2 hours in fresh dialysis buffer containing 1 mM DTT.  
 
MARV polymerase: Sf21 suspension cell cultures in log phase at approximately 1 x 106 
cells/mL were infected with recombinant baculovirus encoding MARV HA-L and His-P 
proteins. 72-84 hours after infection, cells were harvested by centrifugation at 1200 x g for 
15 minutes at 4°C. Supernatant was removed and cells were washed in 10 mL cold sterile 
1X PBS for a 50 mL culture. Cell pellet was centrifuged again at 1200 x g for 15 minutes 
at 4°C and supernatant was removed. For a 50 mL culture, pellet was resuspended in 4 mL 
lysis buffer (50 mM NaH2PO4 (Sigma), 150 mM NaCl (Sigma), 20 mM imidazole (Sigma), 
0.5% NP40 (IGEPAL CA-630, Sigma), pH 8.0) with cOmplete Mini EDTA-free Protease 
Inhibitor Cocktail (1 tablet per 10 mL lysis buffer) (Roche). Cell lysate was incubated on 
ice for 2 hours minutes. 300 μL HisPur Ni-NTA dynabeads (Invitrogen Life Technologies) 
was washed in 500 μL lysis buffer (50 mM NaH2PO4, 150 mM NaCl, 20 mM imidazole, 
0.5% NP40, pH 8.0). Beads were applied to DynaMag-2 magnet (Life Technologies) and 
lysis buffer was removed prior to soluble cell lysate addition. Total cell lysate was 
centrifuged at 22,000 x g for 15 minutes at 4°C. The soluble cell lysate (supernatant) was 
added to the washed beads and binding was allowed to occur for 2 hours at 4°C rocking. 
At end of binding, sample was applied to magnet, and the flow through supernatant was 
discarded. The beads was washed twice with 1 mL 100 mM imidazole wash buffer (50 mM 
NaH2PO4, 150 mM NaCl, 100 mM imidazole, 0.5% NP40, pH 8.0) and twice with 250 
mM imidazole wash buffer (50 mM NaH2PO4, 150 mM NaCl, 250 mM imidazole, 0.5% 
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NP40, pH 8.0). After addition of each wash buffer, the resin was resuspended by pipetting 
gently, incubated on ice for 2 minutes, applied to the magnet, and wash buffer supernatant 
was discarded. The beads were washed an additional three times with 1 mL storage buffer 
(150 mM NaCl, 20 mM pH 7.4, 10% glycerol) to remove imidazole. Beads were 
resuspended in 300 μL storage buffer and stored at -150ºC for on-bead in vitro RNA 
synthesis assays.  
 
HPIV3 polymerase: Sf21 suspension cell cultures in log phase at approximately 1 x 106 
cells/mL were infected with recombinant baculovirus encoding HPIV3 FLAG-L and His-
P proteins. 72-84 hours after infection, cells were harvested by centrifugation at 1200 x g 
for 15 minutes at 4°C. Supernatant was removed and cells were washed in 10 mL cold 
sterile 1X PBS for a 50 mL culture. Cell pellet was centrifuged again at 1200 x g for 15 
minutes at 4°C and supernatant was removed. For a 50 mL culture, pellet was resuspended 
in 4 mL lysis buffer (50 mM NaH2PO4 (Sigma), 150 mM NaCl (Sigma), 20 mM imidazole 
(Sigma), 0.5% NP40 (IGEPAL CA-630, Sigma), pH 8.0) with cOmplete Mini EDTA-free 
Protease Inhibitor Cocktail (1 tablet per 10 mL lysis buffer) (Roche). Cell lysate was 
incubated on ice for 2 hours minutes. 300 μL HisPur Ni-NTA dynabeads (Invitrogen Life 
Technologies) was washed in 500 μL lysis buffer (50 mM NaH2PO4, 150 mM NaCl, 20 
mM imidazole, 0.5% NP40, pH 8.0). Beads were applied to magnet and lysis buffer was 
removed prior to soluble cell lysate addition. Total cell lysate was centrifuged at 22,000 x 
g for 15 minutes at 4°C. The soluble cell lysate (supernatant) was added to the washed 
beads and binding was allowed to occur for 2 hours at 4°C rocking. At end of binding, 
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sample was applied to magnet, and the flow through supernatant was discarded. The beads 
was washed twice with 1 mL 100 mM imidazole wash buffer (50 mM NaH2PO4, 150 mM 
NaCl, 100 mM imidazole, 0.5% NP40, pH 8.0) and twice with 250 mM imidazole wash 
buffer (50 mM NaH2PO4, 150 mM NaCl, 250 mM imidazole, 0.5% NP40, pH 8.0). After 
addition of each wash buffer, the resin was resuspended by pipetting gently, incubated on 
ice for 2 minutes, applied to the magnet, and wash buffer supernatant was discarded. The 
beads were washed an additional three times with 1 mL storage buffer (150 mM NaCl, 20 
mM pH 7.4, 10% glycerol) to remove imidazole. Beads were resuspended in 300 μL 
storage buffer and stored at -150ºC for on-bead in vitro RNA synthesis assays. 
SDS-PAGE gels and PageBlue protein staining 
Protein samples were prepared in 1X Laemmli’s sample buffer with 100 mM DTT, heated 
to 37ºC for 20 minutes if containing imidazole or 70ºC for 10 minutes, and migrated in a 
10% SDS-polyacrylamide gel with 4% stack in 1X SDS-PAGE buffer (250 mM Tris, 1.9 
M glycine, 35 mM SDS) at 80V until dye front reaches stack, then 120V until BPB dye 
front runs off gel. Benchmark Protein Ladder (Invitrogen) was used to size protein bands. 
PageRuler Plus Prestained Ladder (Thermo Scientific) was used to estimate separation of 
protein bands during gel electrophoresis. Gels were fixed using 40% methanol and 10% 
acetic acid for 30 minutes, then stained with PageBlue Staining Solution (Thermo) for 1 
hour to overnight, rocking. Gels were washed with MilliQ H2O until background is 
destained and dried down on Whatman 3MM Chromatography paper at 80ºC for 2 hours. 
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Western blot analysis 
Total cell lysate of the FLAG(2) tagged RSV L variants was prepared by scraping cells 
into media, harvesting pellet by centrifugation at 2000 x g, 5 minutes, 4°C. Pellet was 
resuspended in 50 μL lysis buffer and lysed for 15 minutes on ice (50 mM NaH2PO4 
(Sigma), 150 mM NaCl (Sigma), 20 mM imidazole (Sigma), 0.5% NP40 (IGEPAL CA-
630, Sigma), pH 8.0). 2 μL Turbo DNase (Thermo Fisher) was added and incubated at 
37°C, 1200 rpm, for 5 minutes. 
 
Protein samples were prepared and run on SDS-polyacrylamide gels as described above 
without fixing or staining. Gels were transferred to 0.45 μm nitrocellulose membranes (GE 
Healthcare Amersham Protram Premium) in 1X transfer buffer (480 μM Tris, 3.84 μM 
glycine, 20% methanol or 10% methanol for L protein transfers) for 1 hour (or 2 hours for 
L protein transfers) at 25V. Membranes were incubated in 5% milk solution in PBS-Tween 
(1X PBS and 0.1% Tween-20 (Sigma) with primary antibody for 1 hour at room 
temperature (Table 5). Membranes were washed three times with PBS-Tween and 
incubated with secondary antibody in 5% milk in PBS-Tween for 1 hour at room 
temperature. Membranes were washed three times with PBS-Tween. Membranes were 
scanned using the Odyssey Infrared Imaging system and analyzed using Image Studio 
software. 
Table 5. Antibodies used for Western blot analysis. 
antibody primary or 
secondary 
dilution used source 
mouse anti-HA 
*HA.11 16B12 
primary 1/1000 BioLegend 
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Monoclonal 
mouse anti-
FLAG M2 
primary 1/500 Sigma 
mouse anti-
pentaHis 
primary 1/1000 Qiagen 
goat anti-
mouse IgG 
IRDye 800CW 
secondary 1 μL in 15 mL LI-COR 
 
in vitro RNA synthesis assay 
RNA oligonucleotides were PAGE purified as described, or ordered HPLC purified 
(Dharmacon). RNA oligonucleotides were used as template corresponding to Le or TrC 
promoter sequences unless otherwise noted (Table 6). Conditions used were as described 
below depending on the assay, unless otherwise noted. rNTP concentration, template 
concentration, polymerase concentration, reaction total volume, and incubation times were 
varied in some experiments as indicated. Standard assay conditions for 50 μL reactions 
were as follows: 2 μM RNA template, 10% glycerol, 50 Tris HCl pH 7.4 50 mM DTT, 8 
mM MgCl2 (Sigma), 500 μM rATP (Promega), 500 μM rCTP(Promega), 500 μM rGTP 
(Promega), 500 μM rUTP (Promega), 1 μL (10 μCi) [α-32P] NTP (3000 Ci/mmol), distilled 
RNase-free H2O, and 100 ng L (as determined from BSA standard quantification of L from 
L-P purified recombinant polymerase preps). Reactions were prepared, mixed, and 
incubated at 30ºC for 5 minutes or longer for reactions to reach 30ºC. Polymerase was 
added and mixed by gently pipetting three times. Reactions were incubated at 30ºC for 1 
hour, heat inactivated at 90ºC for 3 minutes, and cooled on ice. Some samples were also 
CIP treated by addition of 1 μL CIP (New England Biolabs) and incubation at 37ºC for 1 
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hour. If CIP treated, RNA was extracted as described below. Some samples not CIP treated 
were also extracted as described below. Samples were either processed immediately for gel 
electrophoresis or stored at -20ºC for later use. Reactions that were extracted were adjusted 
to 50 μL with RNase-free H2O if not already at 50 μL. Samples must also be at least 250 
μM GTP at 50 μL prior to extraction to retain small RNA products. 200 μL 0.25% SDS 
was added and mixed. 250 μL Acid Phenol: Chloroform (1:1) (Invitrogen) was added. 
Reactions were vortexed for 30 seconds, incubated on ice for 5 minutes, and centrifuged at 
full speed for 5 minutes at room temperature. The aqueous phase was transferred to a new 
tube containing 10 μL 4M NaCl and 1 μL GlycoBlue Coprecipitant 15 mg/mL (Invitrogen). 
500 μL 100% ethanol was added and tubes were mixed by inverting and stored overnight 
at -20ºC or chilled at -20ºC for 30 minutes for immediate processing. The RNA was 
precipitated by centrifuging full speed for 30 minutes at 4ºC. The pellet was washed in 1 
mL 70% ethanol, briefly air dried, and resuspended in 8-20 μL RNase-free H2O depending 
on the number and types of gels RNA will be analyzed on. Frequently used assay conditions 
are described below: 
 
RSV TrC14 or Le12: in vitro RNA synthesis assays on the RSV TrC14 or Le12 template 
to detect de novo RNA products initiated from +1 and +3 were performed with the 
following conditions in 50 μL reactions unless otherwise noted: 2 μM RSV TrC14 or Le12, 
1 mM rATP, 1 mM rCTP, 1 mM rGTP, 10 μCi [α-32P] rUTP (3000 Ci/mmol), and 100 or 
300 ng RSV L-P. Reactions were incubated at 30ºC for 30 minutes before heat inactivation, 
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CIP treatment, and phenol chloroform extracted as described above before analysis on 20% 
acrylamide 1X TBE 7M urea gels. 
 
RSV TrC25 [γ-32P]-rATP or rGTP: in vitro RNA synthesis assays on the RSV TrC25 
template to detect de novo RNA products initiated from +1 with rATP or +3 with rGTP 
were performed with the following conditions in 50 μL reactions unless otherwise noted: 
2 μM RSV TrC25, 1 mM rATP, 1 mM rCTP, 10 μM rGTP, 500 μM rUTP, 10 μCi [γ-32P] 
rATP for +1 or [γ-32P] rGTP (6000 Ci/mmol), and 100 or 300 ng RSV L-P. Reactions were 
incubated at 30ºC for 3 hours before heat inactivation. Reactions were treated with 1 μL 
Terminator 5′-Phosphate-Dependent Exonuclease (Epicenter) for 1 hour at 30ºC and 
phenol chloroform extracted as described above before analysis on 20% acrylamide 1X 
TBE 7M urea gels. 
 
TrC25 [α-32P] rGTP: in vitro RNA synthesis assays on the RSV TrC25 template to detect 
de novo RNA products initiated from +1 and +3 and back-priming RNA products were 
performed with the following conditions in 50 μL reactions unless otherwise noted: 2 μM 
RSV TrC25, 500 μM rATP, 500 μM rCTP, 500 μM rGTP, 500 μM rUTP, 10 μCi [α-32P] 
rGTP, and 100 ng RSV L-P. Reactions were incubated at 30ºC for 1 hour. Reactions were 
either mixed 1:1 with 2X STOP buffer or phenol chloroform extracted as described above 
before analysis on 20% acrylamide 1X TBE 7M urea and/or 25% acrylamide 1X TTE 7M 
urea gels. 
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RSV Le14: in vitro RNA synthesis assays on the RSV Le14 template to detect de novo 
RNA products initiated from +1 and +3 were performed with the following conditions in 
50 μL reactions unless otherwise noted: 2 μM RSV Le14 or Le14 2G-to-A, 1 mM rATP, 2 
mM rCTP, 10 μM rGTP, 10 μCi [α-32P] rUTP (3000 Ci/mmol), and 100 or 300 ng RSV L-
P. Reactions were incubated at 30ºC for 30 minutes before heat inactivation, CIP treatment, 
and phenol chloroform extracted as described above before analysis on 20% acrylamide 
1X TBE 7M urea gels. 
 
RSV TrC16 pppGpA analysis: in vitro RNA synthesis assays on the RSV TrC16 template 
to detect de novo RNA products initiated from +3 were performed with the following 
conditions in 50 μL reactions unless otherwise noted: 8 mM MgCl2 or MnCl2 (Sigma), 2 
μM RSV TrC16, 10 or 500 μM rATP as noted, 10 or 500 μM rGTP as noted, 500 μM 
rUTP, 10 μCi [α-32P] rATP (3000 Ci/mmol), and 100 ng L-P. Reactions were incubated at 
30ºC for 1 hour before heat inactivation. Reactions from some experiments were phenol 
chloroform extracted as described above before analysis on 25% acrylamide 1X TTE 7M 
urea gels. 
 
RSV TrC16 or TrC25 pppApC analysis: in vitro RNA synthesis assays on the RSV TrC16 
template or TrC25 template to detect de novo initiated dinucleotides initiated from +1 were 
performed with the following conditions in 50 μL reactions unless otherwise noted: 8 mM 
MgCl2 or MnCl2, 2 μM RSV TrC16 or TrC25, 20 μM – 1 mM rATP as noted, 20 μM - 2 
mM rCTP as noted, 100 μM rUTP, 20 μCi [α-32P] rCTP (3000 Ci/mmol), and 100 ng L-P. 
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Reactions were incubated at 30ºC for 1 hour before heat inactivation. Reactions from some 
experiments were phenol chloroform extracted as described above before analysis on 25% 
acrylamide 1X TTE 7M urea gels. 
 
Primer-mediated elongation: in vitro RNA synthesis assays on the A3 16 nucleotide 
template with a 5-mer primer to detect RNA products resulting from elongation of the 
primer in a templated manner were performed with the following conditions in 10 μL 
reactions unless otherwise noted: 2 μM template, 15 μM primer, 10 μM rATP, 10 μM 
rCTP, 10 μM rGTP, 10 μM rUTP, 5 μCi [α-32P] rUTP, and 20 ng L-P. Reactions were 
incubated at 30ºC for 1 hour before heat inactivation and analysis on 20% acrylamide 1X 
TBE 7M urea gels. 
 
RNA was combined 1:1 with 2X STOP buffer or pellets from phenol chloroform extraction 
were resuspended in 1X STOP buffer and boiled for 5 minutes at 95ºC. RNA was analyzed 
by electrophoresis on 20% urea-acrylamide TBE or 25% urea-acrylamide TTE gels and 
exposed to film and/or phosphorimager screens. Nucleotide lengths and identities were 
determined by comparison to RNA ladders prepared as described above. 
RNA oligos 
RNA oligos (Table 6) were ordered from Dharmacon with 2′ ACE protection. RNA oligos 
were either PAGE purified as described above or ordered HPLC purified.  
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Table 6. RNA oligos used in in vitro RNA synthesis assays 
RNA oligo name Sequence (3′ to 5′) 
RSV TrC14 UGCUCUUUUUUUCA 
RSV TrC14 1A AGCUCUUUUUUUCA 
RSV TrC14 1C CGCUCUUUUUUUCA 
RSV TrC14 1Δ GCUCUUUUUUUCA 
RSV TrC14 2A UACUCUUUUUUUCA 
RSV TrC14 2C UCCUCUUUUUUUCA 
RSV TrC14 2U UUCUCUUUUUUUCA 
RSV TrC14 3U UGUUCUUUUUUUCA 
RSV TrC14 3U/4G UGUGCUUUUUUUCA 
RSV Tr 1-14 marker template UGAAAAAAAGAGCA 
RSV Tr 3-14 marker template UGAAAAAAAGAG 
RSV Le12 UGCGCUUUUUUA 
RSV Le14 UGCGCUUUUUUACG 
RSV Le14 2A UACGCUUUUUUACG 
RSV LeC 1-14 marker template CGUAAAAAAGCGCA 
RSV LeC 3-14 marker template CGUAAAAAAGCG 
RSV TrC25 UGCUCUUUUUUUCACAGUUUUUGAU 
RSV Tr 1-25 marker template AUCAAAAACUGUGAAAAAAAGAGCA 
RSV Tr 3-25 marker template AUCAAAAACUGUGAAAAAAAGAG 
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RSV TrC16 UGCUCUUUUUUUCACA 
A3 CUGCGAAUGAUAACUAA 
5-mer primer 5′OH CGCAG 
 
T7 in vitro transcription of 5′ triphosphorylated RNA products 
Annealing oligos: Prepare annealed oligo samples by mixing 2 μL 100 μM oligo (upper 
strand), 2 μL 100 μM oligo (lower strand), 46 μL TE buffer. Incubated at 90°C for 3 
minutes, then allowed to cool to room temperature. 
 
T7 in vitro transcription: 40 μL reactions were prepared with the following conditions: 40 
mM Tris-HCl (pH 8.0), 20 mM MgCl2, 2 mM spermidine, 10 mM DTT, 0.1 mg/mL BSA, 
2 mM ATP, 1 mM CTP, 1mM GTP, [α-32P] ATP, 0.1 μM DNA annealed oligos, and 1 
unit/μL T7 RNA polymerase (New England Biolabs). Reactions were incubated at 37°C 
for 5 hours. Samples were treated with 1 μL DNase I (New England Biolabs) for 10 minutes 
at 37°C. 1 μL 0.5 M EDTA were added to reactions. Samples were phenol chloroform 
extracted as described above. Samples were analyzed on 25% acrylamide, urea TTE gels. 
Acrylamide gel electrophoresis for analysis of radioactively labelled RNA 
products from in vitro RNA synthesis assays 
Urea acrylamide TBE or TTE gels were prepared as described above. Gels were allowed 
to polymerize for at least 1 hour before pre-running.  
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6 and 8% acrylamide TBE gels: 6 or 8% acrylamide TBE gels were prepared in plates using 
0.8 mm spacers. Gels were pre-run at 35 mA in 1X TBE running buffer for at least 30 
minutes before loading samples. Gels were run at 35 mA until BPB had run off the gels. 
Gels were dried on 3MM Whatman chromatography paper at 80ºC under vacuum for 2 
hours covered in plastic wrap or cellophane. 
 
20% acrylamide TBE gels: 20% acrylamide TBE gels were prepared in plates using either 
0.8 mm or 0.4 mm spacers. Gels were pre-run at 30W in 1X TBE running buffer for at least 
30 minutes before loading samples. Gels were run at 30W until BPB reached 
approximately ¾ the distance of the gel from the wells. 0.8 mm thickness gels were stored 
at -80ºC unless developing films or exposing to phosphorimager screens. 0.4 mm thickness 
gels were dried on 3MM Whatman chromatography paper at 80ºC under vacuum or 4 hours 
covered in cellophane. 
 
25% acrylamide TTE gels: 25% acrylamide TTE gels were prepared in plates using 0.4 
mm spacers. TTE gel mixes were prepared immediately before polymerization. Gels were 
pre-run at 30W in 1X TTE running buffer for at least 30 minutes before loading samples. 
Gels were run at 30W until the XC and BPB dye fronts were separated by approximately 
4.25 inches.  
Chimera Modeler (Homology) 
Generation of predicted RSV L RdRp and capping domain structures based on alignment 
and homology to VSV L RdRp and capping domains was done using the University of 
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California, San Francisco (UCSF) Chimera MODELLER comparative modeling tool (86, 
125, 170). Alignment of RSV and VSV L proteins performed using built-in Clustal 
alignment program in Chimera. Comparative modeling performed on this alignment of 
RSV A2 L to VSV L (Protein Data Bank, PDB: 5A22) (86). 
Quantification and statistical analysis 
All experiments were performed with consistent results at least three times, unless 
otherwise indicated. For quantification of radioactive experiments,  phosphorimager 
analysis was performed on a Personal Molecular Imager (PMI) System (BioRad) using 
Quantity One 1-D Analysis Software (BioRad). Alternatively, TIF files obtained from 
phosphorimager scans or autoradiography films determined to be in the linear range of 
detection were quantified using Quantity One Software or Image Studio Software (LI-
COR). Western blot data was quantified using Image Studio Software (LI-COR). Protein 
bands on SDS-PAGE gels were quantified using ImageJ (NIH). Data are presented as the 
mean ± standard error of three or more independent experiments. 
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CHAPTER THREE: MECHANISM FOR DE NOVO INITIATION AT TWO 
SITES IN THE RESPIRATORY SYNCYTIAL VIRUS PROMOTER 
Note that some figures and text have previously appeared in print: Copyright © 2018, 
[Nucleic Acids Research, 46(13), 2018, 0.1093/nar/gky480]. All Rights Reserved (25). 
Introduction 
Replication and transcription initiation from the RSV promoter 
An intriguing facet of the nsNSVs is that their RdRp is able to use the viral genome RNA 
as a template for two different RNA synthesis processes: transcription, which yields 
subgenomic capped and polyadenylated mRNAs and genome replication (113, 164). In the 
case of RSV, transcription and replication both begin at the Le promoter region at the 3′ 
end of the viral genome (22, 39, 99), but they are initiated at different sites within the Le 
(113, 153). Both processes are dependent on a core promoter element located within the 
first 11 nt of the Le (41). To transcribe the genome, the RdRp initiates RNA synthesis at 
T3C. After a short distance (∼25 nt), the RdRp releases the nascent RNA, but remains 
attached to the template, and scans to the GS signal of the first gene (10, 113, 153). Here 
the RdRp reinitiates RNA synthesis and transcribes the remainder of the genome by 
stopping and restarting RNA synthesis at the gene junctions (33, 84). To replicate the 
genome, the RdRp initiates RNA synthesis opposite the 3′ terminal nucleotide of the Le, at 
position T1U. Unlike the RNA initiated at T3C, RNA initiated at T1U becomes 
encapsidated with the viral nucleoprotein (153). There is evidence to suggest that 
encapsidation is aided by the presence of 5′ AC, which is present at the end of the RNA 
initiated at T1U, but not the RNA initiated at T3C (112). Concurrent encapsidation causes 
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the RdRp to become super-processive, allowing it to synthesize RNA continuously to the 
end of the genome (40, 53). The promoter at the 3′ end of the antigenome (TrC) is identical 
in sequence to the Le for 11 of the first 13 nt (positions 4 and 12 differ), and also signals 
initiation from T1U and T3C to produce full-length genome RNA and a ∼25 nt RNA, 
respectively (101, 111, 124). The small ∼25 nt trailer-specific transcript might function to 
subvert cellular stress granule responses (56). While these findings explain how RSV 
replication and transcription are initiated, they raise the question, how does the RdRp 
initiate from two different sites within the same promoter? The RSV RdRp consists of a 
complex of two proteins, L, which contains the enzymatic domains for synthesizing, 
capping and methylating the mRNA, and the co-factor P (98, 111, 145). Studies using 
purified RSV RdRp in an in vitro RNA synthesis assay showed that the L-P complex alone 
can initiate at the T1U and T3C sites (111, 153), indicating that other RSV proteins required 
specifically for transcription or replication, M2-1 and N (20, 38, 40), do not determine 
initiation site selection. However, it is conceivable that there are distinct sub-populations 
of L-P that allow initiation either at T1U or T3C. Alternatively, the same RdRp might be 
capable of initiating at either site; if so, there must be a factor that determines the relative 
frequencies with which the two initiation sites are used. Studies using a cell based 
minigenome system, in which RNA replication was limited to a single step, showed that if 
a pyrimidine substitution or a deletion was introduced at position 1 of the TrC promoter, 
the RdRp could still produce replication product at ∼60% of wt levels. Remarkably, almost 
all the replication products were initiated at the T1 position relative to the wt promoter 
sequence, with the wt nucleotide, ATP (109). Similar results were obtained with the Le 
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promoter (112). In addition, in a study in which the first nucleotide of an internal GS signal 
was substituted, the mRNA products were initiated with wt GTP with relatively high 
frequency (83). These studies suggest that the RSV RdRp has an affinity for ATP or GTP, 
independent of the template nucleotides. If this were the case, this could be an important 
factor in allowing the RdRp to select the +1 and +3 initiation sites with the appropriate 
frequencies. However, a caveat to these minigenome experiments is that because RNAs 
analyzed were isolated from cells, the analysis would have been biased toward detection 
of stable RNAs. As the sequence at the 5′ ends of the replication and transcription products 
would be expected to affect encapsidation and capping efficiency, respectively, and thus 
RNA stability, a relatively low level incorporation of non-templated ATP or GTP could 
have been magnified. In this study, we utilized an in vitro assay, described below, to 
examine the mechanism of initiation at the RSV promoter.  
Reconstitution of RSV RNA synthesis using an in vitro RNA synthesis assay 
Analysis of intracellular RNA products from viral infections or minigenome assays is 
useful in understanding some aspects of RNA synthesis mechanisms. However, these 
assays are limited in that they only allow analysis of stable end products of RNA synthesis 
and not unstable intermediates. Additionally, it is difficult to alter the cellular environment 
(e.g. NTP concentrations). To facilitate study of the RSV RdRp activities on its promoters, 
we have previously developed an RNA synthesis assay to reconstitute RSV RNA synthesis 
in vitro (111). In this assay, purified recombinant RSV polymerase (L and P proteins) is 
incubated with an RNA template representing promoter sequence, rNTPs (including one 
[α-32P]-rNTP), and Mg2+ cofactor ions. This assay uses an unencapsidated RNA template 
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which was shown to be accepted by the RSV polymerase as a functional template (111). 
This assay recapitulates polymerase activities previously observed in RSV infected cells, 
including initiation at +1 and +3 and a 3′ extension activity (110, 111, 153). In this chapter 
and Chapter Four, we use variations on this assay to analyze RNA intermediates and 
perform mechanistic analysis of RSV RNA synthesis events. 
 
Results 
Some of these experiments were performed by Dr. Sarah Noton, Kartikeya Nagendra, and 
Molly Braun as noted in the Figure legends. For completeness of the story, all work is 
presented cohesively below. 
3.1 The L-P complex and a 14 nt promoter sequence are sufficient for precise initiation at 
T1U and T3C 
Primer extension analysis of RNA isolated from RSV infected cells showed that T1U and 
T3C were the only initiation sites detected in both the Le and TrC promoters, suggesting 
that initiation site selection is precisely controlled (Figure 4A). To characterize the 
mechanism underlying this control, RSV RdRp activity was reconstituted in vitro with an 
RNA oligonucleotide template. This assay recapitulates events that occur during infection, 
after N is displaced from the promoter (10, 111, 114). Purified L-P complexes (Figure 4B) 
were incubated with an oligonucleotide containing nucleotides 1–25 of the TrC promoter, 
and NTPs, including either [γ-32P]-ATP or [γ-32P]-GTP. Incorporation of [γ-32P]-ATP or 
[γ-32P]-GTP at the 5′ position of the RNA product would result in radiolabeled RNA 
transcripts (Figure 4C). Both [γ-32P]-ATP containing RNAs up to 25 nt in length, and [γ-
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32P]-GTP containing RNAs up to 23 nt in length were produced (Figure 4D), consistent 
with initiation from T1U and T3C, respectively (small amounts of longer [γ-32P]-GTP  
products could be due to stuttering of the RdRp on the U tracts within the template, as 
described previously (110). The products smaller than 25 and 23 nt could be RNA 
transcripts that were initiated at T1U and T3C, but that were not elongated to the end of 
the template. However, they could be RNAs initiated from other U or C residues within 
the promoter. Thus, this experiment did not show if the L-P complex alone was sufficient 
for precise initiation, meaning initiation only at positions T1U and T3C. Previous studies 
had shown that there was little difference in RNA synthesis activity from TrC templates 
ranging from 12–25 nt in length (110). Therefore, to determine if L-P was sufficient for 
precise initiation we used a shorter TrC14 template, in which the first A residue was at the 
5′ end, and [α-32P]-UTP as the tracer nucleotide. In this case, radiolabel would only be 
incorporated into the RNA products when the RdRp reached the end of the template (Figure 
4E). Products of 14 and 12 nt were detected, indicating that the RdRp initiated precisely at 
T1U and T3C, and not at other sites within the promoter (Figure 4F). This result indicates 
that all the bands labeled with [γ-32P]-ATP and [γ-32P]-GTP in Figure 4D represent RNA 
initiated at T1U and T3C, respectively. The experiment presented in Figure 4F showed that 
the 12 nt product was more abundant than the 14 nt product, indicating that the RdRp 
preferred to initiate at T3C. The ratio of products initiated at T1U and T3C in vitro was 
different from what was observed by primer extension analysis of RNA from the TrC 
promoter in RSV infected cells. The difference between the relative amounts of +1 and +3 
products in the in vitro assay compared to RSV infected cells could be due to the relative 
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stabilities of the RNAs in the cellular environment, in which the encapsidated +1 
replication product would be expected to be very stable, or could be due to technical 
reasons; for example, because the RNA initiated at T3C is only extended ∼25 nt, it might 
not bind as efficiently to the primer used for primer extension as the RNA initiated at T1U. 
Attempts were also made to examine initiation from the Le promoter using the same 
approach as illustrated in Figure 4E, with [α-32P]-UTP used as the tracer nucleotide (Figure 
5A). Because the minimal Le promoter required for detectable initiation from T1U 
contained the first UTP incorporation site at position 12, a shorter 12 nt template was used 
(Le12). However, because of a significant bias towards initiation at T3C compared to T1U, 
initiation from T1U was not detectable on the Le12 template (Figure 5B, lane 6). A longer 
14 nt Le template (Le14) was also used and compared to TrC14. However, the first UTP 
incorporation site on the Le14 template is located before the template end, making 
identification of the products initiated at T1U and T3C more difficult (Figure 5A). Under 
conditions with 1 mM each ATP, CTP, and GTP, and [α-32P]-UTP tracer, RNA products 
from initiation at T3C are clearly detectable as seen in Figure 5B lanes 8 and 10, whereas 
products from initiation at T1U are much weaker. However, under 1 mM ATP, 1 mM CTP, 
and 10 μM GTP conditions, products initiated at T1U are more readily distinguishable from 
those at T3C by comparing the wt Le14 template to Le14 (2G-to-A), which is expected to 
inhibit initiation at T1U (Figure 5C). Therefore, the Le promoter was technically less 
tractable to study than the TrC promoter. Nonetheless, the analysis showed that the Le 
promoter also signaled initiation from T1U and T3C, similarly to the TrC promoter (Figure 
5).   
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Figure 4. The RSV polymerase initiates precisely at T1U and T3C.(A) Primer extension 
analysis of RSV RNAs produced from the Le and TrC promoters, isolated from infected 
cells at different times post infection, as indicated. Bands representing RNAs initiated at 
the T1U and T3C initiation sites (indicated with +1 and +3, respectively) were identified 
by comparison to 32P-end labeled DNA oligonucleotides of equivalent sequence and length 
(38, 41, 99). (B) SDS-PAGE of purified recombinant wt L-P complexes stained with 
colloidal blue stain. (C) Schematic diagram illustrating how RNAs initiated with ATP or 
GTP were identified. The template consisted of the first 25 nt of the TrC promoter (TrC25); 
sites of radiolabel incorporation in the RNA products are underlined. (D) RNA products 
generated in the presence of [γ-32P]-ATP or [γ-32P]-GTP (i and ii, respectively). Reactions 
contained 500 µM ATP, 1 mM CTP, 10 µM GTP and 500 µM UTP (i) or 500 µM each 
NTP (ii) and were incubated for 3 hours at 37°C. In each case, lane 1 is a ladder consisting 
of a 25 nt [γ-32P] labeled RNA corresponding in sequence to RNA initiated at the +1 site, 
which had been subjected to alkali digest. i lane 2 and ii lane 3 are negative control 
reactions performed with catalytically inactive D811A L protein. (E) Schematic diagram 
illustrating how RNAs initiated at T1U or T3C were identified. The template consisted of 
the first 14 nt of the TrC promoter (TrC14), sites of radiolabel incorporation in the RNA 
products are underlined. (F) RNA products generated in the presence of [α-32P]-UTP. 
Reactions contained 1 mM each of ATP, CTP and GTP, and [α-32P]-UTP tracer. Lanes 1 
and 2 show ladders consisting of 23 or 25 nt [γ-32P] labeled RNA corresponding in 
sequence to RNA initiated at the +3 or +1 sites, respectively, which had been subjected to 
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alkali digest. Lane 3 is a negative control reaction in which the L-P complex was omitted 
from the reaction. Experiments in panel A were done by Molly Braun. Dr. Sarah Noton 
performed the experiments shown in panels D (ii), F, and repeats of the experiment in D 
(i) not shown here.  
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Figure 5. in vitro analysis of initiation sites in the Le promoter.(A) Schematic diagrams 
illustrating how RNA products initiated from T1U and T3C. RNA templates used were: wt 
le12, wt TrC14, wt Le14, and Le14 2G-to-A containing a substation at position 2 of the wt 
Le14 sequence. The sequences and lengths of the radiolabeled products that would be 
generated from the T1U and T3C sites are shown. (B) RNA products generated from 
reactions containing 1 mM each of ATP, CTP and GTP, and [α-32P]-UTP tracer. Lanes 12 
and 13 show ladders consisting of [γ-32P] labeled RNA corresponding in sequence to RNA 
initiated at the +3 or +1 sites, respectively, of the Le promoter, which had been subjected 
to alkali digest. Lanes 1-4 are negative control reactions were performed with catalytically 
inactive D811A L protein. Faint bands appearing at positions 1 nt higher than the full length 
RNA template are visible corresponding to terminal transferase activity on the RNA 
templates. In lane 6, the black arrowhead shows the position of the RNA produced from 
T1U of the Le12 promoter and the white arrowhead is an unknown product. Lanes 8 and 
10 show initiation from +3 on the longer Le14 templates. In addition, a 2G-to-A 
substitution, which is expected to inhibit initiation from position T1U, lane 10, was used 
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to differentiate products due to initiation at +1 from +3 compared to the wt Le template, 
lane 8. Lanes 7, 9, and 11 were empty. (D) RNA products generated from reactions 
containing 1 mM ATP, 1 mM CTP, 10 μM GTP, and [α-32P]-UTP on the wt Le14 and Le14 
2G-to-A templates. Lane 1 is a negative control reaction performed catalytically inactive 
D811A L protein. The data are representative of at least three independent experiments, 
one of which was performed by Kartikeya Nagendra. 
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3.2 Initiation site selection is governed by rATP vs. rGTP concentration 
Given that initiation at T1U and T3C requires ATP and GTP as the initiating NTP, 
respectively, we examined how NTP concentration affected the relative levels of RNA 
produced from the two sites. For this, we used the TrC14 template and measured relative 
levels of 14 and 12 nt products as surrogates for relative levels of initiation from +1 and 
+3. While a caveat to this approach is that these are products of both initiation and 
elongation steps of RNA synthesis, we rationalized that elongation of the RNAs initiated 
at T1U and T3C would be similarly affected by variations in NTP concentration so that 
differences observed would be due to effects on initiation. The concentrations of ATP, CTP 
or GTP were individually varied from low to high concentration, while maintaining the 
other two NTPs at high concentration (Figure 6A–C). Initiation at T3C was dominant 
compared to initiation at T1U, under all NTP concentrations tested, except those in which 
the GTP concentration was very low (Figure 6C, lane 2), demonstrating that the RdRp had 
a strong preference for initiating at T3C. The data obtained provide information on the 
relative requirements for different NTPs for the two initiation events under these assay 
conditions. For optimal initiation at T3C, the initiating NTP, GTP, was required at a 
relatively high concentration (250–500 μM), whereas the second NTP to be incorporated 
(NTP 2), ATP, was required at a significantly lower concentration of 50 μM (Figure 6I and 
G; Figure 7, F and D). For optimal replication initiation at T1U, ATP was required at 500 
μM, but NTP 2, CTP, was required at a very high concentration (2 mM; Figure 6D and E; 
Figure 7, A and B).  
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Other studies have shown that the Km for CTP during elongation is lower than for other 
NTPs (32). A control experiment, with a template containing an inserted G residue near 
the 5′ end, confirmed that a high concentration of CTP was required specifically for 
initiation, and not elongation (Figure 6J, K). This indicates that recruitment of CTP 
presented a barrier to initiation at T1U. In contrast, CTP concentration had no effect on 
initiation from +3 demonstrating that initiation at +3 did not depend on prior initiation at 
T1U (Figure 6B, H).  
 
In addition to providing information regarding NTP requirements for initiation, the data 
showed that variation of NTP concentration affected initiation site selection: increasing 
ATP caused an increase in RNA initiated at +1 and a decrease in RNA initiated at +3 
(Figure 6A, D, G; Figure 7 A and D) whereas increasing GTP caused the opposite effect 
(Figure 6C, F, I; Figure 7 C and F). Given that the template is in significant molar excess 
compared to the RdRp, this result suggests that the same population of RdRp was capable 
of initiating at the two sites, and that initiation site selection was determined by binding 
either ATP or GTP. However, even under low GTP concentrations that were the most 
favorable for initiation from +1 versus +3, the level of initiation from +1 was still relatively 
low (Figure 6C, lanes 2 and 3).  
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Figure 6. NTP requirements for initiation at T1U versus T3C.(A-C) RNA synthesis 
reactions were performed using the scheme shown in Figure 4E. The reactions contained 
1 mM each of ATP, CTP and GTP, except for the NTP being titrated, which was included 
at the indicated concentration; the [α-32P]-UTP trace was at 60 nM. Lanes 1 and 2 of panel 
A contain ladders as described for Figure 4. (D-I) Quantification of the products from the 
+1 (D-F) and +3 (G-I) initiation sites. The data were normalized to the maximum level of 
product from the +1 and +3 initiation sites in each titration, and the graphs show the mean 
and standard error of three (D, I) or four (E, F, G, H) independent experiments. (J) 
Schematic diagram illustrating the experimental design for examining the effect of CTP on 
elongation versus initiation. RNA synthesis reactions were performed using a TrC14 
template with a position 13 C-to-G substitution (indicated with an asterisk), such that 
products from both the +1 and +3 initiation sites would require CTP to be elongated to the 
end of the template. (K) RNA synthesis reactions were performed on the template shown 
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in J, with conditions described for A-C. Lane 8 is a negative control in which the L-P 
complex contained a D811A substitution in the L protein. This panel is representative of 
two independent experiments. Experiments in this Figure were done by Dr. Sarah Noton. 
 
 
 
 
 
 
 
 
 
 
Figure 7. Effect of NTP concentrations on initiation at T1U or T3C. Quantification of the 
products from the +1 (A-C) and +3 (D-F) initiation sites under conditions of varying NTP 
concentration. The graphs show the same data as presented in Figure 6, but focusing on the 
0-500 μM NTP range to show in more detail the effects of low NTP concentrations.  
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It was possible that the reason for this was that 1 mM CTP was insufficient to support 
efficient initiation from +1. To examine this possibility, GTP concentration was varied 
from 10 to 1000 μM, in the presence of 1 mM ATP and 2 mM CTP (Figure 8A). Under 
these conditions, initiation at +1 was dominant at low concentrations of GTP (Figure 8B). 
Quantification of the levels of RNA initiated at +1 and +3 showed that the total level of 
RNA product was similar at all GTP concentrations tested, and that there was an inverse 
correlation between the levels of RNA initiated at +1 versus +3 (Figure 8C). This result 
demonstrates that the RdRp could be switched between initiation sites by either ATP or 
GTP binding. 
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Figure 8. There is an inverse relationship between initiation at T1U or T3C, dependent on 
NTP concentration. (A) Schematic diagram illustrating the experimental design. The 
reactions contained 1 mM ATP, 2 mM CTP and the GTP concentration was varied from 0 
to 1000 μM; the [α-32P]-UTP trace was at 60 nM. (B) RNA synthesis products from the 
reactions. (C) Stacked bar chart showing quantification of the products initiated from the 
+1 and +3 sites. The levels of RNA initiated at +1 or +3 are shown in black and grey, 
respectively. The data obtained from replicate experiments were normalized such that the 
total level of RNA at 1000 μM GTP was 1. The data show the mean and standard error of 
three independent experiments. One of the three experiments used for the quantification 
shown in panel C was done by Dr. Sarah Noton. 
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3.3 The RSV RdRp was constrained to initiate opposite a C or UG motif 
As noted in the Introduction, experiments in the minigenome system suggested that the 
RSV RdRp can select the initiating ATP or GTP independently of the template. 
Unfortunately, it was not possible to test this hypothesis directly, by examining binding 
interactions of L-P and NTPs in the absence of RNA, because the L protein contains 
additional GTP and ATP binding sites in the capping and methyltransferase domains, 
respectively, which would affect affinity measurements (85, 119, 122). Therefore, as an 
alternative means of testing this hypothesis, we examined how mutations at template 
positions 1–3 affected initiation. Analysis of T1 mutations showed that none significantly 
inhibited initiation from T3C, indicating that the RdRp was still able to bind the template 
efficiently (Figure 9A-C). A T1A substitution or deletion (Δ1) inhibited RNA synthesis 
from +1, indicating that although the RdRp could bind the template, the identity of the 
nucleotide at the initiation site affected initiation efficiency. In contrast to the other 
mutations, a T1C substitution did not inhibit initiation from +1, but we consistently 
observed that the RNA produced migrated slightly differently than that from the wt 
template (Figure 9B, compare lanes 2 and 4). This would occur if the RNA product were 
of different sequence, suggesting that it might be initiated with GTP, rather than ATP. This 
possibility was tested by repeating the experiment using an NTP mix containing high 
concentrations of ATP and CTP and a low concentration of GTP (Figure 9D). Under these 
conditions, the intensity of the +1 band from the T1C mutant was low relative to that 
produced from the wt template, indicating that the RNA initiated from T1C was initiated 
with GTP, rather than ATP (Figure 9E, F).  
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Figure 9. The RSV RdRp prefers to initiate +1 opposite UG or C residues.(A, D) Schematic 
diagram showing the sequences of the wt and mutant templates. The asterisks indicate the 
positions of the mutations. (B, E) RNA synthesis products from wt TrC14 template, or 
templates containing mutations at positions 1, as indicated. (B) Lane 1 is a negative control 
in which the L-P complex contained a D811A substitution in the L protein. The 
experiments were performed with 1 mM ATP, CTP and GTP, and [α-32P]-UTP tracer. (E) 
Lanes 1 and 2 contain ladders described in Figure 4, and lanes 3 and 4 are negative controls 
in which the L-P complex was omitted from the reaction, or contained a D811A 
substitution in the L protein, respectively. The experiments contained 1 mM ATP, 2 mM 
CTP, 10 μM GTP, and [α-32P]-UTP tracer. (C, F) Quantification of the 14 and 12 nt 
products (black and grey bars, respectively). Product levels were normalized to those in the 
corresponding reaction containing wt template. The data show the mean and standard error 
of three independent experiments, except for panel F which shows the mean and range of 
two independent experiments. Dr. Sarah Noton performed one of the three experiments in 
panel B used for quantification in panel C and the experiments shown in panel E/F. 
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All three possible substitutions at template position 2 (T2) inhibited initiation from T1U, 
with little effect on initiation from T3C (Figure 10A-C). This showed that position T2G 
also plays an important role in enabling initiation from +1. Similar results were obtained 
with the Le promoter (Figure 5). Interestingly, a T2 G-to-C substitution in the TrC 
promoter resulted in the appearance of a 13 nt band, indicating initiation from +2 (Figure 
10B, lane 7). A template containing a T3U substitution (Figure 10D, G) yielded complex 
results. This template did not generate a 12 nt band, and while a 14 nt band was detectable 
(indicated with an asterisk), unlike the other mutant templates tested, the T3U template 
yielded a ladder of bands (Figure 10E, lane 6; Figure 10H, lane 7). This raised the 
possibility that the substitution affected the ability of the RdRp to initiate precisely and 
augmented its tendency to stutter on the U tract in the promoter (110). If this were the case, 
the 14 nt band might not represent RNA initiated at T1U. To examine this possibility, 
experiments were performed using the wt and T3U templates, with CTP omitted from the 
reaction mix to inhibit initiation from +1. Whereas omission of CTP inhibited production 
of the 14 nt RNA from the wt template, most products from the T3U template were not 
affected (Figure 10H, I). This suggested that RNAs synthesized from the T3U template 
were initiated downstream of +2. Longer products were presumably due to excessive 
stuttering on the template. This finding indicates that position T3C plays an important role 
in stabilizing the initiation complex. Our previous study in the minigenome system had 
suggested that the RdRp can select ATP and CTP independently of the template to initiate 
at +1 (112). If this were the case, the presence of a UG motif at T3 and template position 4 
(T4) might help the RdRp and allow it to initiate at +3. To test this possibility a template 
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containing a double substitution of 3U/4G was tested (Figure 10D). The additional 
substitution at T4 restored efficient initiation from +3 (Figure 10E, lane 7, F). These data 
show that T3C was important for anchoring the RdRp during initiation, but accurate 
initiation was restored if the template contained a UG motif at T3, T4. Together, these 
results show that none of the substitutions at T1 and T2 inhibited the ability of the RdRp 
to bind the template as each resulted in initiation from T3C with equal or greater efficiency 
than from the wt template; in contrast T3C was an important element of the RdRp binding 
site. Although T1U and T2G did not appear to affect RdRp recruitment to the promoter, 
both these residues were required for the RdRp to initiate efficiently at +1. The data 
indicate that a C or UG motif at the initiation site in the template stabilized the initiation 
complex, with a C substitution at T1 or T2 allowing initiation from +1 or +2 with GTP, 
respectively, and a UG motif at T3, T4 allowing efficient initiation from +3. These results 
are consistent with a model in which the RdRp has an affinity for GTP or ATP and CTP, 
independently of the nucleotides at the initiation site of the promoter. 
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Figure 10. The RSV RdRp initiates opposite UG or C residues.(A, D, G) Schematic 
diagram showing the sequences of the wt and mutant templates. The asterisks indicate the 
positions of the mutations. (B, E, H) RNA synthesis products from wt TrC14 template, or 
templates containing mutations at positions 2–3, as indicated. Lanes 1 and 2 contain ladders 
described in Figure 4, and lanes 3 and 4 are negative controls in which the L-P complex 
was omitted from the reaction, or contained a D811A substitution in the L protein, 
respectively. The experiments shown in panels B, E, and H were performed with 1 mM 
ATP, CTP and GTP, and [α-32P]-UTP tracer (with CTP omitted in some reactions in panel 
H as indicated). (C, F, I) Quantification of the 14 and 12 nt products (black and grey bars, 
respectively). Product levels were normalized to those in the corresponding reaction 
containing wt template. Panel F only shows 12 nt product because the 14 nt band generated 
from the mutant template was not initiated at +1. The data show the mean and standard 
error of three independent experiments, except for panel I, which shows the mean and range 
of two independent experiments. Dr. Sarah Noton performed two of the three repeats of 
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experiments shown in panels B/C and E/F. Dr. Sarah Noton performed one of the two 
repeats of the experiments in panel H used for quantification shown in I.  
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3.4 The RdRp could initiate with a non-cognate NTP on a longer template 
Although the conclusion that the RdRp can select initiating NTPs independently of 
template nucleotides is consistent with previous findings (109, 112), the results obtained 
in Figures 10 and 11 differed in that in the minigenome system, deletion of T1U, or a T1U-
to-C substitution resulted in replication product at 50–60% of wt levels, almost all of which 
was restored to wt sequence, whereas this was not the case in the experiments described 
above. As noted in the Introduction, this discrepancy could be due to a bias in the RNAs 
analyzed in the minigenome system. Alternatively, it could be because the conditions used 
in vitro did not support initiation with a sub-optimal complex in which the template and 
initiating NTPs did not match. During the course of this work, a crystal structure of the 
bunyavirus RdRp in complex with promoter RNA became available, and modeling based 
on this structure indicated that the RdRp could bind 20 nt of template RNA (47). We 
reasoned that if the RSV RdRp binds a similar template length, it was possible that the 14 
nt template was too short to allow the RdRp, ATP and template to form a stable initiation 
complex without base-pairing between T1 and ATP. To test this hypothesis, we tested 
templates 25 nt in length and containing a deletion or substitution at T1U, and used [γ-32P]-
ATP as the trace nucleotide (Figure 11A). A similar pattern of products was generated from 
the wt and mutant templates, indicating that with a longer template, the RdRp could initiate 
with ATP irrespective of the identity or presence of position 1 (Figure 11B). We considered 
the possibility that an alternative explanation for the difference between the TrC14 and 
TrC25 templates was that in the case of TrC25, the RdRp had the potential to enter the 
template internally at positions 22 and 23 and generate a pppApC primer that could 
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subsequently be used to initiate at +1. Therefore, the experiment was repeated with 
templates containing a substitution at position 23. In each case the RdRp was able to initiate 
with ATP (Figure 11C). It should be noted that in these experiments the reactions contained 
high concentrations of ATP and CTP and a low concentration of GTP to enhance initiation 
at +1 and allow us to detect the products more readily. Nonetheless, this finding supports 
the conclusion that the RdRp can become preloaded with ATP and shows that initiation 
with a non-cognate NTP depends in part on RNA contacts downstream of nt 14 of the 
promoter. 
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Figure 11. The RdRp could initiate with non-templated ATP on a TrC25 template. (A) 
Schematic diagram illustrating how RNAs initiated with ATP were identified, as described 
in Figure 4C. Reactions contained a TrC25 template with either a deletion or substitution 
at position 1 (indicated with an asterisk). Position 23, which was mutated from a G-to-A 
residue in some templates is indicated. (B and C) RNA products initiated with [γ-32P]-ATP 
from the wt and mutant templates. RNA synthesis reactions contained 500 μM ATP, 1 mM 
CTP, 10 μM GTP and 500 μM UTP, and [γ-32P]-ATP tracer. Panel B lanes 1 and 2 show 
the +3 and +1 ladders, prepared as described in Figure 4. Panel B, lane 5 is a negative 
control reaction performed with catalytically inactive D811A L protein, lane 3 is empty. 
The data in panel B are representative of five or more independent experiments (depending 
on the mutation); the data in panel C are representative of two independent experiments. 
These experiments were done by Kartikeya Nagendra with some repeats performed by me. 
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3.5 The RSV RdRp did not generate a pool of dinucleotide primer independently of the 
template 
The data presented in Figure 9-11 suggest that the RSV RdRp can select ATP and CTP, 
independently of the template to initiate at T1. Other RdRps have been shown to generate 
dinucleotide primers independently of the template (14, 138). Therefore, we examined if 
the RSV RdRp was capable of polymerizing ATP and CTP in a template independent 
manner. In a control experiment containing a wt TrC14 template and ATP, GTP, UTP and 
[α-32P]-CTP a prominent two nucleotide band could be detected provided the reactions 
contained Mn2+, rather than Mg2+, to facilitate initiation (Figure 12A and B, lanes 1 and 8) 
(110). The band could be detected if GTP or UTP were omitted from the reaction, but not 
if ATP was omitted (Figure 12B, lanes 5-7) indicating that it represented a pppApC 
dinucleotide. Reactions performed with all four NTPs, but in which the template was 
omitted did not yield the pppApC dinucleotide. This was also the case if the reaction 
contained a Δ1 TrC14 template (Figure 12B, lanes 3 and 4). These results show that the 
RdRp does not have the capability to reiteratively produce AC dinucleotide in a template 
independent manner, although we could not rule out the possibility that it catalyzed 
phosphodiester bond formation but did not release the resulting dinucleotide, resulting in 
undetectable levels of dinucleotide product. Later experiments with reactions containing 
the catalytic ion Mg2+ did yield a detectable two nucleotide band which migrated at the 
same position as the pppApC dinucleotide identified from reactions containing Mn2+, 
though less of the product was observed with Mg2+ than with Mn2+ even with 5.7 times 
more polymerase in the Mg2+ reaction (Figure 13 A-B). As with Mn2+, this two nucleotide 
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band was detected if GTP or UTP was omitted from the reaction, but not if ATP was 
omitted (Figure 13 C). On these longer exposures in these experiments, in which GTP was 
omitted and thus RNA synthesis should be limited to pppApC production, weaker bands 
larger than two nucleotides were observed. It is thought these are due to misincorporation 
of position 3 in the absence of GTP. 
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Figure 12. The RdRp could not efficiently synthesize a pppApC dinucleotide primer 
independently of the template. (A) Schematic diagram showing the requirements for 
production of a pppApC dinucleotide product. Reactions contained [α-32P]-CTP and the 
site of radiolabel incorporation in the product is underlined. GTP and UTP are shown in 
parentheses because they were included in the positive control reaction, but could be 
omitted without affecting formation of the pppApC dinucleotide. (B) RNA products 
generated in the presence of all four NTPs (lanes 1–4 and lane 8) or in reactions from which 
either GTP, UTP or ATP was omitted (lanes 5–7). Reactions were performed either in the 
presence or absence of TrC14 template RNA, or with TrC14 RNA containing a deletion at 
position 1. Reactions were performed in the presence of Mn2+, rather than Mg2+, except 
that shown in lane 8. Only the region of the gel between the 1 and 2 nt markers is shown 
(note that the markers did not align with the bands because they contain a 5′ 
monophosphate, rather than triphosphate). This panel is one of five independent 
experiments performed by Kartikeya Nagendra. 
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Figure 13. The RdRp could synthesize a pppApC dinucleotide primer with Mn2+ or 
Mg2+(A) Schematic diagram showing the requirements for production of a pppApC 
dinucleotide product. Reactions contained [α-32P]-CTP and the site of radiolabel 
incorporation in the product is underlined. UTP is shown in parentheses because it was 
included in the positive control reactions, but could be omitted without affecting formation 
of the pppApC dinucleotide. (B) RNA products generated in the presence of ATP, CTP, 
and UTP. Reactions were performed in the presence of Mn2+ (lanes 1 and 2) or Mg2+ (lanes 
3 and 4). Lane 1 is a negative control performed with the catalytically inactive D811A 
polymerase. Lanes 1-3 all contain the same amount of polymerase (50 ng L). Lane 4 is 
performed under the same conditions as lane 3, except with 5.7 times the amount of 
polymerase (285 ng). (C) RNA products generated in the presence of ATP, CTP, and UTP 
(lanes 1 and 2) or with ATP omitted (lane 3) or UTP omitted (lane 4). Reactions were 
performed with Mg2+. Lane 1 is a negative control performed with the catalytically inactive 
D811A polymerase. Panels are from the same gel with intervening lanes omitted. 
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Discussion 
The process of RNA synthesis initiation is complex, involving multiple players, including 
the RdRp, promoter and first two NTPs of the RNA product, as well as metal cations for 
catalysis (155). Each of these factors must be positioned appropriately, relative to the 
others, for initiation to be successful. This is even more challenging in the case of viruses 
that initiate RNA synthesis from the 3′ end of a linear template, as there is no template 
upstream of the initiation site to stabilize RdRp contacts. There is another layer of 
complexity in the case of RSV, in which the RdRp initiates RNA synthesis precisely at two 
closely spaced initiation sites within the genomic and antigenomic promoters. This unusual 
feature of RSV RNA synthesis, and the fact that initiation at both the +1 and +3 sites is 
required to allow the virus to perform replication and transcription, respectively, indicates 
that RSV must have evolved a specific initiation mechanism. The information presented 
here provides insight into the relationship between the two different initiation events, and 
the RdRp, NTP and template requirements for them to occur, and suggests a model for this 
initiation process. Studies of vesicular stomatitis virus, another nsNSV in a different 
family, have indicated that there are two functionally distinct pools of RdRp, distinguished 
by associated proteins; one pool initiates at T1 of the Le to begin replication, and the other 
initiates at the GS signal for the first gene, to begin transcription (102, 128, 165). In 
contrast, the data presented here clearly shows that RSV L and P alone are capable of both 
replication and transcription initiation at the T1U and T3C sites (Figure 4). Another 
possible explanation for why the L-P complex could initiate at two different sites was that 
there could be functionally distinct sub-populations of RdRp, with one capable of initiating 
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at T1U and the other at T3C. However, this is also not the case as varying the ATP or GTP 
concentration in the reaction resulted in an increase or decrease in initiation at T1U and 
T3C, with an inverse relationship between initiation at the two sites (Figure 6 and 8). This 
finding indicates that the L-P complex was undifferentiated before beginning RNA 
synthesis and that it became committed to initiation at T1U or T3C, depending on whether 
it associated with ATP or GTP. The data indicate that the RdRp becomes loaded with the 
initiating NTPs prior to binding the template, or at least, without reference to template 
nucleotides. Findings made with the minigenome and a 25 nt template containing a 
mutation of T1U indicated that the RdRp associates with ATP independently of this uracil 
(109, 112) (Figure 11). Furthermore, the data indicate that not only is the RdRp capable of 
selecting ATP independently of T1U, but that it can become loaded with ATP and CTP, or 
GTP. Analysis of mutant TrC14 templates showed that the RdRp could initiate at T1, T2, 
or T3 provided it was initiating opposite either a UG motif, or a C residue. The simplest 
explanation for why the RdRp was stabilized opposite a UG or C motif is that in its pre-
initiation form it has an innate affinity for ATP and CTP, or GTP. Other viral RdRps have 
also been shown to have innate affinity for some NTPs to begin initiation. While in some 
cases the bound NTP binds outside the catalytic site and has a structural role, in other cases 
the NTP is incorporated into polymerized product, as we propose occurs for RSV (14, 18, 
26, 138, 146). As noted above, ATP and GTP had opposing effects on the relative levels 
of initiation from T1U and T3C. In contrast, while CTP was essential for initiation at T1U, 
varying CTP concentration had no effect on initiation at T3C (Figure 6). These results 
indicate that ATP and GTP compete for the same binding site on the RdRp, whereas CTP 
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binds another site; they also indicate that CTP does not influence ATP binding. 
Examination of the concentrations of ATP and GTP required for optimal initiation at T1U 
and T3C, respectively, showed that a lower concentration of GTP was sufficient for optimal 
initiation from +3, than the concentration of ATP required for optimal initiation from +1. 
This suggests that the polymerization domain of the RdRp has a greater affinity for GTP 
than ATP. If this were the case, this would help promote initiation at T3C. Furthermore, 
CTP was required at a very high concentration for optimal initiation at T1U, indicating that 
recruitment of CTP represents a barrier to initiation at this site (Figure 6E). This indicates 
that the initiating form of RdRp has only a low affinity for CTP. Given that CTP 
concentrations in cells would be expected to be approximately five-fold lower than those 
used in the assays described here, this would limit the level of replication initiation from 
T1U compared to transcription initiation from T3C. This would aid transcription at the 
expense of genome replication, and is likely to be important for efficient viral replication. 
In addition to NTP concentrations, the promoter sequence also played an important role in 
governing the relative levels of initiation from the two sites. We have previously shown 
that nucleotides 3, 5, 8, 9, 10, and 11 of the template are a core promoter element, important 
for both transcription and replication initiation (41). This element is almost identical to the 
GS signals at the beginning of each gene, and would be predicted to direct initiation from 
+3 (113, 153). Consistent with this, initiation from +3 was dominant in almost every 
condition tested. This dominance was independent of relative affinity of the RdRp for GTP 
versus ATP because templates containing a C residue at T1 or T2 showed dominant 
initiation at T3C. Likewise, in the case of a 3U/4G template, in which the RdRp had the 
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potential to initiate with ATP and CTP at T1 or T3, the dominant initiation site was at T3 
(Figure 10). Together, these findings indicate that the RdRp preferentially binds the 
promoter such that its catalytic site is positioned opposite T3 and T4. The concept that the 
RdRp preferentially binds the promoter with its catalytic site positioned internally shares 
similarities with that of other RdRps. Seminal work on the mechanism of RdRp RNA 
synthesis initiation by analysis of crystal structures of bacteriophage φ6 RdRp, with or 
without template and NTPs, revealed that in the absence of NTPs, the RdRp bound the 
template such that the catalytic residues were aligned opposite T3 rather than T1. Upon 
binding NTPs, and their base-pairing with T1 and T2, the RdRp ratcheted back on the 
template to reposition T1 opposite the catalytic residues (12). Initial overshooting of the 3′ 
end of the template relative to the catalytic site has since been described for other RdRps, 
although it is not a universal feature (26, 47, 91, 133, 147). Inspection of the RSV promoter 
shows that the sequence at 5, 8, 9, 10 and 11 is also present at 3, 6, 7, 8, and 9, such that 
there is the potential for the RdRp to form similar interactions with template bases when 
its active site lies opposite T1 and T2 rather than T3 and T4 (Figure 14). Therefore, it seems 
likely that the RSV RdRp has stronger promoter interactions when located with its active 
site opposite T3 and T4, but has the potential to move between the two registers. Together 
the data presented here and the information available for other viral RdRps suggest the 
following model for replication and transcription initiation in RSV (Figure 14). According 
to this model, the RSV polymerization domain contains at least two NTP binding sites, 
known as the priming (P) and incoming nucleotide (N) sites. Initially, the RSV RdRp exists 
as single undifferentiated pool consisting of a complex of the viral L and P proteins. The 
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RdRp has the capability to bind ATP or GTP in its P site. ATP binding might affect the 
conformation of the N site, allowing CTP to bind specifically, or the N site might 
preferentially bind CTP. The RdRp binds the promoter, with a tendency to be positioned 
such that the P and N sites are opposite T3 and T4. If the RdRp is preloaded with GTP, it 
can recruit the appropriate NTP to base-pair with T4 and begin RNA synthesis directly 
from T3C to start the process of transcription. If the RdRp is pre-loaded with ATP and 
CTP, base-pairing between these NTPs and T1U and T2G alter the optimal template 
binding site, such that the RdRp is positioned with its P and N sites opposite T1 and T2. 
Having become positioned with the ATP and CTP opposite T1U and T2G, the RdRp could 
catalyze phosphodiester bond formation, and initiate RNA replication from +1. If this 
model is correct, it indicates that the RSV RdRp has evolved to combine features present 
in other RdRps, such as specific interaction with initiating NTPs and a propensity for 
internal binding and template repositioning, to specifically and precisely initiate at two 
different sites within the promoter. In addition, it can explain how the virus has evolved to 
control relative levels of its different RNAs. During infection, RSV produces mRNA at 
higher levels than replicative RNAs, and genome RNA at a higher level than antigenome. 
The Le and TrC promoters differ at T4, with the Le having a G rather than U residue at this 
site. If the N site has affinity for CTP, the difference in the nucleotide at T4 between the 
Le and TrC promoters could strongly promote transcription versus replication initiation at 
the Le promoter, while allowing more efficient genome than antigenome initiation. Thus, 
together these findings indicate that RSV has evolved a simple and efficient mechanism to 
allow the RdRp to begin both mRNA transcription and genome replication from a single 
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promoter, and synthesize appropriate levels of mRNA, antigenome, and genome during 
infection. 
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Figure 14. Model for transcription and replication initiation by the RSV RdRp.Schematic 
diagram illustrating different steps in initiation. The polymerization domain of the L 
protein is shown as a blue oval, with the P (priming) and N (incoming nucleotide) sites 
indicated. The RdRp can become loaded with GTP or ATP and CTP. The RdRp interacts 
with the promoter, possibly forming major contacts with the nucleotides indicated with a 
black dot. This would allow the RdRp to be positioned in two registers with respect to the 
template, with the P and N sites positioned opposite either T3 and T4, or T1 and T2, with 
the register being stabilized by Watson-Crick base-pairing between preloaded GTP or 
ATP/CTP, respectively. This would allow transcription initiation opposite T3C, or 
replication initiation opposite T1U. The model shows the TrC promoter sequence that was 
utilized for most of this study. We propose that a similar sequence of events occurs during 
initiation from the Le promoter. 
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CHAPTER FOUR: THE PUTATIVE PRIMING LOOP OF THE RSV 
POLYMERASE IS INVOLVED IN COORDINATING THE RNA SYNTHESIS 
INITIATION COMPLEX 
Introduction 
Common features of the nsNSV polymerases 
The RSV polymerase consists of a complex of two viral proteins, the 250 kDa L and the 
~40 kDa P. L contains all the enzymatic domains required for genome replication and 
transcription and P is an essential co-factor. Six conserved regions (CRI through CRVI) 
have been identified within the nsNSV L proteins (Figure 15A). The RdRp domain 
includes CRI, CRII, and CRIII (126). The capping domain includes CRIV and CRV and 
the methyltransferase domain contains CRVI. In addition to the conserved RdRp, capping, 
and methyltransferase domains, poorly conserved connector and C terminal domains have 
been identified. The first nsNSV polymerase structure to be resolved was that of VSV 
(Figure 15B) (86). These polymerases, along with a large group of RNA and DNA 
polymerases have been described to share a common shape resembling a cupped right 
hand, which is further divided into fingers, palm, and thumb subdomains (Figure 16).  
  
  
114 
 
Figure 15. Domain organization and structure of the nsNSV L proteins and structure of 
VSV L. (A) Linear representation of nsNSV L protein showing conserved regions (CR) I 
– VI and domains identified by Liang et al (86). Numbering of residues at domain 
boundaries according to RSV L sequence. The polymerase domain is in blue (RdRp), the 
capping domain is in green (capping), the connector domain is in yellow (CD), the 
methyltransferase domain is in orange (MT), and the C terminal domain is in red (CTD). 
N and C termini are labelled (N, C respectively). Black lines indicate linker regions. (B) 
Views of the VSV L structure rotated 180º about y-axis (PDB: 5A22). Domains colored as 
shown in panel A.   
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Figure 16. Examples of polymerases with cupped right hand shape and fingers-palm-thumb 
subdomains.  Common right hand shape to polymerases shown here with fingers 
subdomain in blue, palm subdomain in red, and thumb subdomain in green. Examples 
shown are (A) VSV PDB:5A22 (B) influenza B virus, PDB:4WRT (C) reovirus 
PDB:1MUK (D) rotavirus PDB:2R7Q polymerases. Adapted from Liang et al (86) 
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Models of RNA synthesis initiation by viral polymerases 
RNA virus polymerases have two major strategies for the initiation of RNA synthesis: 
primer-dependent and primer-independent, or de novo, initiation (150). In primer-
dependent initiation, a protein or oligonucleotide primer is utilized to stabilize the initiation 
complex and facilitate the initiation of RNA synthesis. Some polymerases, such as 
influenza A virus polymerase, can also utilize a combination approach of both de novo an 
primer-dependent known as a prime-realign mechanism (31, 45). In de novo initiation, 
polymerases do not utilize a primer and instead use a variety of mechanisms to stabilize 
the initiation complex. Reovirus λ3 polymerase has been shown to utilize a loop inserted 
into the palm domain, along with other residues in the polymerase, to stabilize the initiating 
GTP (147). Bovine viral diarrhea virus utilizes a loop within the thumb domain, along with 
a bound non-templated GTP to form base-stacking interactions with the initiating NTP and 
stabilize the complex (18). Several other RNA polymerases, such as bacteriophage φ6 
polymerase, have been shown to stabilize the initiation complex using a priming loop that 
extends into the central cavity of the RdRp active site and forms base stacking interactions 
between an aromatic or ring-based residue within the loop and the initiating NTPs (12). 
The nsNSV polymerases are thought to utilize the de novo initiation strategy and thus may 
possess priming loops. In the RSV de novo initiation complex, the first and second NTPs 
of the RNA product are base paired with the first two 3′ terminal template bases, T1 and 
T2 respectively. These interactions are not thought to be sufficient to properly coordinate 
the initiation complex and hold the NTPs in the correct position for phosphodiester bond 
formation.  
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Priming loops and residues 
Priming loops in viral polymerases other than nsNSV polymerases have been described 
previously in bacteriophage φ6, reovirus λ3, hepatitis C virus (HCV), dengue virus, West 
Nile virus, permutotetravirus Thosea asigna virus, and influenza A virus polymerases (12, 
43, 63, 94, 147, 149, 171). Such priming loops are a common feature of RNA polymerases 
which perform primer-independent (de novo) RNA synthesis initiation. The first priming 
loop identified was that of bacteriophage φ6 polymerase in which an aromatic residue at 
the tip of the priming loop stabilizes the initiation complex (Figure 17) (12). In this 
structure, base stacking interactions are formed between the tyrosine of the priming loop 
and the first initiating NTP (NTP 1) with NTP 2 also stacked with NTP 1 (Figure 17). The 
template is aligned such that the bases of NTP 1 and NTP 2 form Watson Crick base pairing 
interactions with T1 and T2 (Figure 17). It is thought that priming residues in other viral 
polymerases function by a similar mechanism, acting as a platform for the formation of 
this complex by NTP stabilization for de novo initiation at the 3′ terminus.  
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Figure 17. Priming loop and initiation complex of bacteriophage φ6 polymerase. Structure 
of the bacteriophage φ6 polymerase adapted from Butcher et al (PDB: 1HI0) (12). 
Polymerase shown in grey, priming residue (Y630) in yellow, template in aqua, NTP 1 and 
NTP 2 are multicolored by atom type, and catalytic Mg2+ ions are in green. Structure shows 
the initiation complex with the priming residue forming base stacking interactions with 
NTP 1. NTP 1 and NTP 2 bases are aligned with Watson Crick base pairing interactions 
with the first two bases of the template strand, T1 and T2 respectively.  
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The putative priming loops of the other viral polymerases have been proposed through a 
combination of structural and biochemical analysis, though not all are as definitively shown 
to function base stacking with NTPs as the bacteriophage φ6 polymerase. Nearly all 
priming residues proposed thus far are either aromatics or other ring-based residues, i.e. 
proline or histidine; residues which are capable or forming base-stacking interactions (93). 
Reovirus λ3 polymerase appears to be divergent in that it has a unique insertion in the palm 
domain which does not contain an aromatic or ring-based residue, yet stabilizes the rNTPs 
in the initiation complex (147). It is generally accepted priming residues stabilize the 
formation of the initiation complex to allow for initiation of RNA synthesis at the end of 
linear templates, i.e. terminal initiation. It is possible priming residues may not be as strictly 
required for internal initiation events. Influenza A polymerase is interesting in that it uses 
a de novo initiation mechanism to perform replication from one promoter, and also a 
primer-dependent initiation mechanism by initiating RNA synthesis internally and 
realigning to prime replication from its other promoter (31). It was shown a proline residue 
is required for de novo initiation at the 3′ terminus, but not primer-dependent and internal 
initiation. 
Structures of nsNSV polymerases and priming loops 
Prior to 2019, only two structures were available of nsNSV polymerases, HMPV and VSV 
(86, 122). The HMPV structure only included CRVI, required for cap methylation, and the 
C terminal domain of the polymerase and did not show any of the RdRp and capping 
domains, required for RNA synthesis and capping respectively, where a priming loop is 
expected to exist (122). The VSV polymerase structure did include all of conserved 
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domains of the polymerase including the RdRp and capping domains and shared the right 
hand shape common to other polymerases (86). The VSV structure was solved in a pre-
initiation state and showed a flexible loop extending into the central catalytic cavity of the 
polymerase. It was proposed this may function as a priming loop for the VSV polymerase. 
A later study by Ogino et al. analyzed L variants containing individual alanine substitutions 
in this loop of the VSV and rabies virus (RABV) polymerases in biochemical assays and 
identified a tryptophan residue as the rhabdovirus putative priming residue (117). This 
residue was found to be required for +1 initiation of RNA synthesis but not an internal 
RNA synthesis initiation event for RABV (117). Priming residues for any of the other 
families of Mononegavirales and their similarities to the rhabdovirus putative priming 
residue have not been described, nor until very recently have any structures of the RdRp 
and capping domains of the polymerases of any of these families been available. The 
paramyxovirus, pneumovirus, and filovirus polymerases are more closely related to each 
other than to the rhabdovirus polymerases (Figure 18), thus it is possible the priming 
residue may differ between the rhabdoviruses and other families of the order. A structure 
of the RSV polymerase RdRp and capping domains in an elongation conformation was 
published recently (49). The study presented below was done prior to the availability of 
the RSV polymerase structure and the data will be presented in that context below. 
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Figure 18. Phylogenetic tree diagram of the Mononegavirales order. Phylogenetic tree 
diagram of the families of the Mononegavirales order constructed based on L protein 
sequences. Shows eight of the eleven families of Mononegavirales: rhabdoviridae, 
pneumoviridae, paramyxoviridae, filoviridae, sunviridae, nyamiviridae, bornaviridae, 
and mymonaviridae. Adapted from Ortega et al. (121). 
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Reconstitution of RSV RNA synthesis using the minigenome system 
RSV RNA synthesis was reconstituted in cells using a previously described minigenome 
assay (52). The Le46G minigenome contained the Le promoter at the 3′ end and trailer 
sequences at the 5′ end (153). The naturally occurring RSV genes were replaced with two 
fragments of CAT (Figure 19). Each fragment, CAT1 and CAT2, is flanked by RSV GS 
and GE sequences. To allow for analysis of effects on replication and transcription as 
independent events, a substitution at position 2 relative to the 5′ end was made to inactivate 
the TrC promoter at the 3′ end of the antigenome, as described previously (41). RSV RNA 
synthesis was reconstituted in cells by transfecting BSRT7/5 cells with plasmids 
expressing the minigenome and RSV L, P, N, and M2-1 proteins required for RNA 
synthesis (10, 112). BSRT7/5 cells constitutively express T7 polymerase, which drives 
expression of the minigenome and RSV L, P, N, and M2-1 mRNA, which are translated 
by cellular machinery to produce the RSV proteins (11). Precise 3′ minigenome ends are 
generated by self-cleavage by a hammerhead ribozyme (52). This system allows for 
reconstitution of replication, synthesis of encapsidated antiminigenome, and transcription, 
synthesis of ~25 nt transcripts and capped and polyadenylated CAT1 and CAT2 mRNA 
(Figure 19). We use this system to analyze RNA synthesis activities of variant L 
polymerases by transfecting cells with plasmids encoding for each variant L protein or wt 
L and analyzing the effects on replication and transcription. In addition to the Le46G 
minigenome, a TrC promoter based RSV minigenome was used in these studies, DM124 
(109). In DM124, the Le promoter and the GS signal were replaced with nt 1-36 of the TrC 
promoter (Figure 20). The RdRp still initiates RNA synthesis from +1 for replication and 
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from +3 to synthesize a ~25 nt transcript, but does not synthesize mRNA. To allow for 
analysis of effects on replication and transcription of the ~25 nt RNA as independent 
events, a deletion of 22 nucleotides relative to the 5′ end was made to inactivate the TrC 
promoter at the 3′ end of the antigenome.  
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Figure 19. Schematic of Le46G minigenome assay. RSV negative-sense genome shown at 
the top. Below the genome, is a diagram depicting the negative-sense Le promoter based 
minigenome Le46G (153). Regions of the RSV genome retained in the minigenome analog 
are indicated with dashed grey lines, including the Le, NS1 GS, N GE, N-P intergenic 
region, P GS, L GE, Tr. A 2C-to-G substitution in the Tr (red X) limits replication to a 
single round. GS signals are black boxes. GE signals are white boxes. Genes are in blue. 
Le promoter and direction of RNA synthesis depicted by a green arrow. Minigenome 
plasmid along with plasmids expressing RSV L, P, N, and M2-1 are transfected into 
BSRT7/5 cells. Replication product and transcription products are produced by the RSV 
RdRp using the minigenome as a template. Replication product is the 970 nt 
antiminigenome. Transcription products include the ~25 nt Le transcript, 580 nt CAT 1 
mRNA, and 190 nt CAT 2 mRNA.  
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Figure 20. Schematic of DM124 minigenome assay. RSV positive-sense antigenome 
(replication product) shown at the top. Below antigenome is the negative-sense genome. 
Below the genome, is a diagram depicting the negative-sense TrC promoter based 
minigenome DM124 (109). Regions of the RSV genome retained in the minigenome 
analog are indicated with dashed grey lines, including the 3′ terminal 36 nt of the TrC, N 
GE, N-P intergenic region, P GS, L GE, Tr. A 22 nt deletion in the Tr (red X) limits 
replication to a single round. GS signals are black boxes. GE signals are white boxes. Genes 
are in blue. Promoter and direction of RNA synthesis depicted by a green arrow. 
Minigenome plasmid along with plasmids expressing RSV L, P, N, and M2-1 are 
transfected into BSRT7/5 cells. Replication product and transcription product are produced 
by the RSV RdRp using the minigenome as a template. Replication product is 
antiminigenome. Transcription product is the ~25 nt Tr transcript. 
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In the study discussed in this chapter, we hypothesized a ring-based amino acid residue in 
the RSV RdRp exists and stabilizes the initiation complex by forming base-stacking 
interactions with initiating NTPs. We aimed to identify the RSV RdRp putative priming 
residue and determine whether the RSV priming residue is involved in both +1 and +3 
RNA synthesis initiation.  
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Results 
4.1 Modeling of nsNSV L structures 
At the beginning of this study, there was no available structure for the RSV polymerase 
and the only structure of the RdRp domain of an nsNSV polymerase was that of VSV in a 
pre-initiation state. As a tool, to visualize the primary sequence of the RSV polymerase, I 
constructed a predicted structural model of the RSV L protein based on its homology and 
alignment to VSV L. While structure prediction software is not reliable for detailed and 
accurate modeling of a structure, especially for a large protein such as the 2165 amino acid 
RSV L protein, it was thought this predicted structure may be a useful tool for the three-
dimensional visualization of the alignment of RSV and VSV L amino acid sequences. A 
predicted structural model of the RSV L RdRp and capping domains was constructed using 
the structure of VSV L reported by Liang et al and the MODELLER comparative modeling 
tool in UCSF Chimera (Figure 21) (86, 125, 170). Regions of RSV L that were not 
homologous to VSV L could not be predicted using this structure and were removed from 
the model. This predicted structure of RSV L was used along with primary structure 
alignments and comparison with VSV and other polymerases to identify potential priming 
residues in the RSV polymerase (Figure 21).  
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Figure 21. Predicted structural model of the RSV L RdRp and capping domains.  (A) 
Structure of VSV L RdRp and capping domains (PDB: 5A22) (86) used to construct a (B) 
predicted structure of RSV L RdRp and capping domains. RdRp domains in blue, capping 
domains in green, VSV putative priming loop and homologous region of RSV L shown in 
gold. 
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4.2 Alignment, structure modeling, and literature analysis to identify potential priming 
residues in the RSV polymerase 
Several polymerase structures have been solved for RNA virus polymerases in initiation 
conformations with putative priming residues identified. As a means to identify potential 
RSV priming residues, the distance from the putative priming residues and the catalytic 
aspartic acid residue of these polymerases in initiation conformations was measured using 
the UCSF Chimera software (Table 7). It was of note, that in all of the measured structures 
of other polymerases, these residues were separated by approximately 10-15 Å (Table 7). 
It is thought priming loops must move out of the central catalytic chamber following 
initiation of RNA synthesis, allowing for the nascent RNA strand and template to exit the 
appropriate channels and resulting in a conformational change between initiation and 
elongation states (147). We were interested in determining how much a priming residue 
moves during such conformational changes as the VSV polymerase structure used for 
modeling in this study is in a pre-initiation state, i.e. there was no RNA template or NTPs 
present, and the template and RNA product exit channels were not visible (86). I compared 
RNA polymerase structures that have been solved with and without RNA template and/or 
rNTPs (indication of initiation states) and measured the distance between the putative 
priming residues and the catalytic residue (Table 7). The change in distance between these 
residues ~1 Å. Thus, it seemed reasonable to conclude the priming residue within the RSV 
polymerase predicted structure may be located within 16 Å from the catalytic aspartic acid 
residue. The UCSF Chimera software was used to generate a list of all residues within 16 
Å of the aspartic acid residue of the GDNQ motif in the predicted RSV structural model. 
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As priming residues thus far have been shown to be aromatic or ring-based residues 
(proline or histidine), only tyrosine, tryptophan, phenylalanine, proline, and histidine 
residues within 16 Å were examined further. Residues not highly conserved in the pneumo, 
filo, and paramyxovirus families were also removed from analysis. This gave a curated list 
of potential priming residues based on homology and structural analysis (Table 8). Of 
these, a few were discarded from consideration based on their location within the predicted 
structure (e.g. RSV L H734 was on the outside face of the protein and in the central 
catalytic chamber where RNA synthesis takes place). In addition to this structural analysis 
and identification of potential priming residues, we decided to include RSV L P1274 and 
Y1276 which are the ring-based residues most homologous to the VSV L putative priming 
residue in a sequence alignment. In addition, alignment of the region of the nsNSV L 
proteins adjacent to the putative VSV priming loop revealed conserved proline and 
tryptophan residues just outside of this loop (RSV L P1261 and W1262 respectively) 
(Figure 22). We decided to include RSV L P1261 and W1262 in our analysis, as they were 
so well conserved and close to the VSV putative priming loop. It is generally accepted 
these loops are flexible, and thus it is possible that these residues extend into the central 
catalytic chamber of RSV L. Thus, we decided to pursue RSV L F629, F704, W785, P1261, 
W1262, P1274, and Y1276 as potential priming residues in RSV (Figure 23).  
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Table 7. Distance between priming residue side chain and catalytic aspartic acid residue 
side of GDD motifs. 
 
 
Table 8. Conserved residues in RSV L located within 16 Å of the catalytic aspartic acid 
residue of the GDNQ motif and distance between other residues of interest and the catalytic 
residue. 
RSV 
residue 
distance from catalytic residue (Å) discarded from further analysis 
based on location 
F629 14.8 No 
F704 4.4 No 
F730 16.547 Yes  
H734 13.194 Yes  
W785 8.7 No 
P1258 33.7 No 
P1261 27.4 No 
W1262 30 No 
P1274 16.8 No 
Y1276 19.6 No 
  
polymerase PDB code RNA template and NTPs 
present (Yes/No) 
distance 
(Angstrom, 
Å) 
influenza A 
virus (149) 
4WSB Yes 12.5 
Phi6 (12) 1HI0 Yes 11.4 
1HHS No 10.7 
reovirus λ3 
(147) 
1N1H Yes 15.3 
1MUK No 13.7 
hepatitis C virus 
(2, 3, 116) 
1NB7 Yes 13.8 
1QUV No 13.1 
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Figure 22. Alignment of representative nsNSV L proteins in region homologous to 
rhabdovirus priming residue. Alignment of nsNSV L proteins generated by ClustalW 
program, includes the pneumovirus RSV, filoviruses MARV and EBOV, paramyxoviruses 
HPIV3, MuV, and SeV, and rhabdoviruses VSV and RABV L proteins. Prolines 
highlighted in blue, aromatics (tryptophans, tyrosines, phenylalanines) highlighted in red, 
histidines highlighted in yellow. RSV L residues of interest identified and numbered above 
the alignment. 
  
  
133 
 
 
Figure 23. Visualization of selected residues of interest in RSV L predicted structural 
model. Enlarged view of catalytic chamber of the RSV L predicted structural model. 
Polymerase shown in grey. Catalytic aspartic acid residue of GDNQ motif shown in red, 
highly conserved residues within 16 Å of catalytic residue shown in gold. Poorly conserved 
residues homologous to VSV putative priming residue, and VSV putative priming loop 
shown in green. Highly conserved residues adjacent to VSV putative priming loop 
homologous region shown in blue. 
  
  
134 
4.3 Analysis of effect of alanine substitution of potential priming residues in cell-based 
minigenome assays 
Having identified potential RSV polymerase priming residues as described above, we 
screened them using the cell-based RSV minigenome assays. Single alanine substitution 
variants of RSV L (F629, F704, W785, P1261, W1262, P1274, Y1276) were cloned in 
pTM1-L, a T7 driven vector from which RSV L is expressed (expresses polymerases 
L(629A), L(F704A), L(W785A), L(P1261A), L(W1262A), L(P1274A), L(Y1276A), 
respectively). An RSV minigenome (Le46G) was used to examine the effects of the alanine 
substitutions on replication and transcription from the Le promoter (109). BSRT7/5 cells 
were transfected with pTM1-N, pTM1-P, pTM1-M2-1, Le46G, and pTM1-L wt to 
reconstitute RSV RNA synthesis activities in cells. Cells were alternatively transfected as 
described above, except with each of the pTM1-L alanine substitution variants instead of 
pTM1-L wt to analyze the effects of the substitutions on replication and transcription. To 
analyze relatively early events in RNA synthesis for both replication and transcription, we 
performed primer extension analysis of the RNA products using a primer that hybridized 
at positions 15-39 relative to the 5′ end of the replication product (Figure 24, Table 9). 
Analysis of the RNA generated by wt L protein showed RNA initiated from +1 and +3 as 
shown previously (10). It was predicted an alanine substitution of the priming residue 
would have a severe defect on +1 replication initiation and may also cause a defect in +3 
transcription initiation, however the priming residue may be less strictly required for +3 
initiation as this is an internal initiation event. RSV L variants L(F629A), L(F704A), and 
L(W785A) did not yield detectable levels of RNA relative to wt L from +1 or +3 (Figure 
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24). RSV L variants L(P1261A) and L(W1262A) also did not yield detectable RNA 
initiated from +1, but did yield RNA initiated from +3 at a reduced level compared to wt. 
These results are consistent with RSV L residues F629, F704, W785, P1261, and W1262 
potentially acting as priming residues. RSV L variants L(P1274A) and L(Y1276A) yielded 
RNA from +1 and +3 at reduced but not undetectable levels relative to wt and are not 
consistent with P1274 or Y1276 functioning as priming residues.  
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Figure 24. Analysis of RSV L substitution variants on Le based minigenome.(A) Schematic 
diagram of 3′ end Le promoter based minigenome Le46G. The initiation sites are indicated 
by green arrows (+1, +3) and the small le ~25 nt RNA and antigenome products are shown 
in blue. The region the 15-39 primer anneals to is shown in red. (B) Primer extension 
analysis of RNA generated from +1 and +3. The position of products initiated from +1 and 
+3 were identified by co-migration of end-labeled DNA oligonucleotides corresponding in 
length and sequence to the expected products from +1 and +3 initiation (lanes 1 and 2). 
Markers shown are a different exposure from the same gel, with separation indicated by an 
asterisk. Lane 3 shows a control sample lacking L expression plasmid (-L). (C) Northern 
blot analysis of input minigenome generated by T7 polymerase. (D) Quantification of three 
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replicates of the experiment shown in panel B. Black bars represent RNA from +1 and 
white bars represent RNA from +3. Data are normalized to input minigenome levels 
determined from Northern blot (C) and to the mean of the two wt samples in each 
experiment set to 1. The bars show the mean and standard error of the mean of three 
independent experiments. 
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The TrC promoter is identical in sequence to the Le for 11 of the first 13 nt, and also signals 
initiation from +1 and +3 (101, 111, 124). The above described L variants were also 
examined for the effect on RNA synthesis activities using a minigenome with TrC 
promoter sequence replacing Le promoter at the 3′ end of the minigenome as described 
above. Consistent with the primer extension analysis of the RNA generated by RSV 
polymerases using the Le based minigenome, analysis of RNA generated by L(F629A), 
L(F704A), and L(W785A) on the TrC promoter based minigenome indicated complete 
defects in RNA synthesis from +1 and +3 (Figure 25, Table 9). Analysis of RNA generated 
by L(P1274A) and L(Y1276A) showed detectable levels of +1 and +3 products at or above 
wt L levels. Analysis of RSV L variants L(P1261A) and L(W1262A) had near complete 
defects in both +1 and +3 RNA synthesis. This is in contrast to L(P1261A) and L(W1262A) 
on the Le based minigenome, which had a complete defect in +1 and a defect but detectable 
products in +3. The TrC based minigenome results are still consistent with P1261 and 
W1262 acting as priming residues, as it is possible disrupting the priming residue may 
affect internal initiation at +3 in addition to terminal initiation at +1. The primer extension 
analysis, shown here, indicated RSV L P1274 and Y1276 do not function as priming 
residues whereas F629, F704, W785, P1261, and W1262 may function as priming residues 
in the RSV polymerase.  
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Figure 25. Analysis of RSV L substitution variants on TrC based minigenome.(A) 
Schematic diagram of 3′ end TrC promoter based minigenome DM124. The initiation sites 
are indicated by green arrows (+1, +3) and the small le ~25 nt RNA and antigenome 
products are shown in blue. The region the 13-35 primer anneals to is shown in red. (B) 
Primer extension analysis of RNA generated from +1 and +3. The position of products 
initiated from +1 and +3 were identified by co-migration of end-labeled DNA 
oligonucleotides corresponding in length and sequence to the expected products from +1 
and +3 (lanes 1 and 2). Markers shown are a different exposure from the same gel, with 
separation indicated by an asterisk. Lane 3 shows a control sample lacking L expression 
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plasmid (-L). (C) Northern blot analysis of input minigenome generated by T7 polymerase. 
(D) Quantification of three replicates of the experiment shown in panel B. Black bars 
represent RNA from +1 and white bars represent RNA from +3. Data are normalized to 
input minigenome levels determined from Northern blot (C) and to the mean of the two wt 
samples in each experiment set to 1. The bars show the mean and standard error of the 
mean of three independent experiments. 
 
 
 
 
 
 
Table 9. Statistics of primer extension analysis of +1 and +3 RNA synthesized by RSV 
variant polymerases in minigenome assay. p values from two-tailed paired t test 
comparison of each RNA level from variant polymerases compared to wt on both Le based 
minigenome (Le46G) and TrC based minigenome (DM124). Not significant indicated by 
ns.  
Le46G DM124 
L variant p value (+1) p value (+3) p value (+1) p value (+3) 
F629A 0.0000007 0.0000006 0.0003142 0.0000080 
F704A 0.0000002 0.0000066 0.0001680 0.0000301 
W785A 0.0000000 0.0000031 0.0001887 0.0007880 
P1261A 0.0000124 0.0276481 0.0231369 0.0130988 
W1262A 0.0000208 0.0237999 0.0004917 0.0038155 
P1274A 0.2196747, ns 0.6766312, ns 0.2282818, ns 0.1450539, ns 
Y1276A 0.0041368 0.0218491 0.6140739, ns 0.6590292, ns 
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Further analysis of known priming loops indicated they are largely located in the thumb 
domain of polymerases. As RSV L F629, F704, and W785 are located in the finger region 
on the wrong side of the catalytic residue to encounter NTPs, these residues were discarded 
from future analysis at this point. It is likely that alanine substitutions at these residues 
caused global polymerase defects or decreased expression of RSV L resulting in the 
phenotype discussed above. To confirm the alanine substitutions did not inhibit expression 
of RSV L, a FLAG(2) tag was added to the N-terminus of the P1261A, W1262A, P1274A, 
and Y1276A L variants in the T7 expression vector. The FLAG-tagged L variants were co-
expressed along with P, which L requires to be efficiently expressed, in BSRT7/5 cells and 
analyzed by Western blot (Figure 26). Untagged versions of the pTM1-L vector with each 
mutant were used in transfections for minigenome assays, as tagging the L protein affects 
its activities. Preliminary results indicate L(P1261A), L(P1274A), and L(Y1276A) are 
expressed at levels similar to wt. L(W1262A) was not detected and thus the defect in RNA 
synthesis for L(W1262A) may be due to decreased expression (Figure 26). 
 
Substitution of a priming residue in the RSV L protein would be predicted to cause a 
decrease in +1 and possibly +3 products as detected by primer extension analysis, which is 
the phenotype I observed for RSV L(P1261A) and L(W1262A). However, a defect in 
elongation would also yield a similar phenotype that would not be distinguishable from 
initiation defects in this assay. It is also possible these substitutions could be causing a 
global defect in RNA synthesis activity due to polymerase misfolding. To determine if the 
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P1261A and W1262A substitutions cause a specific initiation defect, we utilized an in vitro 
RNA synthesis assay using purified recombinant RSV polymerases. 
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Figure 26. Western blot of N-terminally FLAG(2) tagged RSV L variants expressed in 
BSRT7/5 cells.  Western blot was performed to confirm alanine substitution variants are 
expressed at levels similar to wt L. BSRT7/5 cells were transfected with pTM1-L plasmid 
expressing the indicated L proteins along with pTM1-P. Minus L shows a control sample 
lacking L expression plasmid. Total cell lysate was analyzed by Western blot using anti-
FLAG antibody. Ladder used was PageRuler Plus Prestained Protein Ladder with 
approximate sizes indicated on the left.  
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4.4 RSV L(P1261A) is defective in de novo initiation but not an RNA synthesis activity 
that is independent of de novo initiation 
We expressed and purified recombinant RSV L-P polymerase complexes for analysis in an 
in vitro RNA synthesis assay, as described in Chapter Three (Figure 27) (111). It has been 
shown the RSV RdRp initiates RNA synthesis from +1 and +3 in vitro as it does in virus 
infection, with +3 products dominant under these assay conditions (Figure 28). 
Comparison of L(wt), L(P1261A), and L(W1262A) RSV RdRps revealed L(P1261A) and 
L(W1262A) both had defects in initiation of RNA synthesis as observed by the 
dinucleotide product from +3 transcription initiation (Figure 28) (111). In this chapter, we 
use Tr RNA templates for in vitro RNA synthesis assays as the Le templates were 
technically challenging to detect +1 products in addition to +3 products as described in 
Chapter Three. To determine if this was a global polymerase defect or specific to initiation, 
we examined the products of an RNA synthesis activity that is not dependent on de novo 
initiation, i.e. back-priming or 3′ extension. The TrC25 template forms a secondary 
structure which the polymerase elongates at the 3′ end to add three or more additional 
nucleotides in a templated manner resulting in products 26 nt and larger (Figure 28A). It is 
expected a substituted priming residue would be defective in initiation but not necessarily 
3′ extension activity. L(P1261A) polymerase retained wt levels of the 3′ extension 
products, consistent with functioning as a priming residue. L(W1262A) had a similar defect 
in 3′ extension to its defect in de novo initiation, which suggests this substitution may have 
caused a global polymerase defect and not an initiation specific defect.  
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Figure 27. Purified recombinant RSV L-P complexes used in in vitro RNA synthesis 
assays. SDS-polyacrylamide gel of purified recombinant RSV L-P complexes. Prestain 
PageRuler Plus Protein ladder (lane 1) and Benchmark ladder (lane 2) with size labelling 
on left from Benchmark ladder. Lanes 3-6 are the final purified recombinant RSV L-P 
complexes used in in vitro RNA synthesis assays. L, hsp70, and His-P identified on the 
right.  
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Figure 28. RSV L P1261A is defective in de novo initiation but not an RNA synthesis 
activity not dependent on initiation. (A) Schematic of the TrC1-25 template used to 
reconstitute RNA synthesis in vitro. RNA products resulting from de novo initiation at +1 
and +3, and 3′ extension product shown. Nucleotides added by 3′ extension underlined. 
Initiation sites shown by green arrows. (B) RNA products generated by the wt or variant 
L-P complexes with [α-32P] ATP, 500 μM of each NTP, were separated on a 20% (top gel) 
or 25% (bottom gel) urea-acrylamide gel. Markers in lanes 1 and 2 were prepared as 
described in Figure 4. Lane 3 shows a negative control reaction performed with the 
catalytically inactive D811A variant. (C) Quantification of 3′ extension (black bars) and de 
novo initiated RNA products (white bars) represented in panel C. Data were normalized to 
the wt L-P sample set to 1, with mean and standard error shown for three independent 
experiments. 
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4.5 RSV L(P1261A) transcription initiation defect is rescued by increasing initiating 
rNTP concentrations 
To further analyze the defect in transcription initiation by the P1261A polymerase, I 
analyzed the variant polymerases in an in vitro RNA synthesis assay under varying 
initiating NTP conditions. For this, I used the TrC16 template and 100 μM UTP, 10 or 500 
μM GTP, 10 or 500 μM ATP, and [α-32P] ATP as the label. CTP was excluded to eliminate 
initiation from +1. Wt polymerase initiates RNA synthesis at +3 to produce a 2 nt product. 
The polymerase elongates that dinucleotide to the end of the template resulting in products 
ranging from 2 to 14 nt in length (Figure 29). It is thought priming residues stabilize the 
initiation complex by forming interactions with the initiating NTPs. Thus, I hypothesized 
increasing the concentrations of initiating NTPs may overcome the defect in transcription 
initiation. I examined the difference in de novo initiation from +3 under “low” (10 μM GTP 
and ATP) and “high” (500 μM GTP and ATP) conditions, varying GTP and ATP separately 
and together. I observed an increase in the level of 2 nt product from P1261A relative to 
wt only under the high GTP and high ATP conditions, suggesting a partial rescue of 
initiation activity. This suggests P1261A is involved in coordinating both of the initiating 
NTPs for transcription initiation.  
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Figure 29. P1261A has a defect in transcription initiation and elongation. RNA products 
from in vitro RNA synthesis assay from wt and P1261A RSV L-P reactions. (A) Schematic 
of in vitro RNA synthesis assay conditions. NTPs in parentheses were omitted from some 
reactions. Initiation sites shown as green arrows. (B) RNA products generated by the wt or 
variant L-P complexes with [α-32P] ATP, 10 or 500 μM each GTP or ATP, 100 μM UTP 
as indicated below the gel, were separated on a 25% urea-acrylamide gel. Lane 1 shows a 
negative control reaction performed with the catalytically inactive D811A variant. Images 
are from different exposures of the same gel as product strength varied based on NTP 
conditions. (C) Quantification of RNA products shown in Panel B. Data were normalized 
to the wt L-P sample with same NTP conditions set to 1, with mean and standard error 
shown for three independent experiments. 
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4.6 RSV L P1261A has a separate defect in elongation 
In the experiment shown in Figure 29, it was observed the partial rescue of the 2 nt product 
synthesized by P1261A did not also result in a proportional rescue of longer products. This 
indicates the alanine substitution at P1261 causes a separate defect in elongation in addition 
to the defect in initiation. 
4.7 RSV L(P1261A) replication initiation defect is not rescued by increasing initiating 
rNTP concentrations 
I further analyzed P2161A in the in vitro RNA synthesis assay to determine if there is a 
defect in replication initiation from +1 as well as transcription initiation from +3 as 
suggested by the primer extension results (Figures 24 and 25). I again analyzed the effect 
of varying initiating NTP conditions from “low” (20 μM ATP and CTP) to “high” (1 mM 
ATP and 2 mM CTP) using the TrC16 template and the label [α-32P] CTP. UTP was 
included in the reactions unless otherwise noted but is not required for synthesis from +1. 
Under these assay conditions, we expected to observe a dominant band at 2 nt but not any 
products resulting from transcription initiation or elongation of the replication initiation 2 
nt product, as GTP was omitted from the reactions (Figure 30). As with transcription 
initiation, I observed a defect in the replication initiation product synthesized by P1261A 
relative to wt. However, in contrast to transcription initiation, the defect in replication 
initiation was not rescued even under high NTP concentrations. These results suggest 
initiation at +1 is more dependent on P1261 compared to initiation from +3. 
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Figure 30. P1261A has a defect in replication initiation. RNA products from in vitro RNA 
synthesis assay from wt and P1261A RSV L-P reactions. (A) Schematic of in vitro RNA 
synthesis assay conditions. NTPs in parentheses were omitted from some reactions. 
Initiation site shown as green arrows. (B) RNA products generated by the wt or variant L-
P complexes with [α-32P] CTP and the NTP conditions indicated were migrated on a 25% 
urea-acrylamide gel. Lane 1 shows a negative control reaction performed with the 
catalytically inactive D811A variant. Images of each set of NTP condition reactions are 
from different exposures of the same gel as product strength varied based on NTP 
conditions.  
  
  
151 
Discussion 
Summary of results 
In this chapter, we show P1274 and Y1276, are unlikely to function as priming residues in 
the RSV RdRp, suggesting a difference between the RSV and VSV RdRp priming residues. 
Our results are consistent with RSV L P1261 functioning as a priming residue. Analysis of 
an alanine substitution at P1261 in vitro indicates this residue is important for both 
replication initiation at +1 and transcription initiation at +3. The +3 initiation defect can be 
partially overcome by increasing initiating NTP levels, suggesting P1261 is involved in 
coordinating the NTPs in the initiation complex. The +1 initiation defect was not rescued 
under any condition tested, which suggests P1261 is more strictly required for +1 initiation 
than +3. W1262 was also analyzed and may function as a priming residue, though this 
cannot be determined as RSV L W1262A was defective in all RNA synthesis activities.  
Initiation of RNA synthesis at terminal or internal initiation sites 
Our results indicate P1261 is involved in both terminal initiation at +1 and internal 
initiation at +3, but the initiation at +1 is more strictly dependent on P1261. This aligns 
with our current understanding of priming residues, as the stable formation of the initiation 
complex opposite the terminal position of the linear RNA template is expected to be less 
stable than the formation of the complex at an internal site. Substitutions of the putative 
priming residues of influenza A virus polymerase and rabies virus polymerase did not cause 
defects in internal initiation events consistent with this model (117, 149).  
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It has been shown that bacteriophage φ6 polymerase binds to its promoter at the internal 
site T3, and upon NTP binding, “ratchets” back on the template such that the active site is 
positioned for initiation at T1 (12). In addition, our findings presented in Chapter Three, 
indicate the RSV RdRp preferentially binds the promoter such that the active site is 
positioned for initiation at T3 and has a similar register of promoter contacts it may use to 
reposition for initiation at T1. We show here P1261 may be involved in initiation at T3, 
however given the RdRp preferentially binds at this position in comparison to T1, the 
P1261A initiation defect may be overcome. Whereas the RdRp may need to ratchet back 
to initiate from T1 after binding at T3, and P1261 may be strictly required for the proper 
positioning of NTPs for initiation at T1.  
Differences between the RSV Le and TrC promoters 
The primer extension analysis of the RSV variant polymerases suggests a difference in 
phenotype on the Le and TrC based minigenomes for P1261A, W1262A, and Y1276A. For 
P1261A and W1262A, +1 RNA synthesis is similarly affected (complete defect) with both 
promoters. However, P1261A and W1262A exhibit detectable levels of +3 product on the 
Le promoter, but not on the TrC promoter. There are several possible explanations for this 
difference. The initiation from T3 on the Le promoter is more favorable than initiation from 
T3 on the TrC promoter, indicating that it is a more energetically stable initiation complex 
(Figure 5). This may allow the RNA synthesis defect caused by these polymerase 
substitutions to be overcome. This may be further explained by sequence differences 
between the Le and TrC. 11 of the first 13 nucleotides are identical, but the first difference 
does occur at position 4, a G in Le and a U in TrC. Thus the Le +3 dinucleotide is 5′ GC 
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and the TrC +3 dinucleotide is 5′ GA. As Le T4G and the C of the 5′ GC product will form 
three hydrogen bonds in Watson Crick base pairing as opposed to the two hydrogen bonds 
formed between the TrC T4U and the A of the 5′ GA product, this increased bonding may 
stabilize Le +3 initiation in the absence of a priming residue more so than TrC +3 initiation. 
A second possibility is that the polymerase may have an innate affinity for C at the NTP 2 
binding site which may stabilize Le +3 initiation over TrC +3 initiation. As the primer 
extension assay results represent stable end point RNA products, and not unstable 
intermediates, it is also possible there are RNA stability differences between the Le versus 
TrC +3 products, potentially due to sequence differences. The apparent difference between 
the promoters could alternatively be explained by differences in primer annealing strength 
as the Le and TrC primer extension assays are performed with different primers. There was 
also a difference in promoter activities with the L Y1276A variant. Y1276A has a moderate 
defect in RNA products on the Le based minigenome, but yielded wt RNA levels on the 
TrC based minigenome. We do not expect the RSV RdRp to require the priming residue 
for one promoter but not the other, nor do we expect there to be two different priming 
residues for the two promoters. Thus, as Y1276A is active on the TrC based minigenome, 
Y1276 is not consistent with it functioning as a priming residue in RSV.  
Structure of the RSV polymerase 
As mentioned in the Introduction, this study was designed prior to the availability of an 
RSV polymerase structure. In September 2019, the structure of the RSV L RdRp and 
capping domains, in complex with P was solved (49). This structure appears to be in an 
elongation conformation, with the loop I have discussed in this chapter located out of the 
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active site, and all four channels visible (Figure 31). It is difficult to make conclusions 
based on this structure of the roles of P1261, W1262, P1274, and Y1276 in initiation as no 
RNA template or NTPs are present and it is not in an initiation conformation (Figure 32). 
The structure does reveal W1262 has a structural role and forms a hydrogen bond with 
another residue to keep important motifs of the polymerase active site in the correct 
conformation (49). As our recombinant RSV polymerase purification strategy requires L-
P interactions, and W1262A L purified at a similar proportion to P as all other purified 
RSV L-P complexes, we can conclude W1262A L is at least folded and stable enough to 
maintain L–P interactions (Figure 27). However, the disruption of the W1262 and S1390 
hydrogen bond may cause structural issues within the RdRp/capping domains, but not the 
region of L which binds to P, which is distant and on the outside face of the polymerase in 
comparison to the location of W1262. This is consistent with our results indicating 
L(W1262A) has a global defect in all RNA synthesis activities, and not specifically 
initiation. It is still possible W1262 is involved in initiation, but this cannot be determined 
at this point. It is possible P1261 and W1262 are working in conjunction or acting in 
redundancy with each other and both are involved in initiation. We considered analyzing a 
double substitution variant of RSV L at these residues, however, as the single substitution 
at W1262 resulted in a global defect in RNA synthesis, it is unlikely the results would allow 
as to determine the roles in initiation specifically. In the RSV L structure, P1274 and Y1276 
are located in the loop, however they are flanked by two structured motifs, an alpha helix 
and a beta-strand (Figure 32). This suggests these residues may be anchored by these 
flanking structured motifs and not rearrange to enter the catalytic chamber during initiation. 
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This is consistent with our results indicated P1274 and Y1276 do not function as priming 
residues in RSV L (Figures 24 and 25). In contrast, P1261 is centered in a long, 
unstructured loop, and thus could be properly positioned in the central catalytic chamber 
in an initiation conformation (Figure 32). In addition, the RSV L structure suggests the 
conserved residues F704 and W785 are involved in the structural stability of the RSV L, 
not in initiation complex specific stabilization, in agreement with the analysis discussed 
above (Figures 24 and 25). 
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Figure 31. Structure of the RSV RdRp and capping domains of L in complex with P.The 
RdRp domain is in blue, the capping domain is in green, flexible loop homologous to VSV 
putative priming loop shown in gold, and the four monomers of P are in grey. Views of the 
RSV L structure rotated 180º about y-axis (PDB: 6ZPK) (49). 
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Figure 32. Visualization of selected residues of interest in RSV L solved structure. 
Enlarged view of catalytic chamber of the RSV L structure (PDB: 6ZPK) (49). Polymerase 
shown in grey. Catalytic aspartic acid residue of GDNQ motif shown in red. Positions of 
RSV L residues of which alanine substitutions were analyzed in this study shown in pink 
including P1261, W1262, P1274, and Y1276. The loop the residues are located on shown 
in green, including the alpha helix and beta strand flanking P1274 and Y1276. 
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Alternative Models for the role of RSV L P1261A in RNA synthesis 
As discussed above, our data is consistent with RSV L P1261 functioning as the priming 
residue. However, there are alternative possible interpretation of our data. Our results 
indicate synthesis of 2 nt and longer products from both +1 and +3 initiation was defective 
upon alanine substitution at P1261. It is possible this substitution, instead of causing the 
defect by not being able to coordinate the initiating NTPs, could affect the ability of the 
polymerase to release the RNA product and template to perform multiple rounds of RNA 
synthesis. In the VSV L pre-initiation structure, the priming loop appears to occlude the 
template and RNA product exit channels (86). If the P1261A substitution affects the ability 
of the loop to move out of the active site and the polymerase to undergo the conformational 
change necessary to reveal these channels, then each P1261A polymerase may remain 
locked once it has made a product. The priming loop may maintain interactions with the 
RNA product as the product moves out of the active site towards the exit channel, until the 
loop is out of the active site and the product exits the channel, and is thus involved in 
initiation and the switch to elongation. This does not seem likely, as increasing NTP 
conditions overcomes the defect from transcription suggesting a specific defect in 
coordinating the NTPs. In addition, the Le minigenome data suggests P1261A can, under 
some conditions, elongate at least to the point to allow of primer annealing. Also the 
priming loop is not expected to be in the active site for back-priming and P1261A 
synthesized back-priming products at wt levels, suggesting this explanation is not likely. 
However, we do not yet understand how the RSV polymerase interacts with the folded 
RNA template. 
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As +1 initiation is more greatly affected than +3 initiation and models are consistent with 
RSV following a ratcheting mechanism to initiate from T1 (25), it is possible this 
substitution is affecting the ability to “ratchet” as well as elongate as discussed above. 
However, +3 initiation is also affected by the substitution which I would not expect if this 
were the case.  
 
Our conclusion that P1261A is causing an initiation defect specifically is drawn from its 
ability to perform back-priming at wt levels. However, while the total amount of back-
priming product is not affected, the ratio of the three major bands is, suggesting a defect in 
elongation. An elongation defect was also suggested from de novo initiated RNAs and 
primer elongation. It is possible the P1261A variant causes an artificial stabilization of the 
back-priming activity specifically that overcompensates and results in wt levels. If that 
were the case, P1261 may instead have a general RNA synthesis defect. However, as 
mentioned above, we do not yet understand how the polymerase encounters the secondary 
structure form of RNA to perform back-priming and cannot determine how this residue 
would be involved in that activity/template association.  
 
Finally, our data are consistent with P1274 and Y1276 not functioning as priming residues 
in the RSV polymerase as may be expected from the work done of the VSV and RABV 
polymerases. However, as discussed above, there are other possible explanations for the 
P1261 data which may indicate this is not the priming residue. Thus, at this point no other 
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potential priming residues have been identified in the RSV polymerase and the question 
may remain unanswered until an RSV polymerase structure in an initiation state is available 
with a priming residue interacting with the initiating NTPs. It is possible RSV does not 
utilize a priming residue as hypothesized here. RSV has been shown to perform de novo 
initiation, but it may utilize a different and potentially unique strategy to stabilize the 
initiation complex. For instance bovine viral diarrhea virus polymerase uses a non-
templated GTP to stabilize the initiating NTPs (18). Reovirus λ3 polymerase uses a loop 
containing no aromatic or ring-based residues to stabilize the initiation complex (147). 
Reovirus λ3 polymerase and the nsNSV polymerases do not show any similarities in this 
region, thus it is predicted the RSV polymerase priming loop will not be similar to that of 
reovirus λ3 polymerase, however these sequences of these polymerases are not very 
similar. Similar mechanisms to bovine viral diarrhea virus and reovirus λ3 polymerases are 
not possible to rule out without an RSV polymerase initiation structure with rNTPs 
showing an interaction.  
Future directions 
It would potentially be informative to analyze a P1261F L RSV variant. Rescue of the 
alanine variant initiation defect would suggest it is a base stacking interaction between the 
proline and initiating NTPs that stabilizes the initiation complex. However, a negative 
result from this experiment could alternatively be explained by a secondary requirement to 
have a rigid proline at this site. As suggested above, it is possible that the P1261A 
substitution is preventing the polymerase from releasing the product and recycling to 
perform multiple rounds of RNA synthesis, or is getting locked at the transition from 
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initiation to elongation. This could be analyzed by performing in vitro RNA synthesis 
assays with heparin to prevent polymerase binding to the template after the first round of 
RNA synthesis and thus limiting the wt and P1261A polymerases to a single round of RNA 
synthesis. If P1261A was preventing multiple rounds of RNA synthesis, this would result 
in no defect in the 2 nt product compared to wt. However, this experiment is technically 
challenging as the amount of RNA product would be very low and unlikely to be readily 
detectable. Our data suggest differences in the priming residue between the rhabdoviruses 
VSV and RABV and the pneumovirus RSV. It is of interest to determine if other viral 
families of the nsNSVs are unique or similar to RSV. The pneumovirus, paramyxovirus, 
and filovirus L proteins are more closely related to each other than to the rhabdoviruses, 
which suggest the priming residue may be conserved among these families (Figure 18). 
However the paramyxoviruses have residues homologous to the VSV polymerase putative 
priming loop more so than the other families and may more closely resemble VSV. We 
have begun work to determine the conservation of P1261 as a priming residue in the 
paramyxovirus HPIV3 and the filovirus MARV polymerases in in vitro RNA synthesis 
assays by cloning, expressing, and purifying alanine substitution variants in the region 
homologous to the RSV priming residue (Appendix Two). As discussed above, there is a 
discrepancy in the +3 defects on the Le and TrC based minigenome assays with P1261A, 
though this may be due to RNA stability differences. To determine if there is a difference 
on the Le and Tr promoters for P1261A initiation from +3, we could analyze the variant 
on Le promoters in vitro. As discussed in Chapter Three, analysis of the RSV Le promoter 
is more technically challenging than on the TrC promoter in vitro, and thus the majority of 
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in vitro RNA synthesis have been done on a TrC promoter template. If careful analysis of 
P1261A was able to be done on a Le template in vitro, and/or use of a TrC template with a 
4U-to-G substitution, these template differences could be further characterized. It would 
be interesting to determine if the increased stability of base pairing between NTP 2 and T4 
in Le compared to TrC explains the discrepancy. This could also be examined in the 
minigenome system using mutant position minigenomes Le46G 4U and DM124 4G.  
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CHAPTER FIVE: EBOLAVIRUS POLYMERASE USES AN 
UNCONVENTIONAL GENOME REPLICATION MECHANISM 
Note that some Figures and text have previously appeared in print: Copyright © 2019, 
[Proceedings of the National Academy of Sciences of the United States of America, 
116(17), 2019, DOI: 10.1073/pnas.1815745116] All Rights Reserved (29). 
Introduction 
At the 3′ and 5′ extremities of the ebolavirus genomes are short non-coding regions, the 3′ 
Le and the 5′ Tr which contain essential regulatory elements for genome replication and 
transcription (75, 156). Genome replication depends on a bipartite promoter, which 
consists of an element within the 3′ Le region and a second element within the first gene 
(160). This promoter directs the viral polymerase to synthesize a full-length, 
complimentary copy of the genome, the antigenome. The replication promoter of the 
antigenome resides in the complementary trailer region (TrC) and directs the viral 
polymerase to begin synthesis of genomic RNA. Both the genome and antigenome RNAs 
are encapsidated as they are synthesized, allowing the polymerase to be highly processive 
during replication (reviewed in (78, 81)).  
 
Studies on other nsNSVs, VSV, RSV, and Nipah virus have shown that their polymerases 
initiate RNA replication opposite the first nucleotide of the promoter by a de novo, or 
primer-independent, initiation mechanism (71, 102, 111). However, although the overall 
genome structures of the ebolaviruses are similar to those of other nsNSVs, and the active 
sites of their polymerases are well conserved (86, 126) ebolavirus genome ends are 
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unconventional. Most nsNSVs have almost identical promoters at the 3′ ends of their 
genome and antigenome RNAs, meaning that their ends show terminal complementarity, 
and these sequences are highly conserved within each virus species, reflecting their 
importance. In contrast, an early report by Kiley and co-workers, describing direct RNA 
sequencing of the 3′ termini of EBOV and SUDV genomes, determined that the 3′ terminal 
sequence was heterogeneous, with the terminal nucleotide being either a G or an A residue 
(75). This A/G heterogeneity is not reflected in more recent sequence analyses of EBOV, 
SUDV, or other ebolaviruses within the GenBank database including the newly discovered 
Bombali virus (50). Instead, the majority of the deposited ebolavirus sequences starts with 
a 3′ terminal G residue, or the first nucleotide is not present (60). Likewise, the deposited 
ebolavirus genome sequences have variable 5′ ends that are not an exact copy of the 3′ 
termini, suggesting that the Le and TrC promoters differ with respect to the 3′ terminal 
nucleotides (Figure 33). These unusual promoter features suggest that ebolaviruses might 
have evolved a replication initiation mechanism that is different from other nsNSVs. 
 
To gain a better understanding of the ebolavirus replication mechanism, we investigated 
the genome ends of ebolaviruses belonging to three different species, EBOV, SUDV, and 
RESTV. We found that they all have a variable 3′ terminal nucleotide on both the genome 
and antigenome RNAs. In contrast, the 5′ ends of the replicative RNAs are highly 
conserved among the different ebolaviruses and are one nucleotide shorter compared to the 
majority of the published 3′ ends. Consistent with these data, we show that in contrast to 
the other nsNSVs studied to date, the ebolavirus polymerase is able to initiate RNA 
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replication opposite position 2 of the template, and we present evidence that suggests the 
non-complementary 3′ terminal sequences are added by a back-priming mechanism. 
Together, these data show that ebolaviruses have evolved a replication initiation strategy 
that is distinctive among nsNSVs.  
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Results 
The virus infections, viral RNA primer extension analysis, RACE, and sequencing were 
performed by Dr. Laure Deflubé-Owen. Data compilation was done by Dr. Laure Deflubé-
Owen and me. I compiled all sequence traces, identified 3′ and 5′ terminal viral RNA 
sequences, and totaled numbers of each sequence incidence. I developed and optimized the 
non-replicating EBOV minigenome system (Appendix Three, Chapter Five). Primer 
extension and Northern blot analysis of RNA from the minigenome system was performed 
by Dr. Adam Hume and me. For completeness of the story, all work is presented cohesively 
below. 
5.1 Sequencing of the 3′ end of ebolavirus RNAs reveals variability of the 3′ terminal 
nucleotide 
The ebolavirus sequences deposited in GenBank show variability at the 5′ terminus of the 
Tr region and suggest that the TrC promoter at the 3′ end of the antigenome has a different 
sequence than the Le promoter at the 3′ end of the genome (Figure 33).  
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Figure 33. Schematic diagram illustrating the variety of published ebolavirus 3′ and 5′ 
genome ends.  The Le region is followed by the GS signal for the first gene, NP. The Tr 
region is preceded by the GE signal for the L gene. Most of the viral genes are not shown. 
– symbols indicate the lack of a nucleotide. The complementary antigenome is depicted 
beneath the genome.  
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Terminal sequences of RNA molecules can be difficult to determine for technical reasons. 
For example, intragenic ligation of the genome ends does not exact assignment of which 
nucleotides lie at the 3′ versus 5′ terminus of the molecule. In addition, the identity of the 
3′ terminal nucleotide and RNA structure affect RNA ligation efficiency which can lead to 
an artefactual bias towards particular sequences that are not representative of the 
population (36, 172). Therefore, to characterize the sequences at the 3′ ends of ebolavirus 
genome and antigenome RNAs, we utilized a 3′ rapid amplification of cDNA ends (3′ 
RACE) method in which the 3′ end of the RNA was tailed with a given NTP and poly(A) 
polymerase, followed by PCR amplification of ebolavirus specific terminal sequences. The 
resulting PCR products were then sequenced. Studies have shown that the identity of the 
3′ terminal nucleotide does not cause a significant bias in tailing efficiency, particularly if 
the RNA is tailed with CTP (130), and so this approach should yield a representative 
analysis of 3′ terminal sequences. Sequence analysis of RNA purified from viral particles 
of the EBOV isolate Mayinga and tailed with ATP showed multiple peaks at the 3′ terminal 
nucleotide position of the traces, confirming heterogeneity at this position (Figure 34 Ai) 
(75). Heterogeneity was also observed when the RNA was tailed with CTP (Figure 34Aii). 
We used the same approach to sequence the 3′ terminus of intracellular genomic RNA, as 
it is possible there is a difference in the population of intracellular genome sequences 
compared to those packaged into viral particles. A similar heterogeneity to the virion-
associated genomic RNA was observed (Figure 34B). We also applied this technique to 
examine intracellular antigenomic RNA (Figure 34C), and again saw heterogeneity at the 
3′ terminal nucleotide.   
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Figure 34. Sequence analysis of the 3´ ends of EBOV Mayinga RNAs. (A-C) Vero cells 
were infected with the indicated ebolavirus species and total cellular or virion-associated 
RNA was used subjected to 3´ RACE and sequence analysis. The traces show sequences 
of the 3´ RACE PCR population obtained from virion-associated genomic RNA (A), 
intracellular viral genomic RNA (B), or intracellular viral antigenomic RNA (C). In each 
case, panels i and ii show results from RNA tailed with ATP or CTP, respectively. Poly(A) 
(panels i) and poly(C) (panel ii) sequences added during the 3´ RACE procedure are 
underlined with a black line. It should be noted that the polymeric sequence may include 
some virus-specific sequence that cannot be distinguished from the poly(A) or poly(C) tail 
(underlined with a dotted line).  
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Similar results were obtained with the virus isolates SUDV Boniface (Figure 35A-C), 
RESTV Philippines 2008 (Figure 36A-C), EBOV Kikwit (Figure 37A-C), and RESTV 
Pennsylvania (Figure 38A-B). Thus, the 3′ terminal position of both genomic and 
antigenomic viral RNAs is heterogeneous.  
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Figure 35. Sequence analysis of the 3´ ends of SUDV Boniface RNAs. (A-C) Vero cells 
were infected with the indicated ebolavirus species and total cellular or virion-associated 
RNA was used subjected to 3´ RACE and sequence analysis. The traces show sequences 
of the 3´ RACE PCR population obtained from virion-associated genomic RNA (A), 
intracellular viral genomic RNA (B), or intracellular viral antigenomic RNA (C). In each 
case, panels i and ii show results from RNA tailed with ATP or CTP, respectively. Poly(A) 
(panels i) and poly(C) (panel ii) sequences added during the 3´ RACE procedure are 
underlined with a black line. It should be noted that the polymeric sequence may include 
some virus-specific sequence that cannot be distinguished from the poly(A) or poly(C) tail 
(underlined with a dotted line).   
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Figure 36. Sequence analysis of the 3´ ends of RESTV Philippines 2008 RNAs. (A-C) Vero 
cells were infected with the indicated ebolavirus species and total cellular or virion-
associated RNA was used subjected to 3´ RACE and sequence analysis. The traces show 
sequences of the 3´ RACE PCR population obtained from virion-associated genomic RNA 
(A), intracellular viral genomic RNA (B), or intracellular viral antigenomic RNA (C). In 
each case, panels i and ii show results from RNA tailed with ATP or CTP, respectively. 
Poly(A) (panels i) and poly(C) (panel ii) sequences added during the 3´ RACE procedure 
are underlined with a black line. It should be noted that the polymeric sequence may include 
some virus-specific sequence that cannot be distinguished from the poly(A) or poly(C) tail 
(underlined with a dotted line).  
  
  
173 
 
Figure 37. Sequence analysis of the 3´ ends of EBOV Kikwit RNAs. (A-C) Vero cells were 
infected with the indicated ebolavirus species and total cellular or virion-associated RNA 
was used subjected to 3´ RACE and sequence analysis. The traces show sequences of the 
3´ RACE PCR population obtained from virion-associated genomic RNA (A), intracellular 
viral genomic RNA (B), or intracellular viral antigenomic RNA (C). In each case, panels i 
and ii show results from RNA tailed with ATP or CTP, respectively. Poly(A) (panels i) and 
poly(C) (panel ii) sequences added during the 3´ RACE procedure are underlined with a 
black line. It should be noted that the polymeric sequence may include some virus-specific 
sequence that cannot be distinguished from the poly(A) or poly(C) tail (underlined with a 
dotted line).  
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Figure 38. Sequence analysis of the 3´ ends of RESTV Pennsylvania RNAs. (A-B) Vero 
cells were infected with the indicated ebolavirus species and total cellular or virion-
associated RNA was used subjected to 3´ RACE and sequence analysis. The traces show 
sequences of the 3´ RACE PCR population obtained from virion-associated genomic RNA 
(A) or intracellular viral genomic RNA. In each case, panels i and ii show results from 
RNA tailed with ATP or CTP, respectively. Poly(A) (panels i) and poly(C) (panel ii) 
sequences added during the 3´ RACE procedure are underlined with a black line. It should 
be noted that the polymeric sequence may include some virus-specific sequence that cannot 
be distinguished from the poly(A) or poly(C) tail (underlined with a dotted line).  
  
  
175 
Close examination of the sequence trace at the 3′ terminal position revealed that if RNA 
was tailed with ATP, the variable nucleotide was typically either a G or an A, but because 
the tail was comprised of adenosine nucleotides, it was not possible to distinguish if the 
heterogeneity was due to the 3′ terminal nucleotide being an A, rather than G, or absent. In 
the sequence traces in which the RNA was tailed with CTP, the terminal nucleotide was 
either G, C, or A. Because a C residue was not present at the 3′ terminal position in the A-
tailed sequences, we concluded that the majority of 3′ termini contained the sequences 3′ 
CCUGUGUG with either an additional 3′ A or G residue, or with no additional nucleotide. 
To confirm our finding, and to determine if there were other more minor populations, the 
3′ RACE products corresponding to EBOV Mayinga RNA were inserted into a plasmid 
vector, and individual clones were isolated and sequenced. Traces representing the most 
frequently observed sequences are shown in Figure 39 A-C, and a full list of sequences 
obtained including the respective clone frequencies is shown in Table 6. Single clone 
sequencing confirmed that the 3′ terminal sequences of the viral genomes and antigenomes 
were typically either 3′ GCCUGUGUG, or 3′ ACCUGUGUG, with 3′ CCUGUGUG in 
some cases.  
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Figure 39. Individual clone sequence analysis of the 3´ ends of EBOV Mayinga RNAs (A-
C) Vero cells were infected with the indicated ebolavirus species and total cellular or 
virion-associated RNA was used subjected to 3´ RACE and sequence analysis. 
Representative traces of the most frequently observed sequences obtained from analysis of 
single cDNA clones of virion-associated (A), intracellular genomic viral RNA (B), or 
intracellular antigenomic viral RNA (C) isolated from Vero cells infected with EBOV 
Mayinga. Poly(A) (panels i) and poly(C) (panels ii and iii) sequences added during the 3´ 
RACE procedure are underlined with a black line. It should be noted that the polymeric 
sequence may include some virus-specific sequence that cannot be distinguished from the 
poly(A) or poly(C) tail (underlined with a dotted line).   
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Other sequences were identified at a lower frequency (Table 10 and Figure 40). One clone 
contained a deletion at the 3′ end, another contained a U residue at the 3′ end, rather than 
an A or G residue, two clones contained two additional residues, 3′ UA or 3′ CA, and six 
clones, representing both genome and antigenome RNAs, contained longer additional 
sequence. Because the tailing reaction occurred prior to the reverse transcriptase and PCR 
steps in the 3′ RACE procedure, this indicates that the additional nucleotides were added 
by the EBOV polymerase rather than by reverse transcriptase. Of note, in the clones 
containing longer additional sequence, the added sequence was palindromic to the 
promoter sequence. This finding suggests that the nucleotide additions occurred by a back-
priming event in which the 3′ end of the genome or antigenome folded back on the template 
and was extended by the EBOV polymerase for a few nucleotides (Figure 40 A-C). In other 
cases, the additional sequence was not an exact complement of the template, but showed 
some similarity. One possible explanation for this is that the 3′ end of the RNA folded and 
refolded more than once, leading to chimeric sequences being added (Figure 40 D-F). 
These data suggest that the 3′ termini of EBOV genome and antigenome RNAs have the 
capability to fold into secondary structures and be extended by the viral polymerase.  
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Table 10. Sequence analysis of 3´ and 5´ ends of EBOV Mayinga genomic and antigenomic 
RNAs. Additional nucleotides upstream of the 3´ CCUGU sequence or downstream of the 
ACAGG 5´ terminus are underlined. * Also could be C(n)CCUGU. ‡ Also could be 
ACAGGG(n). 
 
  
sequence source 
of RNA 
strand 
sense 
tailing number 
of 
clones 
3´             GCCUGU 
3´             ACCUGU  
or 
3´              CCUGU 
3´             UCCUGU 
virion genome A 
3/12 
8/12 
 
1/12 
3´             GCCUGU 
3´             ACCUGU 
3´              CCUGU* 
3´            UACCUGU 
3´     ACACACACACCUGU 
virion genome C 1/10 
5/10 
2/10 
1/10 
1/10 
3´             GCCUGU 
3´             ACCUGU  
or 
3´              CCUGU 
3´            CACCUGU 
3´         CAACACCUGU 
cellular genome A 
6/11 
3/11 
 
1/11 
1/11 
3´             GCCUGU 
3´             ACCUGU 
3´              CCUGU* 
3´AGGGACACACACAACCUGU 
cellular genome C 
3/9 
4/9 
1/9 
1/9 
3´             GCCUGU 
3´             ACCUGU  
or 
3´              CCUGU 
3´               CUGU 
3´           CAGCCUGU 
3´      CACAGGCGCCUGU 
cellular antigenome A 
4/14 
7/14 
 
1/14 
1/14 
1/14 
3´             GCCUGU 
3´             ACCUGU 
3´              CCUGU* 
3´        CAAAAACCUGU 
cellular antigenome C 1/6 
1/6 
1/6 
3/6 
ACAGG   5´ 
ACAGGUC 5´ 
ACAGGC  5´ 
virion genome A 5/7 
1/7 
1/7 
ACAGG   5´‡ virion genome C 4/4 
ACAGG   5´ cellular genome A 5/5 
ACAGG   5´‡ cellular genome C 6/6 
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Figure 40. Schematic diagram illustrating how longer 3´ terminal sequences could have 
been added by back-priming.(A-C) Sequence traces that show evidence of nucleotide 
additions that could have occurred by virtue of a single back-priming event. (D-F) 
Sequence traces that show evidence of nucleotide additions that could have occurred by 
virtue of multiple back-priming events. The palindromic sequences are underlined. In D-F 
palindromes that could have arisen as a consequence of the second or third back-priming 
event are underlined with dotted and dashed lines. Panels A and D illustrate the steps that 
could have occurred for nucleotides to have been added. Note that in most cases, there are 
other back-priming possibilities and that in panel E, there is some sequence that cannot be 
explained by back-priming within the terminal region of the genome.   
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5.2 The EBOV polymerase initiates RNA synthesis opposite the first C residue of the 3′ 
CCUGUG motif 
It is generally accepted that nsNSV polymerases initiate genome replication opposite the 
3′ terminal nucleotide of the template. Given that ebolavirus genomes and antigenomes are 
variable at the 3′ terminal position, this raises the question of where replication is initiated. 
To determine this, the 5′ end of EBOV antigenome RNA was mapped using primer 
extension analysis. Total intracellular RNA was isolated from Vero cells infected with 
EBOV isolates Mayinga or Kikwit and analyzed using primers that annealed near the 5′ of 
the antigenome (Figure 41A). RNA from mock-infected Vero cells was used as control. 
The radiolabeled cDNA products were analyzed by denaturing gel electrophoresis 
alongside DNA oligonucleotide markers representing RNA initiated at position 1 or 2 of 
the template relative to the published 3′ terminal sequence of the Le promoter. In the 
samples from EBOV-infected cells, a single band was detected, which migrated 
comparably to the marker representing initiation at position 2 (Figure 41Ai). These findings 
indicate that antigenome synthesis was initiated opposite the first C residue of the 3′ 
CCUGUGUG motif. To confirm this, the 5′ terminal sequence of the EBOV Mayinga 
antigenome was determined by performing 5′ RACE and sequence analysis of the PCR 
product (Figure 41B). In contrast to the 3′ RACE products described above, there was no 
observable heterogeneity at the 5′ terminus of the antigenome RNA in the population 
analysis, and sequence analysis of single DNA clones revealed that in most cases, the 5′ 
terminal sequence was 5′ GGACAC consistent with initiation from the first C residue of 
the promoter. Only two clones with varying additional nucleotides were observed (Table 
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10). Neither contained the repetitive sequences that were occasionally detected in the 3′ 
RACE analysis, but instead contained one or two additional nucleotides that could either 
have arisen due to the polymerase initiating opposite the 3′ nucleotide, rather than 
internally, or due to nucleotide addition by reverse transcriptase during cDNA synthesis 
(note that in contrast to 3′ RACE, during 5′ RACE, cDNA synthesis by reverse transcriptase 
precedes the tailing reaction, meaning that in this case, reverse transcriptase errors cannot 
be distinguished from the true RNA sequence). The 5′ end of viral genomic RNA was also 
examined and yielded similar results as the 5′ end of viral antigenomic RNA (Figure 42Ai, 
15B - E). Similar results were obtained for SUDV Boniface (Figure 43), RESTV 
Pennsylvania, and RESTV Philippines 2008 (Figure 44).  
 
In contrast to humans and non-human primates who are highly susceptible to EBOV 
infection and develop symptoms of severe disease (42), Rousettus aegyptiacus fruit bats 
are not susceptible, although cell lines derived from these bats are permissive to EBOV 
infection (69, 108, 123). To explore if EBOV replication initiation varies depending on the 
host cell, we infected cell lines derived from non-human primates (Vero cells), humans 
(Huh7 cells), and Rousettus aegyptiacus fruit bats (R05T cells) with EBOV and performed 
primer extension analysis using antigenomic and genomic RNA. In all cell lines, the cDNA 
products migrated with the +2 marker, confirming replication initiation at position +2 
(Figure 41, 42 Aii). In conclusion, our data indicate that RNA synthesis of all tested 
ebolaviruses is initiated opposite the first C residue of the 3′ CCUGUG motif, at position 
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2 relative to the published sequence. The +2 replication initiation does not seem to be 
dependent on the host cell.   
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Figure 41. Mapping the 5´ end of EBOV antigenome RNA by primer extension and 
sequence analysis.(A) Primer extension analysis of antigenome RNAs. The upper panel 
shows a schematic diagram (not to scale) of the EBOV RNA that was analyzed showing 
the hybridization positions of the negative-sense Le 14-35 primer used for primer extension 
analysis. The lower panel shows primer extension analysis. Panel i shows analysis of RNA 
isolated from Vero cells infected with EBOV Mayinga (EBOVM) or Kikwit (EBOVK), and 
panel ii shows analysis of RNA isolated from EBOV Kikwit-infected Vero (non-human 
primate, NHP), Huh7 (human), and R05T (bat) cells. [γ-32P]-ATP end-labeled DNA 
oligonucleotides corresponding in length and sequence to cDNA representing initiation 
from positions +1 and +2, relative to the published EBOV sequences, were used as markers 
(lanes 1 and 2). (B-C) Vero cells were infected with EBOV Mayinga (B) or Kikwit (C) and 
total cellular RNA was used for RACE analysis. The traces show sequences of the 5´ RACE 
PCR population obtained from the 5´ ends of intracellular antigenomic viral RNA. The 
cDNA was tailed with dATP (i) or dCTP (ii). The black line below the sequence traces 
indicates poly(A) or poly(C) tail sequences that had been added to the virus-specific 
sequence during RACE. This may include some virus-specific sequence that cannot be 
distinguished from the poly(A) or poly(C) tail. The first two C residues that belong to the 
viral sequence are underlined with a dotted line in the poly(C)-tailed sequence traces.  
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Figure 42. Mapping the 5´ end of EBOV genomic RNAs by primer extension and sequence 
analysis. (A) Primer extension analysis of genome RNAs. The upper panel shows a 
schematic diagram (not to scale) of the EBOV genome RNA that was analyzed showing 
the hybridization positions of the positive-sense TrC 17-41 primer used for primer 
extension analysis. The lower panel shows primer extension analysis. Panel i shows 
analysis of RNA isolated from Vero cells infected with EBOV Mayinga (EBOVM) or 
Kikwit (EBOVK), and panel ii shows analysis of RNA isolated from EBOV Kikwit-
infected Vero (NHP), Huh7 (human), and R05T (bat) cells. [γ-32P]-ATP end-labeled DNA 
oligonucleotides corresponding in length and sequence to cDNA representing initiation 
from positions +1 and +2, relative to the published EBOV sequences, were used as markers 
(lanes 1 and 2). (B-E) Vero cells were infected with EBOV Mayinga (B-C) or Kikwit (D-
E) and total cellular or virion-associated RNA was used for RACE analysis. The traces 
show sequences of the 5´ RACE PCR population obtained from the 5´ ends of intracellular 
genomic viral RNA (B, D), or virion-associated genomic RNA (C, E). The cDNA was 
tailed with dATP (i) or dCTP (ii). The black line below the sequence traces indicates 
poly(A) or poly(C) tail sequences that had been added to the virus-specific sequence during 
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RACE. This may include some virus-specific sequence that cannot be distinguished from 
the poly(A) or poly(C) tail. The first two C residues that belong to the viral sequence are 
underlined with a dotted line in the poly(C)-tailed sequence traces.  
  
  
186 
 
Figure 43. Analysis of the 5´ ends of SUDV RNAs. (A-B) Primer extension mapping of the 
5´ ends of SUDV antigenome (A) and genome RNAs (B). (i) Schematic diagrams (not to 
scale) of the SUDV antigenome and genome showing the annealing positions of the 
negative- (A) and positive- (B) sense primers used for primer extension analysis. (ii) Primer 
extension analysis of antigenomic (A) and genomic (B) SUDV RNA (SUDV) isolated from 
infected Vero cells, analyzed with a negative- or positive-sense primer (A and B, 
respectively). RNA from mock-infected cells (mock) was used as a negative control. [γ-
32P]-ATP end-labeled DNA oligonucleotides corresponding in length and sequence to the 
respective cDNA representing initiation from positions +1 and +2, relative to the published 
sequence were used as markers. (C and D) Vero cells were infected with SUDV isolate 
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Boniface and the 5´ ends of virion-associated (C) or total intracellular genome RNA (D) 
were amplified by 5´ RACE. The cDNA was tailed with dATP (i) or dCTP (ii). The black 
line below the sequence traces indicates poly(A) or poly(C) tail sequences that were added 
to the virus-specific sequence during 5´ RACE. This may include some virus-specific 
sequence that cannot be distinguished from the poly(A) or poly(C) tail. The first two C 
residues that belong to the viral sequence are underlined with a dotted line in the poly(C)-
tailed sequence traces.   
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Figure 44. Analysis of the 5´ ends of RESTV RNAs. (A and B) Primer extension mapping 
of the 5´ ends of RESTV antigenome and genome RNAs. (i) Schematic diagrams (not to 
  
189 
scale) of the RESTV antigenome and genome showing the annealing positions of the 
negative- (A) and positive- (B) sense primers used for primer extension analysis. (ii) Primer 
extension analysis of antigenomic and genomic RNA from RESTV isolates Pennsylvania 
(RESTV Penn) and Philippines 08 (RESTV 08). Total cellular RNA was isolated from 
infected Vero cells and analyzed with a negative- (A) or positive- (B) sense primer. RNA 
from mock-infected cells (mock) was used as a negative control. [γ-32P]-ATP end-labeled 
DNA oligonucleotides corresponding in length and sequence to the respective cDNA 
representing initiation from positions +1 and +2 relative to the published sequence were 
used as markers. (C-G) Vero cells were infected with RESTV isolate Pennsylvania (D-E) 
or RESTV isolate Philippines 2008 (C, F-G), and the 5´ ends of virion-associated (D, F), 
intracellular genomic viral RNA (E, G) or intracellular antigenomic viral RNA (C) were 
amplified by 5´ RACE. The cDNA was tailed with dATP (i) or dCTP (ii). The black line 
below the sequence traces indicates poly(A) or poly(C) tail sequences that were added to 
the virus-specific sequence during 5´ RACE. This may include some virus-specific 
sequence that cannot be distinguished from the poly(A) or poly(C) tail. The first two C 
residues that belong to the viral sequence are underlined with a dotted line in the poly(C)-
tailed sequence traces..  
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5.3 The Ebola virus polymerase initiates RNA synthesis opposite 3′ CCUGUG, 
regardless of identity of the 3′ terminal nucleotide. 
RACE followed by sequencing of EBOV RNA showed the templates for replication are 
heterogeneous at their 3′ terminal nucleotide. Primer extension analysis of EBOV RNA 
showed the replication products are initiated opposite the first nucleotide of the 
3′CCUGUG motif (the second nucleotide of the genome relative to most previously 
published sequences). However, the sequence analysis does not provide information on 
whether all genome and antigenome sequences were functional templates, or if only a 
subset could be used. For example, it was possible that only the templates lacking the 3′ 
terminal A or G (i.e., containing 3′ CCUGUG) were functional. Therefore, to determine 
what constitutes a functional template, EBOV minigenomes were generated which either 
did not contain an additional nucleotide (1Δ), or contained the additional 3′ terminal A or 
G residue. We also tested minigenomes containing an additional 3′ terminal U or C residue, 
as well as minigenomes that contained additional 3′ nucleotides (+GCCG, +CCG), to test 
the accuracy of initiation. To ensure that the 3′ termini of the minigenomes were not 
modified during multiple replication cycles, the minigenomes were restricted to the 
antigenome synthesis step of replication by deleting the 5′ terminal 25 nucleotides of the 
Tr region (Figure 45). 
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Figure 45. Schematic of non-replicating, non-transcribing EBOV minigenomes with 
different 3′ ends. Schematic diagram (not to scale) showing the different 3′ terminal 
sequences that were tested (Left) and the organization of the single-cycle replicating, non-
transcribing EBOV minigenome and the antiminigenome product (Right). The terminal 25 
nucleotides of the trailer were deleted (Δ1–25). The trailer is flanked by an inactive 
hammerhead ribozyme (HH). The annealing position of the negative-sense primer used for 
primer extension is indicated; mut GS, mutated gene start signal; GE, gene end signal. Dr. 
Adam Hume constructed the 1Δ2Δ, 1Δ2U, and 1G2U minigenomes.  
  
  
192 
In addition, the EBOV-specific GS signal, which is required for mRNA transcription, was 
mutated to suppress minigenome transcription. BSR T7/5 cells were transfected with the 
respective minigenome DNA along with expression plasmids encoding the EBOV proteins 
required for replication (NP, VP35, VP30, and L), and the RNA products generated from 
the minigenome templates were analyzed by primer extension (Figure 46 A-B, Figure 48 
A-B) and by Northern blot hybridization to complement the primer extension analysis 
(Figure 47). All minigenomes with substitutions at position 1, a deletion at position 1, or 
additional nucleotides added to the 3′ terminus were functional templates for replication, 
although the minigenome containing an additional GCCG sequence at the 3′ end yielded 
antigenome RNA at such a low level that it could not be detected by Northern blot (Figure 
47B, lane 2) and was only barely detectable by primer extension analysis (Figure 46A, lane 
4 and B).  
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Figure 46. Analysis of replicated RNA produced from EBOV minigenomes with different 
3′ ends.  (A) Primer extension analysis of antiminigenome RNA from minigenomes with 
+GCCG, +CCG, 1G, 1Δ, 1A, 1U, and 1C 3′ ends using a negative-sense primer that 
annealed within the LeC region. The markers are [γ-32P]-ATP end-labeled DNA 
oligonucleotides corresponding in length and sequence to cDNA representing initiation 
from positions +1 and +2, relative to published sequence. As a negative control, L was 
replaced with the enzymatically inactive Lsynth- mutant N743A. A representative result of 
three independent experiments is shown. (B) Quantification of primer extension products 
shown in B. The data are normalized to the level of product generated by the 1G 
minigenome after subtraction of the Lsynth- negative control. Shown are the mean and SE 
of three independent experiments.   
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Figure 47. Northern blot analysis of replication products from mutant EBOV minigenome 
with different 3´ ends. (A) Northern blot analysis of anti-minigenome RNA products using 
a negative-sense riboprobe specific to the ΔCAT sequence. DynaMarker Prestain Marker 
for RNA High was run alongside RNA products on the same gel. Left panel, image of 
membrane following transfer of RNA. Right panel, autoradiography image. (B) Northern 
blot analysis of anti-minigenome RNA products using a negative-sense riboprobe specific 
to the ΔCAT sequence. The experiment was performed three times and a representative 
blot is shown. Northern blot shown in panel B were performed by Dr. Adam Hume and me. 
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RNA from the remaining mutant minigenomes in Figure 46A could be detected by 
Northern blot analysis (Figure 47), confirming the results by primer extension. 
Interestingly, the primer extension analysis showed that regardless of the minigenome 3′ 
terminal sequence, the EBOV polymerase initiated RNA synthesis at the same position as 
observed in viral infection, i.e., opposite the first C residue of the CCUGUG motif (Figure 
46A). Thus, it initiated RNA replication opposite position +1 in the 1Δ mutant, opposite 
position +2 in mutants 1G, 1A, 1U, and 1C, and opposite positions +4 and +5, respectively, 
in mutants +CCG and +GCCG (Figure 46A). These data suggest that the EBOV 
polymerase locates its binding site within the promoter sequence and initiates RNA 
synthesis accurately, regardless of the identity of the 3′ terminal nucleotide(s) and of the 
position of the promoter sequence relative to the 3′ end. The only exception was mutant 
1C, which presented with a double band in the primer extension analysis (Figure 46A, lane 
10, asterisk). This suggests that, in this case, on some occasions, the EBOV polymerase 
initiated opposite the additional C residue at the first nucleotide of the template. 
5.4 The EBOV polymerase does not initiate RNA synthesis opposite the 3′ CCUGUG 
motif if the first nucleotide of this motif is missing or substituted. 
The data presented above show that EBOV replication products are initiated opposite the 
first nucleotide of the 3′ CCUGUG motif, regardless of the presence or identity of 
additional 3′ nucleotides. Interestingly, the genome ends of the closely related MARV 
begin with a similar 3′ UCUGUG motif, with the only differences between the EBOV and 
MARV genome ends being the terminal nucleotide of this motif (C versus U) and the lack 
of an additional, non-templated nucleotide at the 3′ end of the MARV genome ref 2. To 
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determine the role of the first C residue of the 3′ CCUGUG motif in EBOV replication, 
single-round replicating EBOV minigenomes were generated which lacked both the 3′ 
terminal, non-templated nucleotide and the first C residue of the 3′ CCUGU motif (1Δ2Δ), 
or had this C residue mutated to U in the absence of an additional nucleotide (1Δ2U), or 
had this C residue mutated to U in combination with an additional terminal G residue 
(1G2U) (Figure 45). Intriguingly, none of these minigenomes were accepted as templates 
for replication initiation, as shown by primer extension analysis (Figure 48A, lanes 7–9 
and B).  
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Figure 48. Analysis of replicated RNA produced from EBOV minigenomes with different 
nucleotides at the 3′ end of the 3′ CCUGUG motif. (A) Primer extension analysis of 
antiminigenome RNA from minigenomes with 1G, 1Δ, 1Δ2Δ, 1Δ2U, and 1G2U 3′ ends 
using a negative-sense primer that annealed within the LeC region. The markers are [γ-
32P]ATP end-labeled DNA oligonucleotides corresponding in length and sequence to 
cDNA representing initiation from positions +1, +2, and +3 relative to published sequence. 
As a negative control, L was replaced with the enzymatically inactive Lsynth- mutant 
N743A. A representative result of three independent experiments is shown. (B) 
Quantification of primer extension products shown in A. The data are normalized to the 
level of product generated by the 1G minigenome after subtraction of the Lsynth- negative 
control. Shown are the mean and SE of three independent experiments. Dr. Adam Hume 
constructed the 1Δ2Δ, 1Δ2U, and 1G2U minigenomes and performed the transfections. 
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To confirm the key importance of the first C residue of the 3′ CCUGUG motif in the EBOV 
replication cycle, replication- and transcription-competent minigenomes in which the C 
residue was mutated to U (1G2U and 1Δ2U) were generated and tested. The readout in this 
assay was minigenome-derived reporter gene expression (Figure 49). The mutant 
minigenomes produced only background levels of reporter gene activity in contrast to the 
strong activity seen with the 1G minigenome which was used as a positive control (Figure 
49B). In combination with the primer extension data, these results show that the first C 
nucleotide of the 3′ CCUGUG motif is absolutely required for EBOV genome replication. 
Of note, the second nucleotide in this motif is a C residue, too. The fact that this is not 
sufficient to allow replication shows that a 3′ terminal C residue alone is not sufficient to 
initiate replication; but rather that this nucleotide functions in combination with other 
nucleotides to direct initiation. 
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Figure 49. Luciferase analysis of mutant EBOV minigenomes with different 3´ ends.(A) 
Schematic diagram (not to scale) showing the replication- and transcription-competent 
EBOV minigenome expressing a luciferase reporter gene (3E5E-Luc), the corresponding 
anti-minigenome product, firefly luciferase mRNA, and firefly luciferase. GS, gene start 
signal; GE, gene end signal. (B) HEK 293T cells were infected with minigenome plasmid 
3E5E-Luc along with plasmids encoding the EBOV proteins required for replication and 
transcription (NP, VP35, VP30, and L), the T7 RNA polymerase, and a plasmid encoding 
β-galactosidase. As a negative control, L was replaced with the replication-deficient L 
mutant, Lsynth-. Two days post transfection, cell lysates were harvested and luciferase and 
β-galactosidase activities were measured. Luciferase values were normalized to account 
for differences in transfection efficiency by dividing by the corresponding β-galactosidase 
values. Fold luciferase activity was calculated by dividing the luciferase value of the wt L 
samples by the values of the corresponding samples with Lsynth-. The experiment was 
performed three times and the mean of the results is shown. Standard error of the mean for 
this Figure was calculated using GraphPad Prism software. Experiments were performed 
by Dr. Adam Hume. 
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Discussion 
The data we present here show that the 3′ ends of ebolavirus genomes and antigenomes 
contain a variable nucleotide, and that the polymerase initiates at the first C residue of the 
template, typically at position +2 (Figure 50).  
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Figure 50. Model for RNA synthesis initiation and 3′ terminal nucleotide addition by the 
ebolavirus polymerase. (A) Scheme showing the site of initiation at the Le promoter of the 
genome and at the TrC promoter of the antigenome. The ebolavirus polymerase is indicated 
by a blue ellipse and the initiation site by a green arrow. The experimentally determined 3′ 
terminal nucleotide is highlighted in red. − symbols indicate the lack of a nucleotide. (B) 
Schematic diagram showing how addition of a G or A residue onto the 3′  end of 
antigenome RNA may occur by templating of the 3′ terminal nucleotide using secondary 
structure formations at the 3′ end of the RNA. (C) Schematic diagram showing addition of 
a 3′ terminal purine nucleotide by terminal nucleotidyl transferase activity of the ebolavirus 
polymerase or a cellular terminal transferase. 
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The identity and presence of the +2 nucleotide are crucial for EBOV genome replication, 
suggesting that it belongs to the EBOV promoter region. These conclusions are drawn from 
a number of experiments, including sequence analysis of the 3′ ends of viral genome and 
antigenome RNA, both of populations and individual clones, primer extension, 
minigenome activity, and sequence analysis of the 5′ end of the RNAs. All data obtained 
in this study were consistent, regardless of the technique used. Further, these findings are 
applicable across the ebolaviruses. Importantly, our results confirm previous findings by 
Kiley et al. (95) deduced from chemical RNA sequence analysis that the 3′ terminal 
nucleotide of EBOV and SUDV genomes is either a G or an A residue. A study of EBOV 
Makona isolates had also found heterogeneity at the 3′ termini, reporting that most RNAs 
contained a 3′ G residue, with a minor fraction that was one nucleotide shorter. However, 
in that study a terminal A residue was not reported (60). Our data, and that of Kiley et al. 
(75, 95), differ from most of sequences deposited in GenBank, in which the 3′ terminal 
residue of the ebolavirus genome is shown as a G residue or not present, and the 5′ terminus 
is variable. We believe that the discrepancy between the published ebolavirus genome ends 
is likely due to technical reasons, such as the inherent bias of RNA ligation, PCR artifacts, 
or sequencing of individual clones, rather than the RNA population, and the fact that it is 
not possible to categorically assign the 3′ and 5′ terminal sequences when the RNA is 
circularized before sequencing. Analysis of the 5′ termini of ebolavirus genome and 
antigenome RNAs suggested that the polymerase could initiate RNA replication internally 
on the template, at the first C of the sequence 3′ NCCUGUGUG (Figure 41 and 42). 
However, there were two possible alternative explanations. First, it was possible that the 
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polymerase initiated opposite the 3′ N residue, and that the 5′ terminal nucleotide of the 
replication product was cleaved. A similar mechanism has been shown for the nsNSV, 
Borna disease virus (137). However, other data indicate that this is not the case. If the RNA 
were cleaved, it would contain a 5′ monophosphate rather than triphosphate moiety, but 
previous studies have shown that EBOV genome RNA stimulates retinoic acid-inducible 
gene I (RIG-I) activation, an activity that can be ablated by treating the RNA with 
phosphatase (55). Thus, the 5′ end of EBOV genome RNA contains a 5′ triphosphate, 
excluding the possibility of nucleotide removal by cleavage. The second possible 
explanation was that genomic and antigenomic viral RNAs containing an additional 3′ 
terminal nucleotide were defective, and only RNA templates with the sequence 3′ 
CCUGUGUG were viable. However, experiments with the minigenome system confirmed 
that templates with any nucleotide at the 3′ N position were recognized by the polymerase. 
The polymerase initiated opposite the first C residue of the 3′ CCUGUGUG motif, even if 
the template contained up to four additional nucleotides at the 3′ end (Figure 46). Thus, the 
ebolavirus polymerase can initiate internally on a template. To our knowledge, this is a 
previously unreported instance of nsNSVs initiating RNA replication internally on the 
template as part of their normal replication cycle. Our data also suggest that the promoter 
sequence plays a key role in determining the site of RNA synthesis initiation, as opposed 
to it being determined by the 3′ terminus of the RNA template. This mechanism of initiation 
site selection has also been described for other nsNSVs: while Sendai virus and RSV 
polymerases normally only initiate RNA replication opposite the 3′ terminal nucleotide of 
the template, they are both capable of initiating RNA replication opposite an internal 
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promoter sequence when presented with an artificial template containing additional 3′ 
nucleotides (22, 157, 158). Thus, the ability of the ebolavirus polymerase to initiate at an 
internal site is not unique, but the fact that replication is initiated at an internal site as part 
of the normal replication cycle is distinctive among nsNSVs. While the promoter appears 
to play a dominant role in positioning the polymerase opposite the initiation site, the 
presence of the C residue at the initiation site is also important as a minigenome template 
containing an additional 3′ terminal C residue showed a low level of initiation from the 
first (3′ terminal) C residue, as well as from the typical initiation site (Figure 46A, lane 10). 
Given that the ebolavirus gene start signals begin with a C residue (82, 103), this could 
reflect a preference of the polymerase for initiating with GTP. A recent study of RSV 
initiation showed that its polymerase has a template-independent affinity for the initiating 
NTPs and that this plays a role in initiation site selection (25). Thus, it is possible that 
ebolavirus polymerases preferentially bind GTP due to template-independent affinity, and 
that this affinity combined with positioning by the promoter helps guide initiation at the 
correct site. In contrast to the flexibility seen with the EBOV replication complex with 
regards to accommodating extra, non-templated 3′ terminal nucleotides, data presented 
here indicate that both the identity and the presence of the first C residue of the 3′ 
CCUGUGUG motif are crucial for EBOV replication (Figure 48A and Figure 49). The 
homologous region in the MARV leader starts with a U residue (3′ UCUGUGUG) (75). 
Despite the similarities of the EBOV and MARV leader regions, EBOV is not able to 
initiate replication if the first nucleotide of the 3′ CCUGUGUG motif is mutated to a U. 
Intriguingly, this strict requirement for a C residue at the first position of the CCUGUGUG 
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motif has also been seen with Lloviu virus, a new member of the filovirus family, but not 
with MARV or the recently discovered MARV-like Menglà virus, whose replication 
complexes are each able to replicate the EBOV leader (95, 105, 151, 169). This divergence 
in terms of nucleotide specificity may indicate either a divergent mechanism for the 
initiation of replication between these two branches of the filovirus family tree or, at the 
very least, a relaxed specificity for the MARV/Menglà replication complex. Given that the 
ebolavirus polymerases initiate at position +2 of the template, the 3′ terminal nucleotide of 
the genome and antigenome RNAs is not templated by the complementary strand. This 
leads to the question of how the 3′ terminal nucleotides are added to the genomic and 
antigenomic RNAs. Two possible models exist: 3′ extension by back-priming or nucleotide 
addition by terminal transferase activity (Figure 50). The backpriming model postulates 
that the 3′ end of the RNA folds into a hairpin structure, allowing templated addition of the 
3′ terminal nucleotides. While the dogma in the nsNSV field is that encapsidation of 
replicative RNA by nucleoprotein prevents secondary structure formation, 3′ extension of 
viral replicative RNA by back-priming has been shown to occur in Borna disease virus and 
on some antigenome RNAs in RSV-infected cells  (97, 111), indicating that encapsidation 
of RNA at 3′ ends of the replicative RNA is sometimes incomplete or delayed. The data 
obtained in this study support this model, as some 3′ termini contained palindromic 
sequences, which is consistent with the RNA having been folded into a hairpin and 
extended (Figure 40). In addition, the EBOV RNA has the potential to form more extensive 
and stable secondary structures (24, 156, 160), which would allow templating of either an 
A or G residue, depending on the secondary structure formed (Figure 50B). Regarding the 
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possibility of terminal transferase activity, it has been observed that several RNA-
dependent RNA polymerases possess terminal transferase activity (15, 16, 131, 152, 168) 
and it is possible that ebolavirus polymerases share this property. Given that the additional 
3′ terminal nucleotide is typically an A or G residue, if this model is correct, it suggests 
that the polymerase has a preference for performing terminal transferase addition with 
purine nucleotides. The identity of an extra nucleotide to the 3′ end of the genome did not 
appear to affect sorting of genome RNAs into virions (Figures 32-37) and was not required 
for replication to occur (Figures 43, 44, 46), but it did lead to a marginal increase in 
replication efficiency. Thus, it is possible that the presence of an additional nucleotide 
benefits the virus by providing enhanced stability to the polymerase complex during 
initiation. In addition to direct effects on viral genome replication, ebolaviruses might 
contain an additional 3′ nucleotide to reduce detection by RIG-I and RIG-I-like receptors 
whose binding to double-stranded RNA (dsRNA) is impaired by 3′ overhangs (48, 135). 
Interestingly, EBOV VP35, a viral dsRNA binding protein involved in viral replication and 
suppression of IFN induction, also binds dsRNA with 3′ overhangs with reduced affinity 
compared with blunt and 5′ overhang dsRNA, although if or how this would benefit the 
virus remains unclear (77). It has been shown for other negative-sense RNA viruses that 
they use unconventional replication initiation mechanisms to avoid antiviral responses. 
This includes Borna disease virus, a nsNSV, and Hantaan virus, a segmented negative-
sense RNA virus, which both use distinct replication initiation mechanisms to remove RIG-
I stimulating 5′ triphosphates from their genome ends (45, 55, 137). Similar to ebolaviruses, 
Tacaribe virus, a segmented negative-sense RNA virus that belongs to the arenavirus 
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family, initiates RNA synthesis at position +2 on the template. However, in this case, the 
internally initiated RNA is used in a prime-realign mechanism which results in a one-
nucleotide 5′ overhang that interferes with RIG-I recognition (44, 96). In contrast, our data 
for ebolaviruses suggest prime-realign does not occur and a 3′ overhang is generated. In 
summary, both the 3′ and 5′ ends of ebolavirus replicative RNAs are formed by unusual 
mechanisms, with the 5′ terminus being generated by internal initiation, and the 3′ terminus 
being generated by nucleotide addition by back-priming and/or terminal transferase 
activity with high frequency. These findings reveal an unappreciated variety between 
nsNSVs. 
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CONCLUDING REMARKS 
Summary of results 
In Chapter Three, I present data investigating how the RSV polymerase initiates RNA 
synthesis from two distinct sites with the same promoter, and the NTP and template 
requirements for these events to occur. We showed that RSV L and P alone are capable of 
replication and transcription initiation at the T1U and T3C sites. The RSV RdRp can 
become loaded with ATP and CTP or GTP, with a higher affinity for GTP, and initiates at 
T1U or T3C due to its association with ATP or GTP respectively. Our data suggests the 
RdRp becomes loaded with the initiating NTPs independently of the template sequence. 
We also showed RdRp could initiate at T1, T2, or T3 provided it was initiating opposite 
either a UG motif, or a C residue. These findings also indicate that the RdRp preferentially 
binds the promoter such that its catalytic site is positioned opposite T3. 
 
In Chapter Four, I investigated the structural determinants involved in RNA synthesis 
initiation by the RSV polymerase. We show that P1274 and Y1276, do not function as 
priming residues in the RSV RdRp, highlighting a difference between the RSV and VSV 
RdRps. Our results suggest RSV L P1261 is the putative priming residue and is important 
for both replication initiation at T1 and transcription initiation at T3. The +3 initiation 
defect can be partially overcome by increasing initiating NTP levels, suggesting P1261 is 
involved in coordinating the NTPs in the initiation complex. The +1 initiation defect could 
not be rescued under any condition tested, which suggests P1261 is more strictly required 
for +1 initiation than +3.  
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In Chapter Five, we show the 3′ ends of the EBOV genomes and antigenomes contain a 
variable nucleotide, typically G or A. We also show the polymerase initiates at the first C 
residue of the template of the 3′ CCUGUGUG motif, which is typically at T2. The identity 
and presence of this nucleotide are crucial for EBOV genome replication whereas the 
nucleotides 3′ to this motif are unimportant for RNA synthesis. Thus, the ebolavirus 
polymerase can initiate internally on a template as part of its normal replication cycle. Our 
data also suggest that the promoter sequence plays a key role in determining the site of 
RNA synthesis initiation, as opposed to it being determined by the 3′ terminus of the RNA 
template. Given that the ebolavirus polymerases initiate at T2 of the template, the 3′ 
terminal nucleotide of the genome and antigenome RNAs is not templated by the 
complementary strand.  
Commonalities and divergence of initiation mechanisms among the nsNSV polymerases 
RNA synthesis initiation is a tightly coordinated process with many components required 
to be properly position in the initiation site of the RNA polymerase, including the NTPs, 
template, and Mg2+ cofactor ions. Structural determinants of the polymerase are involved 
in coordinating these elements, including the priming residue which coordinates the 
initiating NTPs. This process is carefully regulated and common to all RNA polymerases 
which perform de novo initiation. However, as I describe in this dissertation, there are 
differences in initiation mechanisms among the nsNSV RdRps that have not been well 
appreciated previously. These viral polymerases must maintain accurate genome ends 
during replication. The majority of RdRps studied thus far accomplish this by initiation 
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from +1, e.g. RSV and VSV. However, EBOV initiates RNA synthesis at position +2 and 
adds a 3′ terminal nucleotide by an as yet unknown mechanism. 
 
An important component to RNA synthesis initiation is the role of NTP recruitment into 
the active site of the polymerase. We have shown here RSV recruits ATP and then CTP 
for initiation from T1 or GTP for initiation from T3. Our results also suggest the RSV 
RdRp can recruit these initiating NTPs independently of template sequence, suggesting an 
innate affinity. Interestingly, while the majority of nsNSVs studied to date initiate genome 
replication with ATP, EBOV initiates with GTP from T2, as well as at the GS signals. We 
have shown the RSV RdRp has a higher affinity for GTP, which is used for initiation at 
T3, than for ATP used for initiation at T1, and GTP is also the initiating NTP at the GS 
signals. There may be a common innate affinity of the nsNSV polymerases for GTP which 
has evolved for the regulation of various types of RNA synthesis. An affinity of the EBOV 
RdRp for purines could explain the majority 3′ A or G additions observed at the 3′ ends of 
EBOV genomes and antigenomes if added by terminal transferase activity. MARV, differs 
from EBOV in its terminal genome/antigenome sequences in that these additional 3′ 
residues are not observed, and RNA synthesis presumably begins at T1 which results in 
initiation with an A from the Le and a G from the TrC. If the MARV RdRp has a higher 
affinity for GTP than ATP, this could potentially be a mechanism for the regulation of 
RNA synthesis, i.e. greater amounts of genome synthesis compared to the antigenome 
replication intermediate.  
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In addition to NTP recruitment, this work adds to our understanding of promoter motif 
recognition. Our work indicated the EBOV RdRp nearly always initiated from the first C 
of the 3′ CCUGUG motif, even when additional sequence was added to the 3′ end. This 
indicated it was not merely the presence of the CC motif or the positioning relative to the 
3′ end of the template, but an internal promoter element which the polymerase was 
recruited to. However, we did also show the first C residue was critical for RNA synthesis. 
These results were somewhat in contrast to our results in Chapter Three showing RSV 
RdRp could initiate from T1, T2, or T3 if there was a UG or C motif present, its native 
initiation sites, suggesting potentially more flexibility. However, if EBOV RNA synthesis 
was examined in vitro on mutant templates, we may observe more flexibility given the cell-
based minigenome assay only allows for the analysis of stable RNA end products and not 
unstable RNA intermediates. Several polymerases, such as bacteriophage φ6 polymerase, 
have been shown to be recruited to templates at an internal, typically +3, position. These 
polymerases may then ratchet back to initiation RNA synthesis from +1. We have shown 
here evidence suggesting RSV RdRp follows a similar model, with the preferred initiation 
site at +3 and a similar register of promoter sequence which would allow the polymerase 
to ratchet back to +1 and maintain similar promoter contacts as those formed at +3. The 
EBOV RdRp likely also binds the template at an internal position, as RNA synthesis is 
initiated from +2, and at the same position with addition of nucleotides to the 3′ end of the 
template. The EBOV RdRp could be recruited directly to the cytidine at position 2 (T2C). 
Alternatively, particularly if the RdRp has recruited GTP, it is possible the RdRp is initially 
recruited to the cytidine at position 3 (T3C) and then ratchets back to initiates at T2C. The 
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above model would also support the possibility the RdRp recruits GG to facilitate initiation 
from T2C and not T3C. Our work with RSV suggests the RdRp recruits two NTPs for 
initiation from +1. If the EBOV RdRp recruits GG to the active site, this could possibly 
explain our results where on a mutant EBOV minigenome template with a 3′ CCCUGUG 
instead of the native 3′ CCUGUG motif, there was a mixture of initiation from the first and 
second cytidines, but not observable product consistent with initiation from the third. 
Recruitment of the polymerases to an internal template position is likely more stable 
compared to the end of the linear RNA template.  
 
In addition to the NTP recruitment and promoter recognition models discussed above, the 
initiation complex of the nsNSV RdRps is likely stabilized by priming residues. It is of 
interest to identify the priming residues, and determine if differences in initiation 
mechanisms reflect in the details of priming residue involvement. 
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APPENDIX ONE: Triphosphorylated RNA marker development 
RNA products synthesized by RNA polymerases, as those shown from the in vitro RNA 
synthesis assays of Chapters Three and Four, contain a 5′ triphosphorylated (5′ ppp) end 
(5′ pppNpN…). The markers co-migrated with these products contain 5′ 
monophosphorylated (5′ p) ends (5′ pNpN…) instead of triphosphorylated. These markers 
are accurate for the sizing of relatively large RNA products (~5 nucleotides and above). 
The charge differences of the 5′ ppp ends compared to the 5′ p end contribute more to the 
migration of shorter RNAs and thus are not accurate for the identification of smaller RNA 
products, such as the dinucleotide products in Chapter Four. We have identified these 
dinucleotide (5′ pppApC or 5′ pppGpA) products through NTP drop out reactions and their 
migration approximately 1 nucleotide higher than the unincorporated [α-32P]NTP. Since 
performing those experiments, I designed a method to synthesize 5′ triphosphorylated 
markers to more confidently identify these small RNA products in our in vitro assays. I 
designed DNA oligos which, upon annealing, will form a T7 RNA polymerase promoter 
from which the T7 polymerase will utilize an overhanging sequence to synthesize RNA 
products in vitro, based on previous studies (118, 119). The design allows T7 transcription 
to be precisely stopped by running off the DNA template after the desired product sequence 
is synthesized (Figure A1). I designed DNA oligo combinations that should yield the RNA 
products shown in Table A1. Analysis of the T7 polymerase in vitro transcribed products 
on a 25% urea-acrylamide TTE gel suggests most reactions occurred as predicted and 
synthesized the 5′ pppNpN… products. Further work to use these markers, particularly the 
5′ pppApC and 5′ pppGpA is in progress.  
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Figure A1. Synthesis of 5′ triphosphorylated RNA markers by T7 in vitro transcription.(A) 
Schematic of example annealed oligo combination for the in vitro transcription of 5′ 
pppApC. T7 polymerase initiation site shown in green. Annealed oligo overhang 
nucleotides templating for pppApC are underlined. (B) RNA products from T7 in vitro 
transcription. Sequences of identified RNAs with a 5′ A shown on the left, sequence of 
identified RNA 5′ pppGpA shown on the right. RNA products in reactions 8-10 are not as 
expected, possibly due to imprecise RNA synthesis on the repetitive templates (Table A1). 
(C) Expected full-length RNA products from the reactions shown in panel B. Bands shorter 
than the full-length expected product are likely due to abortive in vitro transcription 
resulting from the T7 polymerase falling off the template prior to the polymerase reaching 
the end  
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Table A1. DNA oligos used for T7 in vitro transcription synthesis of 5′ triphosphorylated 
RNA markers. 
RNA product 
(5' to 3') 
short primer/ upper 
strand (5' to 3) 
overhang primer/lower strand (3' 
to 5') 
pppApC V1 TAATACGACTCACTATA ATTATGCTGAGTGATATATGAA 
pppApC V2 TAATACGACTCACTATA ATTATGCTGAGTGATATTG 
pppApCpG TAATACGACTCACTATA ATTATGCTGAGTGATATTGC 
pppApCpA TAATACGACTCACTATA ATTATGCTGAGTGATATTGT 
pppApApC TAATACGACTCACTATA ATTATGCTGAGTGATATTTG 
pppApCpGpA TAATACGACTCACTATA ATTATGCTGAGTGATATTGCT 
pppApCpGpApG TAATACGACTCACTATA ATTATGCTGAGTGATATTGCTC 
pppGpA TAATACGACTCACTATA ATTATGCTGAGTGATATCT 
pppGpApG TAATACGACTCACTATA ATTATGCTGAGTGATATCTC 
pppGpApGpA TAATACGACTCACTATA ATTATGCTGAGTGATATCTCT 
pppGpApGpApA TAATACGACTCACTATA ATTATGCTGAGTGATATCTCTT 
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APPENDIX TWO: HPIV3 and MARV polymerase complex expression and 
purification 
To determine whether residues homologous to RSV P1261 are functioning in a similar 
manner in polymerases from other nsNSV families, individual alanine substitution variants 
were cloned into full length L ORFs for HPIV3, a paramyxovirus, and MARV, a filovirus. 
In the region of L homologous to RSV for HPIV3 there are three potential residues of 
interest: P1213, Y1214, and F1215 with P1213 being most homologous to RSV P1261. In 
the region of L homologous to RSV for MARV there are two potential residues of interest 
P1217 and Y1218, with P1217 being most homologous to RSV P1261. I have expressed 
and purified these variant polymerases using the baculovirus system as described with the 
RSV L-P complex, based on work done by Afzaal Shareef on the HPIV3 wt L-P and 
MARV wt L-P complexes (Figure A2).  
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Figure A2. SDS-PAGE gels of purified wt and variant HPIV3 and MARV L-P complexes. 
Benchmark ladder in Lane 1 with markers sizes indicated on the left of gels. (A) Purified 
HPIV3 L-P complexes. (B) Purified MARV L-VP35 complexes. 
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APPENDIX THREE: Development of Ebola virus non-replicating minigenome 
system 
In order to analyze the role of the 3′ terminal nucleotides of the EBOV genome in RNA 
synthesis initiation as shown in Chapter Five, we needed to develop a robust EBOV 
minigenome restricted to a single round of replication. I worked to establish and optimize 
this system. I generated the non-replicating EBOV minigenome based on the wt 
minigenome that is inserted in a T7 expression plasmid and contains a firefly luciferase 
reporter gene (p2,0 3E5E Fluc ΔTr). The non-replicating EBOV minigenome had a 25 nt 
deletion in the trailer region. Northern blot analysis of RNA from this minigenome system 
suggested the signal was not robust enough, possibly due to high background around the 
area of ribosomal RNA and the size of the antiminigenome RNA running within this region 
of high background (Figure A3). We decided to reduce the length of the non-replicating 
minigenome as much as possible, so that it would migrate away from the area of 
background on Northern blots and it could potentially be replicated and encapsidated more 
efficiently. To accomplish this, I shortened the Le and Tr regions such that only the 
sequences required for RNA synthesis were retained, and replaced the ~1700 nt firefly 
luciferase reporter gene with the ~300 nt ΔCAT gene fragment (3E’5E’ ΔCAT ΔTr). This 
minigenome did yield detectable RNA product as analyzed by Northern blot and primer 
extension (used in Chapter Five). In addition to the minigenome optimization, it was 
observed the LEBOV gene in the pTM1-LEBOV vector had the AUG start site positioned at a 
non-optimal position relative to the internal ribosome entry site (IRES). I constructed a 
new version of pTM1-LEBOV with the AUG start site at the optimal location relative to the 
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IRES. Comparison of the two versions of pTM1-LEBOV by minigenome assay with the non-
replicating firefly luciferase minigenome with shortened Le and TrC sequences (3E’5E’ 
Fluc) did not suggest a major improvement with the new construct (Figure A3). These 
results did indicate 100 ng of pTM1-L, regardless of which construct was used, was optimal 
compared to 1 μg pTM1-L in a 6 well format that was previously being used. 
 
Figure A3. Optimization of EBOV non-replicating minigenome assay.  (A) Northern blot 
of positive-sense RNA products from 3E’5E’ Fluc ΔTr minigenome. As a negative control, 
wt L was replaced with the replication-deficient L mutant, Lsynth. (B) EBOV 3E’5E’ firefly 
luciferase assay from cells transfected with varying amounts of pTM1-LEBOV and pTM1-
LEBOV with the proper AUG start site relative to the IRES. Data shown is the mean and 
range of two independent experiments. 
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